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Malaria affects over half of the world’s population and causes half a million deaths 
annually, especially in Sub-Saharan Africa. Four species of the apicomplexan 
Plasmodium parasite (P. falciparum, P. ovale, P. malariae and P. vivax) are 
responsible for malaria in Africa. Both parasite and host factors contribute to 
heterogeneity in the risk of developing malaria, clinical manifestation of the disease as 
well as the number of treatments required to clear parasites. The epidemiology of the 
different species, and the role of exposure to mixed-species Plasmodium co-infections 
in generating heterogeneity remains poorly studied. Being an obligate intracellular 
parasite the blood-stage life cycle of the Plasmodium parasite takes place in the 
erythrocytes of the human host. The surfaces of these erythrocytes are the medically 
important ABO blood group antigens that have been reported to influence the 
susceptibility or otherwise of an individual developing severe malaria. In this thesis I 
have considered the contributions of the species of Plasmodium parasites and the ABO 
blood group of the host in driving heterogeneity in human malaria. 
The aims of this thesis were to determine:  
(i) the seroepidemiology of the different Plasmodium species in two 
mesoendemic African populations (Zimbabwe and Sudan); 
(ii)  to determine if heterogeneity in clinical presentations of malaria (history 
of fever, body temperature and parasitaemia) and response to drug 
treatment is related to exposure to single vs. mixed-Plasmodium species 
infection;  
(iii) the spatial and temporal dynamics of malaria prevalence and Plasmodium 
species distribution in a mesoendemic village in eastern Sudan;  
(iv) gene expression changes in 3D7 P. falciparum parasites as they infect 
erythrocytes of different ABO blood group donors.  
For aims (i to iii) I developed an enzyme-linked immunosorbent assay using antigens 
derived from Plasmodium merozoite surface protein 1, also known as MSP-119, to 




populations. In the Zimbabwean study, plasma samples from 100 individuals each 
(aged 5-18 years) from three villages (Burma Valley, Mutoko and Chiredzi) were 
screened for exposure to Plasmodium parasites. In Daraweesh, Sudan, plasma samples 
from 333 individuals (aged 1-74 years) who had experienced a first malaria episode 
between 1990 and 2000 were recruited into the study. For study aim (iv) I cultured a 
single clone of 3D7 P. falciparum parasite using erythrocytes of individuals of 
different ABO blood group types, harvested parasite RNA and sequenced it to 
determine gene expression changes in the different hosts.  
I showed that human IgG antibodies to MSP-119 antigens of the four Plasmodium 
species are species-specific and do not cross-react. In both study populations almost 
all antibody responses involved P. falciparum, and single-species responses were 
almost exclusively directed against P. falciparum antigens. Mixed-species responses 
accounted for more than a third of responses, and were associated with chloroquine 
treatment failure, with significantly high proportion of individuals with mixed-species 
infections requiring repeated treatment with chloroquine/sulfadoxine-pyrimethamine 
for parasite clearance. This finding highlights the need for a sensitive method for 
detecting mixed-species malaria infections to enable the assessment of the true 
prevalence and magnitude of the disease burden caused by the non-falciparum species 
in endemic populations. Drug treatment failures associated with mixed species 
infections have significant impact on malaria morbidity and mortality. Treatment 
failure or partial parasite clearance has the potential to allow dormant liver stages of 
P. vivax and P. ovale to become a source of parasite reservoir for onward transmission. 
Furthermore, untreated low-grade chronic infections caused by P. malariae have been 
reported to cause systemic diseases many years after the primary infection. Spatial 
analysis of malaria epidemiology showed that malaria parasite transmission in 
Daraweesh was focal, and that infections are not randomly distributed in the village. 
Two space-time clusters of significantly increased malaria risk were identified (1993-
1999, and 1998-1999) with marked variations between households, but little or no 
variation in the species of Plasmodium over time. Similarly, multiple significant 
clusters were identified for the parasite species; three for P. falciparum, two for P. 




frames, with some of the species significantly infecting the same households. This 
suggests that even in a small geographic area malaria transmission shows 
heterogeneity, and that such data can provide useful information to guide malaria 
control efforts. Finally, I demonstrated that 3D7 P. falciparum parasite growth was 
similar in the erythrocytes of different blood group donors, and provide preliminary 
data to show that the non-coding RNA gene, PF3D7_1370800, is differentially 
expressed in blood group A donors relative to blood groups B and O donors. Further 
research is needed to better understand the role of this gene in malaria pathology.  
All together, these findings will aid malaria researchers and other stakeholders in 
making informed choices about tools for diagnosing Plasmodium species, and control 
programmes targeting eradication of malaria caused by all Plasmodium species, as is 








































This thesis focussed on malaria, a parasitic disease caused by Plasmodium parasites. 
The disease affects over half of the world’s population, most especially in Sub-Saharan 
Africa. Four species of Plasmodium (P. falciparum, P. ovale, P. malariae and P. vivax) 
are responsible for malaria in Africa. Individuals can be exposed to or infected with 
more than one species of the Plasmodium parasite (defined as mixed-species 
infections) either at the same time or sequentially. However, in clinical diagnosis, 
mixed-species infections are often not recognised by microscopy, which is the most 
widely used laboratory method for diagnosing the disease. In view of this the 
prevalence and magnitude of disease burden caused by the non-falciparum species in 
endemic population are not well documented. The Plasmodium parasite is an obligate 
intracellular parasite, meaning it must continuously live in a living cell. Its blood-stage 
life cycle in humans takes place within the red blood cells. On the surfaces of these 
red blood cells are the ABO blood group antigens that have been associated with an 
individual’s likelihood of being susceptible or resistant to developing severe malaria. 
However, there has been no study on the gene expression changes when a single clone 
of Plasmodium parasite infects individuals of different blood groups.  
In this thesis, I assessed ways of improving the diagnosis of the species of malaria 
parasites using proteins derived from the surface of the Plasmodium parasite called 
merozoite surface proteins (also known as MSP-119). I further investigated the 
contribution of these species to the clinical and treatment outcomes, and determined 
the spatial and temporal dynamics of malaria. Finally, I determined gene expression 
changes in P. falciparum parasites as they infect red blood cells of different ABO 
blood groups. The blood samples used for the laboratory work in this thesis were 
obtained from studies carried out in three villages in Zimbabwe (Burma Valley, 
Mutoko and Chiredzi), Daraweesh in eastern Sudan, and Edinburgh in the UK. 
I found that the MSP-119 antigens are very sensitive and capable of detecting the 
specific type of Plasmodium species an individual has recently or previously been 
exposed to. Although most people were usually infected with or exposed to P. 




infections involving P. falciparum and one or more of the other species. Majority of 
these people with mixed-species infections failed to clear the parasites with the 
standard single course of chloroquine treatment and required repeated treatment with 
either chloroquine and/or sulfadoxine-pyrimethamine. Analysis of the space-time 
dynamics of malaria in the small village of Daraweesh in Sudan showed that malaria 
parasite transmission was very focal and localised in certain parts of the village at 
certain transmission seasons. I identified two significantly increased clusters of 
malaria risk (1993-1999, and 1998-1999) which varied very much between 
households. Similarly, multiple significant clusters were identified for the four parasite 
species; three for P. falciparum, two for P. vivax and P. malariae, and one for P. ovale. 
These clusters had overlapping time frames, with some of the species significantly 
infecting the same households. Parasite growth in the red blood cells of different ABO 
blood group donors was similar. The non-coding RNA gene, PF3D7_1370800, for 
which not much is currently known was found to be expressed more in blood group A 
donors relative to blood groups B and O donors. 
This thesis highlights the need to explore MSP-119 antigens as a diagnostic tool for 
malaria diagnosis. This will enable a better assessment of the prevalence and 
magnitude of the disease burden caused by all Plasmodium species in malaria endemic 
population. Drug treatment failure associated with mixed-species infections has major 
implications on morbidity and mortality of disease. There is therefore the need for 
healthcare providers to identify the specific type of Plasmodium parasite(s) an 
individual is infected with so as to administer appropriate medication, and monitor 
treatment to prevent the development of drug resistant parasites. The findings of the 
space-time analysis suggests that even in a small geographic area malaria parasite 
transmission shows heterogeneity, and that such data can provide useful information 
to guide malaria control efforts. The findings presented in this thesis will aid malaria 
researchers and other stakeholders in making informed choices about intervention 
tools for control programmes targeting eradication of malaria caused by all 
Plasmodium species. These findings are currently being incorporated into future 
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ACD Acid citrate dextrose 
ADCC Antibody dependent cellular cytotoxicity 
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ANOVA Analysis of variance  
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EIA Enzyme immunoassay 
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MDA Mass drug administration 
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ncRNA Non-coding Ribonucleic acid 
OD Optical density 
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PBS Phosphate buffered saline 
PBST Phosphate-buffered saline Tween 
PCR Polymerase chain reaction 
PfEMP1 P. falciparum erythrocyte membrane protein 1 
PfSUB P. falciparum subtilisin  
pLDH Parasite lactate dehydrogenase 
RDTs Rapid diagnostic tests 
RPMI Roswell Park Memorial Institute 
RNA Ribonucleic acid 




SD Standard deviation 
SDS Sodium dodecyl sulfate 
SP Sulfadoxine-pyrimethamine 
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Chapter 1.  General introduction 
Malaria is a vector-borne disease caused by unicellular protozoan parasite of the genus 
Plasmodium. It is one of the most important public health diseases, with both economic 
and health implications in tropical and Sub-Saharan Africa (WHO 2015). The disease 
remains a major cause of death and morbidity worldwide, affecting the lives of people 
in over a 100 countries and is responsible for the annual worldwide death of 
approximately half a million people, mostly in Sub-Saharan Africa (WHO 2015, WHO 
2014).  
In malaria endemic areas children under the age of five years and pregnant women 
carry the heaviest burden of disease (Milner 2017). Early disease diagnosis, treatment 
and close monitoring/management are crucial in preventing the development of severe 
or life-threatening malaria (Bhatt et al. 2015). Severe malaria is a rare clinical 
outcome, and is mostly seen in children below the age of five years; it is caused 
predominantly by Plasmodium falciparum (Goncalves et al. 2014). However, the non-
falciparum species are equally capable of causing chronic or fatal disease when they 
are undetected by conventional diagnostic tools, or parasitaemia caused by them 
becomes sub-clinical without full cure (Vinetz et al. 1998). For example, acute febrile 
episodes of P. vivax infections are associated with anaemia, intrauterine growth 
retardation (McGready et al. 2012), miscarriage, and severe and fatal disease (Baird 
2013, Rodriguez-Morales et al. 2008, Tjitra et al. 2008, Barcus et al. 2007). Both 
parasite and host factors play key roles in the clinical outcomes and the heterogeneity 
that arise following infection with Plasmodium parasites (Vignali et al. 2011, Gupta 
et al. 1994). Parasite factors include the species and genotype of the Plasmodium 
causing disease (Ariey et al. 2001), parasite genes expressed during infection (Vignali 
et al. 2011), and polymorphism in parasite antigens on infected red cells (Smith et al. 
2013). Host factors may include age, genetics (Driss et al. 2011, Luzzatto 1974), and 
red cell surface antigens such as the ABO blood group antigens (Cooling 2015, Gupta 
and Chowdhuri 1980). In this thesis I have considered the contribution of the species 
of Plasmodium parasite and the ABO blood group system to heterogeneity in clinical 





Malaria in Sub-Saharan Africa is caused mainly by four species of the Plasmodium 
parasite, (P. falciparum, P. vivax, P. malariae and P. ovale). In the forest regions of 
South-East Asia, P. knowlesi is increasingly being reported in human populations as 
causing zoonotic disease (Cox-Singh and Singh 2008, Cox-Singh et al. 2008). In terms 
of research, drug and vaccine developments, attention has been heavily devoted to P. 
falciparum because it is the species associated with increased mortality (PATH 2011, 
Oliveira-Ferreira et al. 2010). In several countries currently implementing malaria 
control programmes, the control strategies are mainly directed toward malaria caused 
by P. falciparum (Abeyasinghe et al. 2012, Oliveira-Ferreira et al. 2010). Further 
evidence demonstrating the neglect of the non-falciparum species is seen in worldwide 
malaria endemicity surveys that are only focussed on P. falciparum mortality owing 
to limited availability of data on the other species (Gething et al. 2016, Hay et al. 
2009). This attention on one Plasmodium species poses a danger as knowledge on the 
non-P. falciparum species and their clinical and treatment profiles in endemic areas is 
not well understood. The health implication of focusing on one species is seen in the 
relative rise in the prevalence and the overall malaria burden caused by the non-
falciparum species in areas where progress has been made at controlling P. falciparum 
malaria (Abeyasinghe et al. 2012, Oliveira-Ferreira et al. 2010). 
 
The diagnosis of malaria has long been achieved by microscopy of blood films stained 
by Giemsa (Fleischer 2004, Giemsa 1904). This method is considered the ‘gold 
standard’ and is based on detailed examination of stained blood films for characteristic 
Plasmodium species blood-stage morphological features such as the size and shape of 
asexual blood-stage parasites, pigment granules, presence of cell inclusions, as well as 
the size and shape of the infected erythrocyte (Obare et al. 2013, Payne 1988). 
Although microscopy is the reference method, it has some limitations, including the 
need for highly experienced technicians, variability in smear quality, the inability to 
determine malaria species at low parasitaemia, and the loss of slide quality with time 
(Barber et al. 2013, Payne 1988). In view of this, the presence or absence of blood 
stage parasites is frequently reported rather than determining the species of 





In malaria endemic areas, humans may be infected and harbour mixed-Plasmodium 
infections in various combinations and there are several reports of deficit of mixed 
infection possibly owing to undiagnosed cases or underestimation of mixed-infections 
(Mayxay et al. 2004, Bruce and Day 2002, Bruce et al. 2000). Mixed-species 
infections are therefore far more common than is generally reported (Mayxay et al. 
2004, Mehlotra et al. 2000). P. malariae and P. ovale infections have been 
underestimated or under researched, and morbidity and mortality associated with these 
species, either as mono- or in mixed-infection are still poorly defined and quantified 
(Collins and Jeffery 2007, Collins and Jeffery 2005). In recent years, however, there 
has been a greater focus on malaria caused by P. malariae and P. ovale, with a view 
to understanding their long-term contribution to disease and pathology (Daniels et al. 
2017, Sutherland 2016, Rayner 2015). These recent developments in malaria research 
have heightened the need for a clear knowledge of the epidemiology of these species 
and their associated clinical outcomes and treatment requirements. 
 
On the surface of human erythrocytes are antigens belonging to the various blood 
group systems (Cooling 2015, Fung 2014, Reid 2012, Daniels 2002). Antigens of the 
ABO blood group system are the most important of all blood group antigens, owing to 
their importance in ABO compatibility and transfusion medicine (Fung 2014). The 
Plasmodium parasite’s life cycle in the human host (discussed in Section 1.1.1 on page 
5) takes place inside the erythrocytes (White et al. 2013a), the surfaces of which are 
found these blood group antigens. In malaria, the ABO blood group plays a role in the 
susceptibility or resistance of individuals to developing severe malaria (Rowe et al. 
2009b, Rowe et al. 2007). This finding is further strengthened by the worldwide 
distribution patterns of ABO blood group types and malaria endemicity. Blood group 
O individuals are more prevalent in malaria endemic regions compared to higher 
prevalence of blood group A individuals in regions where malaria is rare (Reid 2012, 
Cserti and Dzik 2007). In spite of the relationship between ABO blood group antigens 
and malaria, gene expression changes that occur when the same parasite clone infects 
host erythrocytes of different blood groups have not been characterised.  
This thesis is divided into two components: a seroepidemiological study (Chapters 3-




determined human IgG antibody responses to the four Plasmodium species in two 
African populations (Zimbabwe and Sudan). I used an enzyme-linked immunosorbent 
assay (ELISA) of Plasmodium merozoite surface proteins (discussed in more detail in 
Section 1.7) from all four human parasite species as a diagnostic tool. Subsequently, I 
characterised the outcomes of some observable clinical features (fever and 
parasitaemia) and treatment requirement associated with malaria caused by single P. 
falciparum versus mixed-Plasmodium species. Furthermore, the spatio-temporal 
dynamics of malaria based on malaria epidemiology in Daraweesh, a village in eastern 
Sudan has been characterised.  
 
For the gene expression study, I cultured a single clone of P. falciparum 3D7 parasite 
in the erythrocytes of individuals belonging to three different ABO blood groups 
(Groups A, B and O), harvested and sequenced parasite RNA, and determined the 
differential parasite gene expression changes that occurred between the different blood 
group types.  
 
The findings of the seroepidemiological work highlight the higher prevalence of 
mixed-species Plasmodium infections in Africa and their associated drug treatment 
failures, and provide important information that could be incorporated into new 
malaria research and malaria elimination programmes by African governments and 
policy makers, as is the case in Sudan. The gene expression study provides some 
preliminary data that could be investigated further to better understand the role of ABO 












1.1 Plasmodium species and malaria 
1.1.1 The biology of Plasmodium parasites 
Plasmodium parasites have a complex life cycle (summarised in Figure 1.1.1) that 
takes place in both the invertebrate definitive host, the female Anopheles mosquito, 
and the vertebrate intermediate human host. The exogenous sexual cycle, sporogony, 
takes place in the mosquito, while the asexual cycle, schizogony, occurs in the human 
host (White et al. 2013a). The cycle begins with the inoculation of between 10-100 
motile sporozoites from the salivary duct of an infected female Anopheles mosquito 
into a susceptible host’s subcutaneous tissues during blood meal by the vector 
(Prudencio et al. 2006). The most prevalent of these mosquito species in Africa are 
Anopheles gambiae sensu stricto, An. funestus, and An. arabiensis (Sinka et al. 2010). 
In the human host the Plasmodium paraites’ life cycle occurs in the liver and the blood. 
The sporozoites enter the host’s hepatocytes, undergo nuclear divisions, multiply and 
produce between 10,000 and up to 30,000 daughter merozoites in 5·5–16 days 
(depending on the species of Plasmodium) within a hepatocyte (Bruce and Day 2002, 
Bruce et al. 2000, Murphy and Oldfield 1996, Garnham 1988b). Some biological 
differences in the life cycle of the four human Plasmodium species that may affect the 
growth potential of the parasites in the human host are summarised in Table 1.1.1 
(Bruce and Day 2002). 
In P. vivax and P. ovale infections, some intrahepatic forms remain dormant as 
hypnozoites for between two weeks to more than a year, and these may serve as 
reservoir responsible for the relapses that are characteristic of infections caused by 
these two species (Markus 2011b, White 2011, Douglas et al. 2011, Krotoski et al. 
1980). When the hepatic schizont ruptures, merozoites are liberated that invade new 
erythrocytes (Miller et al. 2002, Weatherall et al. 2002). On the surface of these 
merozoites are merozoite surface protein 1 (MSP-1) (Holder 1988, Holder et al. 1985, 
Holder and Freeman 1982) that I have used for the serological work described in this 
thesis (MSP-1 is discussed later in more detail in Section 1.7). These merozoites 




erythrocyte, depending on the species (Bruce et al. 2000), that in turn invade new 
erythrocytes to propagate the cycle.  
 
 
Figure 1.1.1: Lifecycle of Plasmodium parasite in the mosquito and human hosts. 
Sporozoites from the salivary duct of an infected female Anopheles mosquito are injected into 
a host’s subcutaneous tissues during blood meal, that travel to the liver. After the liver stage 
development, tens of thousands of merozoites are released into the blood that invade red blood 
cells. The parasites then undergo repeated rounds of asexual multiplication. In each cycle, a 
small proportion of parasites commit into the development of the sexual form of the parasite, 
the gametocyte. The merozoite surface protein 1 (MSP-1) (discussed in more detail in Section 
1.7) which is the most abundant protein on the merozoite surface (Holder et al. 1992) and the 
ABO blood group antigens on red blood cells (Fung 2014) are the focus of the data presented 
























P. falciparum  5.5–7 30 000 48 16-24 Yes No All types 
P. vivax 6-8 10 000 48 14-20 No Yes Reticulocytes 
only 
P. malariae 14-16 15 000 72 8-10 No No Older RBC 
P. ovale 9 15 000 50 6-12 No Yes Reticulocytes 
only 




The asexual cycle in the erythrocytes takes approximately 48 h for P. falciparum, P. 
vivax, and P. ovale, and 72 h for P. malariae (White et al. 2013a, Bruce and Day 2003, 
Biggs and Brown 2001, Gilles 1993, Garnham 1988b, Shute 1988). This blood stage 
asexual replication cycle is associated with exponential growth in parasite numbers, 
such that in a susceptible individual, the parasite population can expand by between 
six and 20 times per cycle (Simpson et al. 2002). The work in Chapter 6 of this thesis 
discusses the gene expression patterns when a single clone of P. falciparum grown in 
the erythrocytes of different ABO blood group individuals 
At a parasitaemia of approximately 50 parasites/μL of blood, Plasmodium blood-stage 
parasites and parasite antigens are respectively detectable by microscopy and rapid 
diagnostic tests (White et al. 2013a). The period of time from sporozoite innoculation 
by the mosquito and the first appearance of trophozoites in the erythrocytes is called 
the “prepatent period” (Murphy and Oldfield 1996). This period is species-dependent 
and ranges from 9 days in P. falciparum, to 15 days in P. malariae (White et al. 2013a). 
It is at this stage that the symptomatic manifestation of clinical complications such as 
chills, fever, anaemia, and multiple organ failure associated with malaria become 
evident (McQueen and McKenzie 2006, Mackintosh et al. 2004, Ramasamy 1998). It 
has long been suggested that the fever and chills associated with malaria are a 
consequence of paraite waste products such as haemozoin, a malaria pigment, released 
from the degradation of haemoglobin in the erythrocytes by the actively growing 
merozoites (Golgi 1889). Nutrient importation and disposal of toxic waste are brought 
about by the intraerythrocytic merozoites’ ability to modify the cell membrane (White 
et al. 2013a).  
All four human Plasmodium species are capable of rosette formation (Lowe et al. 
1998, Angus et al. 1996, Udomsanpetch et al. 1995). Rosetting is a phenonemon in 
which Plasmodium-infected erythrocytes adhere to non-infected erythrocytes with 
pathological consequences (Newbold et al. 1999, Newbold et al. 1997, Rowe et al. 
1995). After several cycles of erythrocyte invasion, release and re-invasion, some 
blood-stage parasites develop into long-lived sexual forms, male microgametocytes 
and female macrogametocytes. These sexual forms can be ingested by competent 




development of the parasites in the vector (Biggs and Brown 2001). In the stomach of 
the mosquito, fusion of micro- and macrogametes occurs by meiosis leading to the 
formation of a zygote, which is able to penetrate the mosquito’s midgut and develops 
into an oocyst. Asexual division of the mature oocyst leads to the formation of 
sporozoites that migrate to the salivary glands in readiness to be injected into a new 
susceptible human host (Gilles 1993). 
1.1.2 Global burden, distribution and epidemiology of malaria 
Malaria is estimated to affect the lives of nearly 3 billion people in over a 100 countries 
(WHO 2015), the distribution of which is illustrated in Figure 1.1.2 on page 10. 
Malaria is responsible for the annual worldwide death of more than half a million 
people (WHO 2015, WHO 2014, WHO 2013). The geographical distribution of 
malaria parasites depends on the ecology and the vectorial capacity of the Anopheles 
mosquito host (Hay et al. 2004, Murray and Lopez 1997). 
P. falciparum is found in almost every malaria endemic region of the world and causes 
the heaviest burden of disease, both in terms of morbidity and mortality (White et al. 
2013a). This burden is predominantly highest in children under the age of five years 
and pregnant women in Sub-Saharan Africa (WHO 2015, WHO 2013).  
P. vivax has the widest geographic area of all the human malaria parasites, extending 
into temperate climates (Howes et al. 2016, Howes et al. 2015). Although mortality 
associated with this species is lower than P. falciparum, morbidity associated with it 
is high (Poespoprodjo et al. 2009). P. vivax accounts for 6% of all global malaria cases, 
and outside of Sub-Saharan Africa, it contributes to more than half of all malaria cases 
(Howes et al. 2016, WHO 2014). Intracellular dormant liver stages of this species 
serve as a parasite reservoir and are protected from host immune response. P. vivax 
requires the Duffy antigen for merozoite invasion of red blood cells. Most populations 
in Sub-Saharan Africa lack these Duffy antigens and are considered to be refractory to 
P. vivax infection (Howes et al. 2011, Carter and Mendis 2002). Recent evidence from 
epidemiological studies from Africa, however, suggests the contrary (Fru-Cho et al. 






Figure 1.1.2: Worldwide distribution of malaria endemic areas according to high, 
moderate and low prevalence areas in 2014.  
Sourced from the World Health Organization online resource: 
http://www.who.int/malaria/publications/world_malaria_report_2014/wmr-2014-no-
profiles.pdf [Accessed 20/09/2016]. 
P. malariae is found throughout the tropical world from Africa to South America, and 
remains the most understudied species among the four human malaria parasite (Collins 
and Jeffery 2007). This is partly because it causes low-grade chronic infections and is 
often seen in mixed infections with P. falciparum rather than as a monospecies 
infection, and therefore is frequently undiagnosed (Rayner 2015, Dinko et al. 2013, 
Mueller et al. 2007, McKenzie and Bossert 1999, Black et al. 1994). The worldwide 
distribution of P. malariae overlaps with that of P. falciparum (Collins and Jeffery 
2007). Malaria caused by this species is mostly diagnosed only when molecular 
techniques such as polymerase chain reaction (PCR) are employed (Snounou et al. 
1993), as they are frequently missed by microscopy owing to the low-level 
parasitaemia associated with it (Collins and Jeffery 2007). P. malariae is 
morphologically identical to P. rhodaini in African apes, and P. brasilianum in New 
World monkeys in South America (Coatney et al. 1971). Recent evidence of cross-
species transmission of P. brasilianum from monkey to man (Lalremruata et al. 2015) 




infection (Rayner 2015). The few epidemiological studies focusing on this species are 
largely on hospital-based case studies and in returnees who have recently or previously 
visited a malaria-endemic country (Sutherland 2016, Savargaonkar et al. 2014, 
Badiane et al. 2014, Senn et al. 2014, Hommel et al. 2013). 
P. ovale has a much more limited distribution, and can be found in tropical Africa, 
New Guinea, the eastern parts of Indonesia and the Philippines (Collins and Jeffery 
2005, Lysenko and Beljaev 1969), as well as in the Middle East (Al-Maktari et al. 
2003) and in parts of India (Jambulingam et al. 1989). Much of the epidemiological 
studies on this species are confined to studies in highly endemic areas in Africa and 
the Southwest Pacific, with not many documented studies from South America and 
Asia (Mueller et al. 2007). Similar to P. vivax, this species also forms dormant liver 
stage parasite that can persist in the host for a long time (Markus 2015, Markus 2011a, 
Markus 2011b). 
1.2 Clinical manifestations of malaria 
The species and genotype of the infecting Plasmodium parasite, and the 
immunological status of the infected individual contribute to the clinical outcomes 
associated with malaria (Milner 2017, Miller et al. 2013). The pathology of malaria 
arises as a consequence of the release of parasite toxins into the bloodstream (Miller 
et al. 2013), destruction of infected erythrocytes (Buffet et al. 2011), host immune 
response to parasite antigens (Clark et al. 2006) and sequestration of infected 
erythrocytes by P. falciparum (White et al. 2013b). Fever, though non-specific to 
malaria, and undifferentiated from that caused by other pathogens is a classical 
hallmark of malaria (Gazzinelli et al. 2014).  
 
Fever is defined as an increase or a rise in body temperature caused by the actions of 
thermoregulatory pyrogens on the hypothalamus (Walter et al. 2016, Oakley et al. 
2011). The American College of Critical Care Medicine, the International Statistical 
Classification of Diseases, and the Infectious Diseases Society of America, all define 
fever as a core body temperature of 38.3°C (Walter et al. 2016, O'Grady et al. 2008). 




are generally defined as having fever (Seyoum et al. 2017, McKenzie et al. 2006, 
Creasey et al. 2004). In 1886, Camillo Golgi recognized that malaria fever coincides 
with the cyclical release of merozoites during schizont rupture of the infected 
erythrocyte (Golgi 1889). Such fevers occur every 48 h (defined as tertian fever) in P. 
falciparum, P. ovale and P. vivax infections, and every 72 h (defined as quartan fever) 
in P. malariae infections (Bruce and Day 2002, Gilles 1993, Garnham 1988b). Fever 
may be is beneficial to the host and plays important roles such as inhibition of 
Plasmodium parasite growth (Kwiatkowski 1990), and the enhancement of both the 
innate and adaptive immune response against pathogens through higher maturation 
rates of immune cells (Tomiyama et al. 2015, Tournier et al. 2003). 
 
The WHO recommends all cases of suspected malaria to be confirmed by 
parasitological diagnosis before treatment (referred to as “test, treat and track”) (WHO 
2015, WHO 2014). However, in resource-poor malaria endemic areas, presumptive 
treatment of malaria especially in children under the age of five years is based on fever 
presentation (Singh and Sharma 2014) and the clinical judgement of health care 
providers, without laboratory confirmation (Kyabayinze et al. 2010, Chandler et al. 
2008). This usually leads to overdiagnosis and overestimation of the malaria burden 
(Bhatt et al. 2015), since all fevers are not a consequence of malaria.  
 
For example, a study in Kenya found between 7 and 57.2% of children who were 
presumptively diagnosed and treated with antimalarial drugs to be negative for malaria 
upon examination of blood for the presence of parasites (Onchiri et al. 2014). 
Similarly, in Angola, overdiagnosis of malaria cases based on clinical presentations 
was found to have an average error rate of 85% after microscopic examination of blood 
smears (Manguin et al. 2017). Given that other bacterial and viral diseases may present 
with fever that are undifferentiated from that caused by malaria (Kallander et al. 2004, 
Genton et al. 1994, O'Dempsey et al. 1993), treatment of every childhood fever with 
antimalarial drugs without laboratory confirmation might contribute to drug misuse 
and wastage (Manguin et al. 2017), and promotes the emergence of drug-resistant 




overestimated in such settings, while other causes of fever may remain undiagnosed 
(Manguin et al. 2017, Chandler et al. 2008). 
 
Other characteristic symptoms associated with malaria include headache, nausea, 
abdominal discomfort and vomiting, as well as muscular and joint aches (Gazzinelli et 
al. 2014). While prompt diagnosis and treatment will ensure parasite clearance and 
avert any complications (Singh and Sharma 2014, Lambrechts et al. 1999), untreated 
cases of malaria may lead to severe malaria characterised by metabolic acidosis 
(Greenwood et al. 2005), respiratory distress (Schellenberg et al. 1999), prostration 
(Demissie and Ketema 2016), severe anaemia (haemoglobin concentration below 5 
g/dl) due to erythrocyte destruction and impaired erythropoiesis (Haldar and 
Mohandas 2009), repeated convulsions, hypoglycaemia (blood glucose <2.2 mmol/l), 
coma and death (WHO 2014). 
 
Of the four species of human Plasmodium parasites, P. falciparum is responsible for 
life-threatening disease and complications such as severe anaemia (Haldar and 
Mohandas 2009), cerebral malaria (Schofield and Grau 2005), renal failure and hepatic 
dysfunction (Badiane et al. 2014). P. vivax and P. ovale infections may result in the 
development of relapse many months or years after the primary infection, due to 
reactivation of the dormant liver-stage forms, the hypnozoites (Markus 2011b, 
Krotoski et al. 1980). P. malariae although causes very low morbidity, is capable of 
causing long-term chronicity that can result in nephrotic complications (Badiane et al. 
2014, Gilles and Hendrickse 1960) and splenomegaly (Vinetz et al. 1998). This species 
has also been associated with drug treatment failures in undiagnosed mixed-species 
infections by unknown mechanisms (Smith et al. 2011). 
 
1.3 Malaria diagnosis 
Early and effective diagnosis of malaria is key to the treatment and management of 
disease, thereby reducing associated complications and mortality (McKenzie et al. 
2003, Lambrechts et al. 1999). Ideal diagnosis of malaria involves a combination of 
physical examination for clinical signs and symptoms of the disease and confirmation 




Bain et al. 1997). Clinical signs and symptoms of malaria such as fever, headache, 
chills and abdominal pain (WHO 1990), are however non-specific, as these are also 
common with other parasitic, viral and bacterial infections (Kallander et al. 2004, 
O'Dempsey et al. 1993). In view of this, clinical diagnoses of malaria alone is often 
imprecise (Manguin et al. 2017, Onchiri et al. 2014), although it is the basis of 
therapeutic care for the majority of febrile patients in resource-poor malaria endemic 
areas, where laboratory confirmations are unavailable (Manguin et al. 2017, Roucher 
et al. 2012).  
Confirmatory diagnosis of malaria is accomplished by identifying asexual blood-stage 
parasites by microscopy (WHO 2000, Bain et al. 1997, Payne 1988), detection of 
parasite antigens and antibodies in blood using rapid diagnostic tests (RDTs) (Wilson 
2012, Moody and Chiodini 2002) and the application of molecular techniques such as 
the polymerase chain reaction (Snounou et al. 1993). 
1.3.1 Microscopy of Giemsa-stained blood films 
Conventional laboratory diagnosis in clinical settings is by microscopic examination 
of Giemsa-stained thick and thin peripheral blood smears for parasite identification 
and species differentiation respectively of the asexual blood stages of the Plasmodium 
parasites (Bain et al. 1997). This involves identifying morphologic characteristics such 
as the size of the infected red blood cell, cytoplasmic inclusions (e.g. Schuffner’s dots 
found in P. vivax and P. ovale) and features of the parasite blood stages (McKenzie et 
al. 2003, Bain et al. 1997). Microscopy has the advantage of parasite identification, 
species differentiation (when performed by expert microscopists), quantitative 
enumeration of parasite density and pigment identification (Bronzan et al. 2008, 
Chotivanich et al. 2007).  
In spite of the above advantages, microscopy has many challenges. It is influenced by 
the type of species, endemicity and parasitaemia, host immunity, sequestration, and 
observer factors (Obare et al. 2013). In most African countries where malaria is 
endemic, laboratory facilities for the confirmation of the disease at the periphery of the 
health care system are inadequate or unavailable (Cibulskis et al. 2011), owing to lack 




2000). Additionally, the processes from blood sampling, slide preparation, staining, 
and examination are time consuming (Barber et al. 2013). This often results in clinical 
decisions being taken without laboratory confirmation, especially for children under 
five years old (WHO 2000). Microscopy has the added limitation of an observer’s 
inability to differentiate between the blood-stages of the different Plasmodium species 
(Barber et al. 2013), as the morphological differences between these species are very 
subtle. Examples of these morphological differences among the four Plasmodium 
species are summarised and illustrated in in Table 1.3.1 and Figure 1.3.1 on page 16 




Table 1.3.1: Morphological differences exist in the blood-stage parasites of human Plasmodium Species.  
Plasmodium 
spp. 
Rings Trophozoites Schizonts Gametocytes Appearance of ring-
infected RBC 




Seldom seen in peripheral 
blood; compact cytoplasm; 
dark pigment 
Seldom seen in 
peripheral blood; dark 
pigment clumped in 
one mass 
Crescent or sausage shape; 
chromatin in a single mass or 
diffused; dark pigment mass 
Normal size; multiple 
infection common 
P. vivax Large cytoplasm; large 
chromatin dot 
Large amoeboid cytoplasm; 
large chromatin dot; 
yellowish-brown pigment 




Round to oval; may almost fill 
RBC; chromatin compact, 
eccentric or diffused; scattered 
brown pigment 
Normal to 1.25x nRBC; 
occasionally fine 
Schuffner’s dots 
P. malariae Sturdy cytoplasm; large 
chromatin dot 
Compact cytoplasm; large 
chromatin dot; dark brown 
pigment 
Large nuclei, clustered 
around mass of coarse; 
dark-brown pigment 
Round to oval; may almost fill 
RBC; chromatin compact, 
eccentric or diffused; scattered 
brown pigment 
Normal to 0.75x nRBC 
P. ovale Sturdy cytoplasm; large 
chromatin dot 
Compact with large 
chromatin; dark-brown 
pigment 
Large nuclei, clustered 
around mass of coarse; 
dark-brown pigment 
Round to oval; may almost fill 
RBC; chromatin compact, 
eccentric or diffused; scattered 
brown pigment 
Normal to 1.25x nRBC; 
round to oval; 
occasionally Schuffner’s 
dots 
Adapted from Centers for Disease Control and Prevention (CDC) (accessed https://www.cdc.gov/dpdx/malaria/dx.html, on 15/05/2017). 





Figure 1.3.1: Morphological differences exist in the blood-stage parasites of 
human Plasmodium Species. Giemsa-stained thin blood film of asexual blood-stage 
parasite development (ring, trophozoite and schizont) of P. falciparum, P. vivax, P. 





The difficulty in differentiating the morphology of the different species may lead to 
misdiagnosis of the type of Plasmodium species and in cases of mixed-species 
infections, result in underestimation (Obare et al. 2013, Harris et al. 2010, Mayxay et 
al. 2004). This is often seen even when expert research microscopists are involved in 
malaria diagnosis by microscopy (Obare et al. 2013, McKenzie et al. 2006), as 
detection levels of parasites by microscopy is 40 parasites per µL of blood (Bruce et 
al. 2008, Zimmerman et al. 2004).  
In very low transmission regions, low parasitaemia of <5 infected erythrocytes per 
microliter of blood can make species identification by microscopy very difficult, if not 
impossible (Zimmerman et al. 2004). Moreover, microscopists who are not frequently 
‘exposed’ to examining the different Plasmodium species often misdiagnose mixed-
species infections or report the presence of parasites without speciation (Obare et al. 
2013). The ‘non reporting’ of the species of Plasmodium an individual is infected with 
owing to the above outlined limitations of microscopy is addressed in this thesis by 
the application of a sensitive diagnostic tool based on Plasmodium merozoites surface 
proteins (discussed in more detail in Section 1.7 and Chapters 3 and 4). 
1.3.2 Rapid diagnostic tests (RDTs) 
Rapid diagnostic tests (RDTs) are based on immunochromatographic methods for the 
detection of antigens derived from Plasmodium parasites in lysed blood (Moody and 
Chiodini 2002, Shiff et al. 1994). Most RDTs employ a dipstick or test strip with 
monoclonal antibodies incorporated and directed against the target parasite antigens 
(Wilson 2012).  
Three parasite antigens commonly targeted in commercial RDTs kits include histidine-
rich protein II (HRP-II) (Shiff et al. 1993), parasite lactate dehydrogenase (pLDH) and 
aldolase (Palmer et al. 1998). HRP-II is a water-soluble protein produced by 
trophozoites and young gametocytes of P. falciparum and abundantly expressed on 
red blood cell membrane (Rock et al. 1987, Howard et al. 1986). Plasmodium parasite 
LDH is an enzyme produced by both the asexual and sexual stages of Plasmodium 
parasites (Makler and Hinrichs 1993). Both pLDH and aldolase are enzymes essential 




pan-specific antigens such as aldolase, or pan-Plasmodium pLDH (Wilson 2012, 
Tangpukdee et al. 2009, Meier et al. 1992).  
RDTs offer the advantage of being simpler to perform and to interpret, requiring no 
electricity or special equipment or training and thereby making it possible for 
peripheral health workers to be trained on its usage (Harvey et al. 2008).  
There are currently over 86 varieties of RDTs on the market, examples of which 
include Paracheck, ParaHit-F, ParaSight-F test, SD Bioline, ParaScreen, and 
OptiMAL test (Tangpukdee et al. 2009, Palmer et al. 1998, Shiff et al. 1994, Shiff et 
al. 1993). Test kits currently available that report detection of pLDH from all four 
Plasmodium species that infect humans are able to distinguish P. falciparum from P. 
vivax, but not between P. vivax, P. ovale and P. malariae infections (Hemingway et 
al. 2016, Graves et al. 2015, WHO 2013, Wilson 2012, WHO 2000). Such test kits 
although claim to detect all four Plasmodium species make mention of only P. 
falciparum and P. vivax in their brand name or marketing material (WHO 2013). At 
very low parasitaemia, most RDTs are less sensitive for the detection of P. vivax 
(White et al. 2013a). This is an essential shortcoming of these RDTs as they are unable 
to detect mixed Plasmodium species, especially of P. malariae and P. ovale. RDTs 
have the added disadvantage of high cost, making them not readily available at all 
peripheral health facilities. Sensitivity of >90% is usually reported for RDTs in the 
detection of P. falciparum at densities above 100 parasites per μL of blood, however, 
sensitivity decreases markedly below this parasite threshold (Wilson 2012, WHO 
2000).  
Table 1.3.2 on the next page shows examples of the most commonly used RDTs or 
commercial kits available on the market, the target antigens incorporated and the 











Para Sight F Becton-Dickson, USA HRP-II P. falciparum 
Paracheck Orchid Biochemical, India HRP-II P. falciparum 








Malaria EIA Trinity Biotech’s Captia, 
USA 
MSP-119 of P. 
falciparum 










RDT: Rapid diagnostic test, HRP-II: Histidine Rich Protein II, pLDH: parasite lactate 
dehydrogenase, MSP: merozoite surface protein, EIA: enzyme immunoassay 
1.3.3 Immunofluorescence and molecular techniques  
In epidemiological surveys and screening of blood donors in most developed countries 
immunofluorescent antibody assay (IFA) which detects antibodies against asexual 
blood stage malaria parasites are employed (She et al. 2007). The use of IFA is simple 
and sensitive, but time-consuming (Tangpukdee et al. 2009). In most research 
laboratories, diagnosis of malaria is based on molecular techniques such as polymerise 




Molecular techniques such as PCR amplifies a selected region of the malarial 
genome, and offer the advantages of species identification, detection of parasites as 
low as 5 parasites/µL of blood (Snounou et al. 1993) and its application in 
identifying the development of drug-resistance parasites. However, PCR is of limited 
use in clinical settings in most developing countries, except in research laboratories, 
because it is expensive and requires a sophisticated laboratory manned with well-
trained staff (Daniels et al. 2017, Nkumama et al. 2016). 
1.4 Treatment of malaria  
Historically, treatment of uncomplicated malaria had been based on monotherapy (i.e. 
the administration of a single drug over the course of a number of days) with the 
administration of either chloroquine or amodiaquine until the emergence of 
chloroquine-resistant Plasmodium species in the mid-1980s (Wernsdorfer et al. 1995). 
Following two guidelines by the WHO in 2006 and 2010 most malaria endemic 
countries have moved away from chloroquine to artemisinin combination therapies 
(ACTs), which is the recommended treatment regime for uncomplicated malaria in 
children and adults (Dondorp et al. 2010, Baird 2008, Bosman and Mendis 2007).The 
exception is in pregnant women who are in their first trimester in which a seven day 
course of quinine with clindamycin is recommended (WHO 2015, Cui and Su 2009).  
ACT is a combination of artemisinin derivative which has a shorter elimination half-
life of about 1 hr (Cui and Su 2009, Nosten and White 2007) and a partner drug with 
a longer half-life (Chang 2016, White 1999a). The artemisinin component is effective 
against both asexual and sexual blood-stages of the Plasmodium parasites (Bousema 
et al. 2010b, Skinner et al. 1996), but has limited or no effect on hepatocytic parasites 
such as the hypnozoite forms of P. ovale and P. vivax (Chang 2016). The partner drug 
is subsequently able to clear any remaining parasites and also delays the development 
of resistance to artemisinin (Cui and Su 2009, White 1999a, White 1999b). 
Recommended ACTs combinations include artemether with lumefantrine, artesunate 
with either amodiaquine or mefloquine, dihydroartemisinin with piperaquine, and 




ACTs are administered based on patient age and body weight (Nosten and White 
2007). In addition to ACTs being generally tolerable by patients, they are generally 
very effective and safe (Cui and Su 2009, Nosten and White 2007). In malaria patients 
in which the species of Plasmodium is unknown it is recommended to treat as 
uncomplicated P. falciparum infection (WHO 2015). In areas with both chloroquine-
resistant and chloroquine-susceptible infections, the recommendation is to treat adults 
and children with confirmed P. vivax, P. ovale, or P. malariae malaria with the 
standard ACTs (Cui and Su 2009, Nosten and White 2007). Intravenous or 
intramuscular administration of artesunate in the first 24 hours is strongly 
recommended for severe malaria cases until such a time that patients can tolerate oral 
medication (WHO 2015, Cui and Su 2009).  
1.5 Antimalarial drug resistance 
Global malaria control and elimination efforts are hampered by the emergence and 
spread of antimalarial drug resistance parasite strains that follow the development of 
new drugs. This cyclical historic development has plagued malaria therapeutics for 
more than six decades. The first effective drug for treating malaria was the alkaloid-
type of compound, quinine. This was isolated in 1820 from the bark of cinchona tree 
by the French pharmacists, Pierre-Joseph Pelletier and Joseph-Bienaimé Caventou 
(Kaufman and Ruveda 2005). Quinine was the drug of choice widely used as 
prophylaxis or for the treatment of malaria until World War II (Chang 2016, Packard 
2014, Peters 1990). The mechanism of action of quinine is poorly understood, but it is 
generally believed to act on the asexual intra-erythrocytic stages of the four 
Plasmodium species (Peters 1990, Peters 1987a). The drug interferes with the 
parasite's ability to dissolve and metabolize haemoglobin (Peters 1970). This enables 
the free and toxic haem components to accumulate in the erythrocytes at higher 
concentrations and eventually kill the Plasmodium parasites. The first reported 
resistance of Plasmodium parasites to quinine was in 1910 in Thailand (Peters 1982). 
Resistance to this drug was however not widespread; and that even in the era of 
increased use of artemisinin-based combination therapies, quinine remains a first-line 




In 1934, German chemists developed a new antimalarial quinine derivative, 
chloroquine (Coatney 1963), which became the most widely used synthetic 
antimalarial drug during the 1950s to the 1970s. However, within a decade, 
chloroquine-resistant P. falciparum strains emerged (Eyles et al. 1963), notably in 
Colombia and at the Cambodia-Thailand border (Payne 1987, Peters 1970), an area 
that has become a historical site of emerging antimalarial-drug resistance. The reasons 
often cited for this high prevalence of drug resistance at the Cambodia-Thailand border 
include the way the drugs are used and the social and economic conditions prevailing 
at this location (Packard 2014). Resistant strains from the Cambodia-Thailand foci 
spread steadily in the 1960s and 1970s through South America, Southeast Asia, and 
India (Peters 1987a) (see map on Figure 1.5.1 on page 27). In Africa the first reported 
case of chloroquine-resistant P. falciparum was detected in Kenya in 1979 (Fogh et al. 
1979); followed by a wave of resistant P. falciparum across the continent within a 
decade (Peters 1987a, Mutambu et al. 1986, Ekue et al. 1983). The insurgence of 
chloroquine-resistant P. falciparum contributed to increased malaria-associated 
morbidity and mortality, notably among children in Africa (Anderson and Roper 2005, 
Trape et al. 1998, Greenberg et al. 1989).  
Chloroquine is a diprotic weak base and, at physiological pH (7.4), can be found in 
three forms, the uncharged, mono-protonated and di-protonated. The uncharged 
chloroquine is the only membrane permeable form of the drug and it freely diffuses 
into the erythrocyte up to the lysosomal isolated acidic compartment known as the 
digestive vacuole. In the digestive vacuole, the drug molecules become charged and 
accumulates into the acidic digestive vacuole, since the membranes are not permeable 
to charged species (Yayon et al. 1984, Homewood et al. 1972). It has been known that 
P. falciparum strains that are chloroquine sensitive accumulate much more 
chloroquine in the digestive vacuole than strains that are resistant to the drug (Saliba 
et al. 1998, Yayon et al. 1984). Chloroquine resistant is as a result of point mutations 
in the gene encoding for the P. falciparum chloroquine resistance transporter (PfCRT) 
protein (Djimde et al. 2001, Fidock et al. 2000, Wellems et al. 1991). However, there 




chloroquine sensitivity of parasites that carry the PfCRT mutation (Wellems 2004, 
Johnson et al. 2004). 
Chloroquine is still the first-line treatment for P. vivax malaria in areas where this 
species is endemic (Seifu et al. 2017). When chloroquine is given with primaquine, 
the combination is highly effective against both the acute infection and in preventing 
relapses caused by hepatic hypnozoite forms. Although P. vivax accounts for nearly as 
many cases of malaria as P. falciparum in areas where these two species are co-
endemic, and is exposed to similar high levels of chloroquine pressure, resistances to 
this species were not reported until 1989 in Papua New Guinea (Whitby et al. 1989), 
i.e. about three decades after chloroquine-resistant P. falciparum strains were first 
reported. Chloroquine-resistant P. vivax is now widespread across most countries 
endemic for the disease, especially in the regions of Southeast Asia (Baird et al. 1997) 
and in South America (Whitby 1997). In a systematic review and meta-analysis of the 
global extent of chloroquine-resistant P. vivax, Price et al., 2014 found that of the 129 
eligible clinical trials involving 21,694 patients at 179 study sites, and 26 case reports 
describing 54 patients, chloroquine resistance was present in 53% of 113 assessable 
study sites (Price et al. 2014). These were spread across most countries that are 
endemic for P. vivax. Clearance of parasitaemia assessed by microscopy in 95% of 
patients by day 2, or all patients by day 3, was 100% predictive of chloroquine 
sensitivity (Price et al. 2014). 
In an effort to combat resistant strains, a number of alternative synthetic antimalarial 
drugs were developed, including, sulfadoxine–pyrimethamine (commonly called 
Fansidar) and mefloquine. Sulfadoxine–pyrimethamine interferes with the synthesis 
of folic acid and by extension, the synthesis of nucleotides required for the parasite’s 
DNA synthesis. Sulfadoxine–pyrimethamine is often used as a second line drug in 
areas where chloroquine-resistant P. falciparum species are present (Creasey et al. 
2004). The drug’s resistance is conferred by a single mutation in the gene encoding 
the enzyme dihydrofolate reductase (Wu et al. 1996). Unlike chloroquine resistance to 
P. falciparum that took many years to develop in a limited number of foci, resistance 
to sulfadoxine–pyrimethamine was reported to have arose rapidly on many 




Since the year 2001 about forty countries have adopted the WHO’s recommended 
artemisinin-based combination therapy for treating uncomplicated malaria caused by 
P. falciparum (WHO 2006). About half of these countries have adopted the 
artemether-lumefantrine combination (commonly known as Coartem) as their first- or 
second-line treatment. The introduction of ACT therapy has resulted in the reduction 
of global malaria-related morbidity and mortality (Bhattarai et al. 2007, Carrara et al. 
2006, Barnes et al. 2005). Artemisinin and its derivatives are very potent antimalarial 
drugs and are capable of reducing parasite biomass to the order of ∼1/10 000 per 
cycle (White et al. 1999). Artemisinin works by accelerating parasite clearance (White 
2008) of young, circulating, ring-stage parasites and preventing the further maturation 
and sequestration of these parasites (ter Kuile et al. 1993). Artemisinin resistance 
parasite strains have been reported in Southeast Asia (Ashley et al. 2014, Dondorp et 
al. 2009, Noedl et al. 2008). This resistance has been shown to be associated with 
polymorphisms in the P. falciparum kelch protein gene located on chromosome 13 
(kelch13) (Ashley et al. 2014). In spite of its effectiveness and excellent safety and 
efficacy profile (White 2008), a decline in the parasite clearance rate by artemisinin 
has been documented in the last decade among patients near the Thai–Cambodian 
border (Dondorp et al. 2009). This area is most notable as resistances to other 
antimalarial drugs in the previous decades had originated from (Verdrager 1986). In 
this same area, increased numbers of copies of the mefloquine resistance gene 
PfMDR1 (Price et al. 2004) has been associated with high failure rates with 
artesunate–mefloquine therapy (Wongsrichanalai and Meshnick 2008, Alker et al. 
2007). The first reported indigenous artemisinin resistant P. falciparum strain from 
Africa was contracted from Equatorial Guinea by a Chinese returnee who had no 
previous clinical history of malaria (Lu et al. 2017).  
 
In parts of Africa, the median parasite clearance half-life by artemisinin is faster (1.9 
hours) compared to that seen along the Thailand–Cambodia border (7 hours) (Ashley 
et al. 2014). These slow clearing infections (parasite clearance half-life >5 hours) are 
strongly associated with kelch13 mutations (Ashley et al. 2014). There are also social 




Generally, the emergence of antimalarial drug resistant Plasmodium species are 
believed to be the consequence of widespread use and the drug’s availability over the 
counter in many countries where malaria is endemic (White 2004). For example, the 
high emergence of antimalarial drug resistance seen in Cambodia is often attributed to 
the migration of mine workers to the Pailin province from neighbouring regions of 
Cambodia, Thailand, Vietnam, and Myanmar, as well as from Bangladesh (Packard 
2014). It is estimated that about 1000 to 1200 migrant workers (80% with no immunity 
to malaria) arrive in Pailin each month (Verdrager 1995). The mining activities create 
hundreds of shafts, which collect water from seepage and rains. These shafts become 
a good breeding sites for Anopheles dirus population that are very highly efficient in 
transmitting Plasmodium parasites. These miners are said to usually stay for 3 to 4 
months, live in the open air and sleep under very rudimentary shelters, exposing them 
to multiple infective bites (Packard 2014). This cycle of drug development and the 
development of resistant parasite strains threatens worldwide initiatives to control and 
eliminate malaria. This development calls for a global concerted efforts to curb the 
spread of resistant parasites, and also support the development of the next generation 
of antimalarial drugs. 
Figure 1.5.1 on page 27 illustrates the timeline of the development of chloroquine-
resistance P. falciparum species from the Worldwide Antimalarial Resistance 
Network. I have also summarised the historic discovery of the major antimalarial 
drugs, their mode of actions, and the years and countries where resistance to these 







Figure 1.5.1: Chloroquine-resistance P. falciparum species first reported in 1957 at the Thai-Cambodia border and spread across 
continents. The arrows represent the spread of the drug resistance across continents. Reproduced with permission from Packard 2014. Data 
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1(David and Jacoby 2005, Pukrittayakamee et al. 1994, Peters 1982), 2 (Wellems 2002, 
Wernsdorfer et al. 1995, Bjorkman and Phillips-Howard 1990b, Bjorkman and 
Phillips-Howard 1990a, Eyles et al. 1963), 3(Sibley et al. 2001, Hurwitz et al. 1981), 
4(Dondorp et al. 2009, Cui and Su 2009, Noedl et al. 2008). 
 
1.6 Mixed-Plasmodium species infection, why do we 
need to know more? 
In malaria-endemic regions, infections involving more than one Plasmodium species 
are common and yet the epidemiology of the different species, especially the non-
falciparum species has received very little attention (Sutherland 2016, Rayner 2015). 
Over a decade ago, Zimmerman et al. reviewed the importance of knowing more about 
mixed-Plasmodium species infections as knowledge about the dynamics of mixed 
infection was limited (Zimmerman et al. 2004). One of the key knowledge gaps 
highlighted in that review was the lack of diagnostic methods that could best detect all 
Plasmodium species commonly found in malaria-endemic areas, especially in very low 
transmission settings where low-level infections are common. As previously 
discussed, there are still no RDTs on the market capable of detecting all four human 
Plasmodium species in Sub-Saharan Africa. I believe the antigens derived from 
Plasmodium merozoite surface used in this thesis for the seroepidemiological work 
provide key answers for their development into RDTs applicable in malaria endemic 
settings, which can detect recent exposure to infections caused by the different 
Plasmodium species. 
The focus of malaria research since Zimmerman’s review is still concentrated on P. 
falciparum as this species is the one that causes life-threatening disease. Adequate 
knowledge of the species of Plasmodium will enable accurate quantification of the 
prevalence of the different species and the magnitude of the disease burden associated 
with each species in malaria-endemic populations. It is essential to know the species 
of Plasmodium causing malaria in order to ensure targeted treatment of infecting 
parasites and to improve the management of patients with malaria. Misdiagnosing 
mixed-Plasmodium infections could lead to a prolonged parasite clearance time, 




falciparum species poses a danger of relapse by P. vivax and P. ovale (Coldren et al. 
2007, Collins and Jeffery 2005), whiles low-grade parasitaemia of P. malariae has 
potential long term health effects (Badiane et al. 2014, Hase et al. 2013, Hommel et 
al. 2013, Collins and Jeffery 2007).  
As malaria control and elimination efforts are intensified, it is important to focus 
attention on all parasite species so that the non-P. falciparum species which can persist 
in the host for many months and years (Badiane et al. 2014, Collins and Jeffery 2007) 
do not serve as reservoirs for future malaria epidemics even when P. falciparum is 
eliminated. 
1.7 Plasmodium merozoite surface proteins 
The Plasmodium asexual life cycle in human involves both parasite and infected host 
proteins that are essential for the survival and continuity of the parasite’s development. 
Proteins on the surface of merozoite elicit immune response in infected persons and 
contribute to protective immunity in malaria (Beeson et al. 2016). Important parasite 
proteins on the surface of the merozoite include apical membrane protein 1 (Peterson 
et al. 1989), merozoite surface proteins (Holder et al. 1992, Holder 1988) and 
erythrocyte binding antigen 175 (Camus and Hadley 1985). All these antigens are 
expressed as asexual blood stage antigens, and have been shown to be key targets of 
protective immunity mediated by antibodies (Fowkes et al. 2010, Osier et al. 2008, 
Polley et al. 2006, Polley et al. 2004). In spite of their antigenicity, high rates of 
antigenic polymorphism exhibited in these proteins have hindered their use as malaria 
vaccine candidates (Thera et al. 2011).  
 
In this thesis I have extensively used antigens derived from merozoite surface protein 
1 (also known as MSP-119) of the four human Plasmodium species as well as P. 
falciparum-specific MSP-1 Block 2 and MSP-2 serogroups A and B for my 
seroepidemiological work. These antigens have been described in more details in 
Section 1.7. The choice of MSP-119 antigens is based on evidence that these antigens 
are immunogenic (Holder et al. 1999, Cavanagh et al. 1998, Holder et al. 1992), and 
that the antigens of P. falciparum and P. vivax are currently incorporated in one 
commercial kit that is used extensively for the screening of blood donors in many 




Since the recent isolation and characterisation of P. malariae and P. ovale MSP-119 
antigens (Birkenmeyer et al. 2010) with limited characterization of the responses to 
these parasite proteins in human population (Muerhoff et al. 2010), there has been no 
human study utilising all four parasite MSP-119 antigens for seroepidemiological 
studies. The P. falciparum-specific MSP-1 Block 2 and MSP-2 serogroups A and B 
are also immunogenic and have been extensively used in studies exploring the 
dynamics of malaria transmission intensity and protective immunity to Plasmodium 
infection (Cavanagh et al. 2004, Metzger et al. 2003, Cavanagh et al. 2001, Cavanagh 
and McBride 1997). 
 
1.7.1 Merozoite structure and erythrocyte invasion 
The merozoites are one of three invasive stages of the Plasmodium parasite’s life cycle. 
Although Plasmodium parasites are obligate intracellular pathogens, merozoites spend 
a brief extracellular life prior to host erythrocyte invasion (Bannister and Mitchell 
2009, Bannister and Mitchell 2003). Merozoites are unicellular and are the smallest 
cells of all the Plasmodium life cycle stages and appear as ovoid-shaped cells, 
measuring ~1.6 μm long and 1.0 μm wide, and sufficiently equipped for invasion and 
life in the host erythrocytes (Bannister and Mitchell 2009, Bannister and Mitchell 
2003, Bannister et al. 2000). The structure of P. falciparum merozoite is shown in 
Figure 1.7.1 on page 32.  
Merozoites are covered by a proteinaceous fibrillar coat that is 15-20 nm thick (Garcia 
et al. 2008, Bannister et al. 1986, Langreth et al. 1978). Merozoites have a unique 
ultrastructural organization of organelles within their apical membrane, characteristic 
of which are the three sets of secretory vesicles: the rhoptries, the micronemes, and the 
dense granules (Bannister and Mitchell 2003). These apical organelles play key roles 
in merozoite attachment to, and invasion of host erythrocytes, as the molecules 
necessary for erythrocyte invasion are stored within them (Bannister and Mitchell 
2003, Bannister et al. 2000).  
The micronemes are smaller organelles, but more abundant elongated vesicles that 
stain densely and are clustered apically (Garcia et al. 2008, Bannister and Mitchell 
2003). It is suggested that the microneme subpopulation may be more than one, and 




different phases of merozoite invasion of host erythrocytes (Cowman et al. 2012, 
Singh et al. 2007).  
 
Figure 1.7.1: Structure of Plasmodium falciparum merozoite. Three-dimensional 
organization of a Plasmodium falciparum merozoite, with the pellicle partly cut away 
to show the internal structure. Inset: relative sizes of merozoites and the host 
erythrocyte being invaded. Figure reproduced with permission, from (Bannister et al. 
2000). 
The rhoptry are twin pear-shaped organelles, measuring 650 nm long and 300 nm 
wide, and hence much larger than micronemes, and have their apical ends converging 
on the centre of the apical prominence (Kats et al. 2006, Bannister and Mitchell 2003, 
Bannister et al. 2000). Rhoptries are functionally subdivided into the rhoptry neck and 
the rhoptry bulb, having distinct contents that are released at different time points 
during host erythrocyte invasion (Cowman et al. 2012, Kats et al. 2006). The release 
of the rhoptry neck’s content has been shown to precede that of the rhoptry bulb (Kats 
et al. 2006).  
The dense granules appear as small rounded vesicles scattered nearer the apical half of 
the merozoite (Garcia et al. 2008). At the apical end of the merozoites are the three 




invasion by merozoites (Garcia et al. 2008). At the posterior-basal end are located a 
single nucleus, a mitochondrion, and a plastid called apicoplast that are responsible for 
genetic and metabolic processes (Bannister and Mitchell 2009).  
In the mature merozoite both the rough endoplasmic reticulum and Golgi complex are 
either absent or residual (Garcia et al. 2008). Beneath the plasma membrane are two 
additional membranes, the pellicular cisterna, that form the inner membrane complex 
(IMC) (Cowman et al. 2012, Bannister et al. 2000). The IMC functions to provide 
anchorage to several accessory proteins and by extension support the actin-myosin 
motor within the merozoite (Farrow et al. 2011). The IMC together with the plasma 
membrane, form the merozoite pellicle that lines the whole cell with the exception of 
the apical end of the structure (Garcia et al. 2008, Bannister and Mitchell 2003).  
The sequence of event leading to merozoite invasion of host erythrocytes is described 
below. The merozoite attaches to uninfected host erythrocytes in a process that 
involves binding between molecules, usually proteins, on host and parasite surfaces 
(depicted in the insert of Figure 1.7.1 on page 32) (Bannister and Mitchell 2009, 
Bannister et al. 2000). The parasite then reorients itself so that its apical end is in close 
proximity to the host cell membrane; this triggers secretion from the apical organelles 
(Wright and Rayner 2014, Bannister and Mitchell 2009, Bannister and Mitchell 2003, 
Bannister et al. 2000). Although the sequence of secretion is not well characterised in 
Plasmodium, in Toxoplasma, another apicomplexan, it is known that micronemes are 
the first organelle to secrete their contents, followed by the rhoptries and finally the 
dense granules (Carruthers and Sibley 1997). Using the actomyosin motor and a host 
of invasion-related molecules, merozoite are able to invade the host erythrocyte and 
forms a parasitophorous vacuole (Kats et al. 2006). 
The two most essential merozoite surface proteins in terms of their relative abundance, 
immunogenicity and the extensive research in human malaria studies are the MSP-1 
and P. falciparum-specific MSP-2. These antigens are the focus of the 
seroepidemiology work conducted in this thesis. I will discuss these antigens in more 






1.7.2 Merozoite surface protein 1 (MSP-1) and processing 
The merozoite surface protein 1 (MSP-1) was the first surface protein to be described 
among the families of MSP antigens, and has been previously described as a leading 
malaria vaccine candidate (Holder 1988, Holder and Freeman 1982). MSP-1 has been 
variously referred to as gp195, p190, polymorphic schizont antigen (PSA), precursor 
to the major merozoite surface antigen (PMMSA), merozoite surface antigen 1 (MSA-
1), and MSP-1. It is the product of a single-copy gene of about 5 kbp and the most 
abundant parasite protein on the surface of the asexual blood stage merozoite, 
constituting about 31% of the glycosylphospatidylinositol-anchored (GPI-anchored) 
protein coat (Gilson et al. 2006, Blackman et al. 1990, McBride and Heidrich 1987, 
Holder et al. 1985). MSP-1 is present in all four human Plasmodium species 
(Birkenmeyer et al. 2010, Pizarro et al. 2003).  
 
Because of its abundance and presence on the merozoite surface, it is a target of 
antibody mediated immune responses (Cavanagh et al. 1998, Cavanagh and McBride 
1997, Tolle et al. 1993). MSP-1 has an approximate molecular weight of 195 kDa and 
is synthesised as a precursor protein by the intracellular schizonts of both the 
hepatocytes and blood stage asexual cycle in the human host (Suhrbier et al. 1989, 
Holder 1988). The exact function of the protein has yet to be fully elucidated, but it is 
generally believed to be essential for merozoite invasion of erythrocyte, based on 
evidence of its surface location, relative abundance and the limited diversity in the C-
terminal fragment (Beeson et al. 2016). In recent years, a role of MSP-1 processing in 
maintaining the viability of P. falciparum has been proposed, based on evidence that 
parasites with an inefficiently processed MSP1 mutant often exhibit delayed egress, 
while merozoites that lack surface-bound MSP1 display a severe egress defect (Das et 
al. 2015). 
 
In P. falciparum, MSP-1 protein undergoes two proteolytic cleavages; a primary 
processing by P. falciparum subtilisin 1 (PfSUB1) that yields four polypeptide 
fragments of different molecular weights 83, 28, 38 and 42 kDa (McBride and 
Heidrich 1987, Holder et al. 1987, Holder et al. 1985). These fragments are held 
together in a non-covalent complex (Holder et al. 1992, McBride and Heidrich 1987) 
with two other proteins MSP 6 (Trucco et al. 2001) and MSP 7 (Kadekoppala and 




there is a secondary processing of the 42-kDa C-terminus fragment by PfSUB2 that 
yields a 33-kDa N-terminal and a 19 kDa C-terminal fragment (MSP-119) (Harris et al. 
2005). The MSP-119 fragment is retained on the surface of the merozoite during its 
invasion of erythrocytes (Blackman et al. 1990). All other parasite proteins as well as 
the MSP 6 and MSP 7 are shed off just before or during erythrocyte invasion (Holder 
et al. 1992). These events are shown in Figure 1.7.2 on page 36. Immunization with 
whole MSP 1 elicited complete protection to monkeys challenged with a homologous 
parasite strain (Siddiqui et al. 1987); however, when these monkeys were challenged 







Figure 1.7.2: Processing of Plasmodium merozoite proteins before, during, and 
after erythrocyte invasion. (A) Prior to invasion, PfSUB1 is released from the 
merozoite into the parasitophorous vacuole lumen where it processes SERA proteins 
and a number of MSP. (B) Around the time of rupture, PfSUB2 is released and 
translocates to the apex of the merozoite. PfSUB2 cleaves MSP1-42, AMA1 and 
PTRAMP. During invasion, cleaved and peripherally-associated surface proteins are 
shed at the point of tight junction, while other proteins such as MSP2 and MSP4 are 
internalized during invasion. (C) Following invasion, MSP2 and other proteins are 
rapidly degraded, whereas MSP119 and MSP4, are maintained post-invasion and may 






1.7.3 Sub divisions of MSP-1 gene 
The MSP-1 protein can be divided into 17 blocks, with sequence analysis revealing 
that the P. falciparum MSP-1 gene is made up of highly conserved (91- 96% 
homology), semi-conserved (65-75% homology) and polymorphic sites (10-38% 
homology) (Tanabe et al. 1989, Tanabe et al. 1987), as illustrated in Figure 1.7.3. For 
the purpose of the seroepidemiology work in this thesis, the MSP-1 Block 2, and Block 




Figure 1.7.3: Schematic diagram of P. falciparum msp-1 gene divided into 17 
Blocks according to the degree of polymorphism. Conserved (open boxes), 
dimorphic (full), semi-conserved (hatched boxes), polymorphic (speckled box). The 
four fragments produced by the primary enzymatic cleavage are illustrated below the 
Blocks with their respective sizes. The structures of the three allelic types of Block 2 
are enlarged and examples of each type are given (Cavanagh et al. 1998, Tanabe et al. 
1987).  
The MSP-1 Block 1 and Block 2 antigens have been shown to respectively possess 
conserved and type-specific epitopes, with sera from malaria endemic areas capable 
of recognising these type-specific epitopes (Cavanagh et al. 1998). The N-terminus 
Block 1 is relatively conserved and contains the sequence YSLFQKEKMVL, which 
MSP119














is incorporated in the Spf66 vaccine (Masinde et al. 1998). The Block 1 has T-cell 
epitopes within it and at its junction with the Block 2 and is capable of inducing cellular 
and humoral responses (Parra et al. 2000, Quakyi et al. 1994). In a longitudinal study 
in eastern Sudan (Cavanagh et al. 1998) and a cross-sectional study in Gabon (Mawili-
Mboumba et al. 2003), antibody responses to the conserved MSP-1 Block 1 region 
were rarely observed.  
 
The most polymorphic region of the MSP-1 gene is the Block 2 which contains over a 
100 variants and is found in the 83kDa N-terminus region of the MSP-1 gene (shown 
previously in Figure 1.7.3). The Block 2 sequences fall into three basic serotypes, 
named as K1, MAD20 and RO33, after representative clones in which they were first 
described (Certa et al. 1987, Tanabe et al. 1987, Holder et al. 1985). Among these 
three serotypes, the RO33 is largely conserved with few point mutations and without 
repetitive sequences (Jiang et al. 2000, Certa et al. 1987). The K1 and MAD20 
serotypes have centrally polymorphic repetitive sequences comprising of tripeptide 
repeat patterns that are unique to each serotype; these are flanked by semi-conserved 
sequences (Jiang et al. 2000, Cavanagh and McBride 1997). The repetitive sequences 
in both K1 and MAD20 vary with respect to length but of approximate size of about 
90 amino acid residues (Tetteh et al. 2005).  
 
Unlike the Block 1 and its junction with Block 2 (Parra et al. 2000, Quakyi et al. 1994), 
the Block 2 region has been suggested to lack T-cell epitopes (Cowan et al. 2011). In 
both Africa and Southeast Asia, in terms of allelic frequency, Block 2 has been 
identified as the locus with the lowest inter-population variability, with serum IgG 
antibodies against the K1 and MAD20 serotypes reported to be strongly associated 
with protection from P. falciparum malaria (Conway et al. 2000).  
 
The allele frequency of Block 2 varies in different geographical settings. In Africa, the 
K1-type predominates followed by the MAD20-type and RO33-type (Mwingira et al. 
2011). A recent study in Mauritania showed that about 90% of P. falciparum isolates 
were of the K1 family, either carried alone or in association with the MAD20 and 
RO33 alleles (Salem et al. 2014). The allelic frequencies in Africa contrasts with that 
observed in Asia. For example, in Malaysia, 80% of isolates were found to be of the 




MAD20-type predominates followed by the K1-type and RO33-type (Atroosh et al. 
2011).  
 
Antibody responses to MSP-1 Block 2 are short-lived (Cavanagh et al. 1998), 
predominantly of the IgG3 subclass type followed by IgG1 in African population 
(Cavanagh et al. 2004, Cavanagh et al. 2001). This is contrary to higher prevalence of 
IgG1 to IgG3 ratios reported in South American populations (Da Silveira et al. 1999). 
A synthetic MSP-1 hybrid comprising the Block 1 and Block 2 variants has been 
characterised and found to be immunogenic in mice (Cowan et al. 2011). When 
antibody reactivity from Africans naturally exposed to malaria parasites were 
compared between individual Block 2 serotypes and the hybrid, it was observed that 
reactivity to MSP-1 hybrid was stronger than with the individual Block 2 serotypes 
with an observed association to reduced incidence of clinical malaria (Cowan et al. 
2011). 
 
The C-terminus MSP-1 Blocks 15-17 contain the 42 kDa fragment whose secondary 
cleavage product is the MSP-119 that is unique in all four Plasmodium species 
(Birkenmeyer et al. 2010). The MSP-119 contains approximately 100 amino acids, the 
majority of which are conserved in P. falciparum isolates from different malaria 
endemic countries (Kang and Long 1995). Generally, antibody responses to MSP-119 
antigens are short-lived following drug treatment of malaria and in the absence of 
repeated exposure (Akpogheneta et al. 2008, Cavanagh et al. 1998), and are 
predominantly of the IgG1 subclass (Tongren et al. 2006, Cavanagh et al. 2001, Egan 
et al. 1995). Higher levels of IgG1 in children positively correlate with reduced 
parasitaemia (Shi et al. 1996). IgG3 response against MSP-119 antigens is the second 
most prevalent subclass observed (Tongren et al. 2006, John et al. 2004b). IgG2 and 
IgG4 responses against MSP-119 antigens are detectable in only a minority of African 
populations (9.4-31%) (John et al. 2004b, Shi et al. 1996, Egan et al. 1995).  
 
These observations in Africa contrasts that of studies in Brazil, in which higher 
frequencies of IgG2 and IgG4 subclasses against MSP-119 antigens have been reported 
(Scopel et al. 2006, Scopel et al. 2005, Ferreira et al. 1998). Moreover, IgG subclass 
responses to MSP-119 antigens appear to be unaffected by the clinical malaria state of 




et al. 2005). Furthermore, the age of an individual, and the seasonal variation in 
malaria transmission do not affect responses, as sera from all age groups usually show 
a similar pattern of response to these IgG subclasses (Cavanagh et al. 2001, Branch et 
al. 2000, Egan et al. 1996, Egan et al. 1995). 
 
A rise in IgG response to either the Block 2 or the MSP-119 is mostly observed only 
during or after a documented clinical malaria episode (Cavanagh et al. 1998). Similar 
to the Block 2 antigens, the overall frequency of antibody responses to the conserved 
C-terminal MSP-1 region (including MSP-119) also varies geographically. These 
frequencies have been reported to be from 45 to 60% in The Gambia (Riley et al. 
1992), over 75% in Kenya, and about 90% in Sudan (Cavanagh et al. 1998). In view 
of this, IgG response to MSP-119 antigens is a good marker for detection of exposure 
to malaria parasites. This is the reason for using the MSP-119 antigens from all four 
African human Plasmodium parasites to investigate the seroepidemiology of human 
IgG antibody responses to these antigens in the two mesoendemic African populations 
(Zimbabwe and Sudan) investigated in this thesis. Details of the study populations are 
given in Chapter 2.  
 
1.7.4 Merozoite surface protein 2 (MSP-2)  
Merozoite surface protein 2 (MSP-2) (Figure 1.7.4 on page 41) is a 45-55 kDa protein 
present on the surface of the asexual blood stages of the ring, mature schizonts and 
merozoites of P. falciparum of which there is no known homologue in the other three 
human Plasmodium species (Smythe et al. 1988). It is the second most abundance 
protein on the surface of the Plasmodium merozoite accounting for about 21% of all 
GPI-anchored proteins (Gilson et al. 2006). Similar to the MSP-1, this protein is 
anchored to the cell membrane by a GPI domain and is shed from the merozoite surface 
prior to erythrocyte invasion by merozoites (Smythe et al. 1991, Smythe et al. 1988). 
MSP-2 is highly polymorphic and exhibits sequence and antigenic variation between 
isolates (Smythe et al. 1991). The protein has a central polymorphic region which 
constitutes over 60% of the approximately 220-residue mature polypeptide chain 








Figure 1.7.4: The structural layout of Plasmodium msp-2 gene. The conserved 
(black), repeat (white), and family specific dimorphic (hatched) regions. Adapted from 
(Zhang et al. 2008). 
The MSP-2 protein exhibits variable number, length and sequence repeats and is 
flanked by non-repetitive motifs and by the relatively conserved N- and C-terminal 
domains (Smythe et al. 1991, Fenton et al. 1991). Based on the non-repetitive 
sequences, the different alleles of MSP-2 are grouped into two major serogroups 
(Fenton et al. 1991, Smythe et al. 1991), namely serogroup A which includes the 
strains T9/96, Camp, 3D7, and IC1, and serogroup B which includes the strains FCQ-
27, K1, and Dd2 (Taylor et al. 1995). The extensive polymorphism in MSP-2 has been 
suggested to be accounted for by selection pressure of protective host immune 
responses (Conway and Polley 2002). 
 
MSP-2 is highly immunogenic and induces an IgG response in persons exposed to P. 
falciparum parasites (Taylor et al. 1995). Antibody responses to the full-length MSP-
2 variants are age dependent (al-Yaman et al. 1994). Allelic family-specific antibody 
responses are detectable in naturally immuned individuals and this is seen in the ability 
of sera from semi-immune individuals to react strongly to a significant number of 
recombinant MSP 2 antigens compared to malaria naïve individuals, who show no or 
weaker reactivity to varying numbers of antigens (Felger et al. 2003). High prevalence 
levels of antibody response to MSP-2 serogroups are generally observed in malaria 
endemic regions (Polley et al. 2006, Taylor et al. 1995). In a study of adults from The 
Gambia, seventy-nine percent of sera tested showed reactivity to the full length MSP-
2A and 2B serogroups (Taylor et al. 1995), and in Kenya, as high as 100% reactivity 
was observed (Polley et al. 2006). In other studies from Papua New Guinea, antibody 




for more than 90% (al-Yaman et al. 1994). These antibody responses to MSP-2 
antigens have been associated with protection (al-Yaman et al. 1994), reduced risk of 
severe malaria (Polley et al. 2006), and recognise epitopes within the dimorphic and 
polymorphic regions of the protein (Taylor et al. 1995). In the Gambian study above, 
the authors found no evidence of cross-reactivity between the two serogroups 
indicating antibody specificity to the different serogroups (Taylor et al. 1995).  
 
Similar to the MSP-1 Block 2, antibody responses to MSP-2 are predominantly of the 
IgG3 followed by IgG1 subclass, although serogroup B responders tend to have 
approximately equal level of reactivity to both IgG3 and IgG1 (Taylor et al. 1995). 
This trend that is independent of age (Taylor et al. 1998). Again, similar to the 
comparison made between African and South American cohorts, the above trend is 
reversed in studies from South America (Tonhosolo et al. 2001). Several studies in 
which the full length MSP-2 antigens were expressed in Escherichia coli have shown 
that individuals with antibody response to these antigens have significantly reduced 
risk of clinical malaria episodes (Polley et al. 2006, Metzger et al. 2003, Taylor et al. 
1998, al-Yaman et al. 1995). 
 
1.7.5 General immuno-epidemiology trends to MSP antigens 
General trends observed in immuno-epidemiology studies of antibody response to 
merozoite surface proteins (both MSP-1 and MSP-2) include higher prevalence 
responses in adults compared to children (Polley et al. 2006), higher prevalence in 
higher transmission areas and during peak transmission seasons than at the end of 
transmission seasons or during the long dry seasons when vector population is low and 
malaria is rare (John et al. 2005, Drakeley et al. 2005, John et al. 2004a, Braga et al. 
2002), higher prevalence when blood samples are collected during the acute phase of 
malaria (Cavanagh et al. 1998), and higher prevalence in parasitaemic individuals 
compared to aparasitaemic cohorts (Osier et al. 2008, Osier et al. 2007, Polley et al. 
2006, Polley et al. 2004, Tami et al. 2002, Tolle et al. 1993). These information on the 
response patterns based on transmission season and parasitaemic state of the patient 
were relevant in the selection of the study populations and samples used in this thesis, 





1.8 Antibodies and immunity to malaria 
Antibodies play a key role in humoral immunity to malaria. In this section I will briefly 
introduce the structure and functions of antibodies and their role in conferring 
immunity in malaria. One of the cardinal properties of antibodies which is of 
significant importance to the work in this thesis is their specificity to a target antigen 
or protein. Specificity of antibodies ensures that an immune response to a particular 
antigen or protein is targeted against that particular antigen or protein alone. This 
property of antibodies is the basis of the seroepidemiology work using Plasmodium 
MSP-119 antigens described later in Chapter 3. 
1.8.1 Characteristics of antibody 
Antibodies are circulating proteins secreted by B-lymphocytes in vertebrates in 
response to exposure to antigens which the body considers foreign. An antibody is a 
large protein molecule that appears as a flexible Y-shape, and responsible for an 
organism’s humoral immune responses (Abbas 2011). An antibody is a tetrameric 
molecule consisting of four polypeptide chains; two identical heavy chains (α, δ, ε, γ 
and μ) of about 50-70 kDa that pair with each other, as well as with two identical light 
chains (κ, λ) of about 25 kDa, covalently linked together by inter-chain disulfide bonds 
and by non-covalent interactions. The type of heavy chain present defines the class of 
antibody, and based on these heavy chains, there are five classes (also known as 
isotypes) of antibodies in humans and other vertebrates, namely, IgA, IgD, IgE, IgG 
and IgM (Abbas 2011, Paul 2008).  
In humans, IgA and IgG can be subdivided into two and four subclasses respectively, 
namely, IgA1 and IgA2, and IgG1, IgG2, IgG3 and IgG4 (Abbas 2011, Paul 2008). 
The subclasses differ in the number of disulfide bonds and length of the hinge region. 
All these five classes of antibody molecules share the same basic structural 
characteristics although there is some variability among them with regards to the 
antigen binding sites. Variability within the antigen binding site accounts for the 





Of the five immunoglobulin classes IgG is the most abundant immunoglobulin in 
blood and extracellular fluids, accounting for between 70 and 75% of the total serum 
immunoglobulin pool. It has a serum concentration of approximately 13.5 mg/mL and 
a half-life of between 12-25 days depending on the subclass. The secreted form of IgG 
exists mainly as monomers. IgG is responsible for the majority of humoral immunity 
against foreign antigens in human (Abbas 2011, Delves et al. 2011). It is the most well 
studied class of antibodies and due to the above characteristics has attracted most of 
the interest towards the development of antibody-based therapeutics for various 
diseases. The serological work in this thesis is also therefore mainly based on human 
IgG responses to Plasmodium merozoite proteins. 
1.8.2 Functions of antibodies 
Immunoglobulin G (IgG) in humans is involved in opsonisation, plays a role in 
complement activation, involved in antibody-dependent cell-mediated cytotoxicity, 
neonatal immunity, as well as providing feedback inhibition to the B-lymphocytes that 
produce them (Abbas 2011). It is the only antibody type capable of crossing the 
placenta. IgA is produced in large quantities for immune protection of mucosal 
surfaces, while IgE functions in antiparasite immunity and is also involved in 
immediate hypersensitivity reactions (Abbas 2011, Danilova and Amemiya 2009).  
IgM appears in two forms, monomeric and pentameric forms. The monomeric form 
functions as a naïve B cell antigen receptor while the pentameric form is capable of 
activating complement. IgM is the first antibody to be produced in response to an 
antigenic challenge. Although δ expression follows that of μ in immature B cells it is 
subsequently shut down in activated B cells, and hence the function of IgD remains 
puzzling although it serves as a naïve B cell antigen receptor (Abbas 2011, Danilova 
and Amemiya 2009). Table 1.8.1 on the next page shows some of the characteristics 

















IgA IgA1, 2 (α1 
or α2) 
3.5 6 Mainly dimer; 
also monomer, 
trimers 
IgD None (δ) Trace 3 Monomer 
IgE None (ε) 0.05 2 Monomer 
IgG IgG1-4 (γ1, 
γ2, γ3 or γ4) 
13.5 23 Monomer 
IgM None (µ) 1.5 5 Pentamer  
Abbreviations: H, heavy chain region. Table adapted and modified from (Abbas 2011). 
1.8.3 Immune response to Plasmodium infection 
Three levels of immune response to malaria parasites have been established in humans 
according to the parasite stages that are targeted; these are anti-infection, anti-parasite 
and anti-disease immune responses (Crompton et al. 2014, Doolan et al. 2009). Anti-
infection immunity is targeted against the pre-erythrocytic sporozoites and infected 
hepatocytes (Roland et al. 2006, Pied et al. 2000). Antibodies may play a role by 
binding to and blocking sporozoite invasion of hepatocytes (John et al. 2008, John et 
al. 2005) and promote CD8+ cytotoxic T-cells killing of infected hepatocytes 
(McKenna et al. 2000, Pied et al. 2000). This may potentially lead to a reduction of 
blood-stage infection and thus manifestations of the disease. Additionally, cytokines 
induced by these cells, and CD4+ cells and other non-T cells are capable of killing 
infected hepatocytes or aiding hepatocytes to kill intracellular parasites (Roland et al. 
2006, Pied et al. 2000).  
Anti-parasite immunity is stage-specific, acquired slowly and over a long period of 




blood parasitaemia (Doolan et al. 2009). Anti-disease immunity is also acquired 
rapidly and protects against severe malaria episodes. This level of immunity is 
normally observed readily in areas of intense transmission and protects children 
against death (Doolan et al. 2009). During the Plasmodium life cycle different parasite 
antigens are expressed at different stages and these elicit specific host responses. 
Immunity to malaria is therefore species, strain, and stage-specific (Holder 1999), and 
involves a concerted response from both the innate and adaptive arms of the human 
immune system.  
1.8.3.1 Cellular immune response 
Parasite antigens induce a specific immune response that causes the release of 
proinflammatory cytokines from mononuclear cells (Doolan et al. 1994), that in turn 
activate other host cellular machinery against both liver and blood stage antigens. 
Immune cells such as B and T cells, macrophages, dendritic cells and soluble pro-
inflammatory cytokines such as interferon gamma (IFNγ), tumour necrosis factor 
(TNF) α, interleukin (IL)-12, IL-18 and anti-inflammatory cytokines IL-4, and IL-10 
coordinate a regulated immune response against malaria infection (Doolan et al. 2009, 
Doolan et al. 1994).  
Sporozoites antigens such as circumsporozoite protein and liver-specific antigens are 
the first to be recognized by the host and are rapidly processed on the surface of 
infected hepatocytes into peptides in association with the major histocompatibility 
complex class I (MHC-class I) and presented to cytotoxic T-cells (Weiss et al. 1990), 
leading to killing of infected hepatocytes. IFNγ produced by stimulated NK cells and 
CD4+ T-cells are able to trigger a cascade of immune response, leading to the death 
of the parasite (Wang et al. 1996, Weiss et al. 1990). 
Merozoites from ruptured erythrocytes trigger TNFα response to merozoite proteins 
(Snounou et al. 2000). The effector functions of other proinflammatory cytokines such 
as IL-12 and IL-18 also help to propagate the immune response against Plasmodium 
parasites (Malaguarnera and Musumeci 2002). Surface antigens such as MSP-1 and 
MSP-2 are exposed to the host immune system and are therefore targets of host 
antibodies (Polley et al. 2006, Polley et al. 2004, Howard and Pasloske 1993). Host 




crystallizing-mediated (Fc) killing by macrophages or activating complement 
pathways (Saul 1999). Naturally occurring antibodies are able to inhibit the secondary 
proteolytic processing of the MSP-1 protein, thereby preventing the dissociation of its 
C-terminus MSP-119 from the entire protein complex (Nwuba et al. 2002). 
1.8.3.2 Humoral immune responses  
The serological work in this thesis is based on human IgG antibody responses to 
merozoite surface proteins. Humoral immune responses are important against blood-
stage parasite antigens. Antibodies play a crucial role in malaria infection and have 
been implicated in protection against severe malaria. Acquired immunity to malaria is 
largely mediated by IgG (Hviid 2005), and there is evidence to suggest that passively 
acquired maternal IgG (Amaratunga et al. 2011) and secretary IgA from breast milk 
(Kassim et al. 2000) protect children under the age of six months from both severe 
disease and high parasitaemia (Doolan et al. 2009). These maternal antibodies, 
however, wane to undetectable levels as early as four months of life when infants begin 
to make their own antibodies (Duah et al. 2010). Maternal antibodies are acquired in 
the order of IgM, followed by IgG1 and IgA (Duah et al. 2010). IgG1 appears early in 
life and gradually switches towards IgG3 in older children as they become more 
exposed to malaria parasites (Duah et al. 2010). In primary infection, IgM predominate 
while in re-infection, IgG subclasses are the predominant isotypes seen (Garraud et al. 
2003). Foetal haemoglobin also play a role in protection by inhibiting parasite growth 
and development (Snow et al. 1998). 
Passively transferred sera from hyper-immune adults protects naïve individuals from 
severe malaria (Bouharoun-Tayoun et al. 1990). Moreover, sera from malaria endemic 
regions normally have antibodies to several malarial antigens (Cavanagh et al. 1998, 
Tolle et al. 1993), with some antigens correlating positively with protection from 
severe malaria in some regions (al-Yaman et al. 1996). These responses are however, 
short-lived in the absence of exposure to parasites and parasitaemia (Cavanagh et al. 
2001), and are dependent on the longevity of the plasma cells that produce the 
antibodies (Duah et al. 2010, Akpogheneta et al. 2008). 
Generally, anti-malarial immunity is acquired early in life, develops slowly with age, 




‘sterile immunity’ (Tran et al. 2013, Marsh and Kinyanjui 2006, Smith et al. 1999), as 
shown by the persistent presence of gametocytes in asymptomatic adults (Doolan et 
al. 2009). The slow development of acquired immunity has been attributed to be partly 
due to suboptimal or defective induction of CD4+ T cells (Thompson et al. 2008) 
which are required for both antibody production and cytotoxic T cell responses (Weiss 
et al. 1993). The lack of sterile immunity is also partly explained by the extensive 
antigenic variation and polymorphism in several antigens of the Plasmodium parasite 
(Marsh and Kinyanjui 2006). It has been widely hypothesised that individuals may 
need to accumulate immune responses against various forms of the genetically distinct 
polymorphic antigens over a lifetime. In low endemicity, immunity in both children 
and adult develops slowly (Cavanagh et al. 1998). This is contrasted by protection 
against severe disease and high-density parasitaemia in people who are repeatedly 
exposed to the parasites, i.e. repeated exposure enhances anti-parasite immunity 
(Marsh and Kinyanjui 2006, Smith et al. 1999). Immunity against malaria wanes 
following a long absence of exposure to parasite and may render individuals 
susceptible to severe disease upon re-exposure to parasite (Doolan et al. 2009). A 
historic example was the malaria related loss of about 400,000 lives in Madagascar 
after malaria parasite re-emergence following intensive control measures which had 
reduced the exposure levels necessary for the development of acquired immunity 
(Romi et al. 2002, Mouchet et al. 1997, Fontenille and Rakotoarivony 1988). 
Antigens with polymorphic and repetitive regions, such as MSP-2, MSP-3, MSP-7 and 
CSP, predominantly induce IgG3 responses, in contrast to IgG1 subclass responses 
that are induced by non-polymorphic and non-repetitive antigens, for example MSP-
119, AMA-1, MSP-5 and MSP-6 (Tongren et al. 2006, Cavanagh et al. 2001). Within 
a single parasite protein, there are differential antibody responses to distinct regions 
(Cavanagh et al. 2001). For example while the MSP-119 region induces an IgG1 
response (Tongren et al. 2006, Cavanagh et al. 2001), responses to the polymorphic 
MSP-1 Block 2 is of the IgG3 subclass (Cavanagh et al. 2001). This may explain the 
short-lived responses to this unique region and requiring an individual to be 
continually exposed to malaria parasites to maintain protection against clinical 
episodes of the disease (Cavanagh et al. 2001). The frequency of IgG responses to 
MSP-2 antigens in malaria patients is very high, predominantly of the IgG3 subclass 




1.9 Malaria and the ABO blood group system  
1.9.1 Biochemistry of ABO blood group antigens 
Blood group antigens are surface markers present on the outside of the red blood cell 
membranes (Reid 2012). They are polymorphic traits genetically inherited from 
parents. There are currently 34 blood group systems recognized by the International 
Society for Blood Transfusion (Fung 2014, Reid 2012). The functions of many of the 
blood group antigens are unknown, and this is evident in individuals lacking certain 
antigens (such as blood group O individuals) not being seriously affected compared to 
those who possess it (Reid 2012). Among the blood group systems, the ABO is 
arguably the most immunogenic and the most important owing to its prime importance 
in blood group compatibility in transfusion medicine and haemolytic disease of the 
new born (Chung et al. 2005) and its associations with cancers and infectious disease 
(Rummel and Ellsworth 2016, Reid and Bird 1990).  
The discovery of the ABO blood group systems dates back over a century ago (Larsen 
et al. 1990, Landsteiner 1900). The ABO blood group genes are located on 
chromosome 9q34.1-q34.2 (Yamamoto and Hakomori 1990) and are surface markers 
on the human erythrocytes that consist of proteins and carbohydrates attached to lipids 
or proteins. There are three major carbohydrate antigens expressed on 
glycosphingolipids and glycoproteins (A, B and H antigens) and four inheritable ABO 
blood types (types A, B, AB, and O) (Cooling 2015, Daniels 2002). The H antigen is 
the biosynthetic precursor and serves as the backbone to the A and B antigens which 
are the products of the ABO gene and are inherited as autosomal codominant (Cooling 
2015). The group O phenotype is inherited as an autosomal-recessive and is due to a 
mutation that leads to premature termination of translation and, hence, no production 
of active glycosyltransferase (Cooling 2015, Berg et al. 2002).  
The H antigen is synthesized by the FUT1/H gene, an α1,2-fucosyltransferase that adds 
a terminal fucose to lactosamine to form Fucα1-2Galβ1-4GlcNAc-R (Cooling 2015). 
The A, B and O blood groups have a common oligosaccharide structure called the O 
or H antigen (Berg et al. 2002) (see Figure 1.9.1 on page 51). For the A and B antigens 
a specific glycosyltransferase adds an extra monosaccharide to the basic O antigen 




al. 2002). The type A transferase specifically adds N-acetylgalactosamine, whereas 
the type B transferase adds galactose (Figure 1.9.1) (Berg et al. 2002). In individuals 
with the Bombay (Oh) and para-Bombay phenotypes, the A, B, and H antigens are also 
absent as these individuals are unable to synthesize the basic H antigen due to 
mutations in FUT1 (Cooling 2015). 
In clinical practice, the ABO blood group of an individual is determined by a forward 
reaction for determining the presence or absence of A and B antigens on the surface of 
the red blood cells, and in a reverse typing for determining the presence or absence of 
antibody A or antibody B in the serum of an individual (Khan et al. 2013, Cooling 
2008). Thus, the red blood cells of blood group A individuals possess antigen A with 
antibody B in their serum while blood group B individuals have antigen B on their red 
cells and antibody A in their serum. Blood type O individuals do not express antigen 
A nor B, but have both the A and B antibodies in their serum. Antibodies to ABO 
antigens are usually of the IgM class. The expression of ABO antigens is reduced on 
the surface of the red cells of new-borns, who also lack the ABO antibodies in the early 







Figure 1.9.1: Structures of the O, A and B antigens. Abbreviations: Fuc, fucose; 
Gal, galactose; GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine. 
Figure reproduced with permission from (Berg et al. 2002). 
1.9.2 Malaria and the ABO blood group system 
People with the most common ABO blood group type (blood group O) express neither 
the A nor B antigen on the surface of their red blood cells, but remain perfectly healthy, 
suggesting that there may be no association between the lack of expression of an ABO 
blood group antigens and disease (Dean 2005). However, several reports have 
associated a role of the ABO blood group type of the human host to increased 
susceptibility to certain diseases. For example, the ABO phenotype has been linked 
with gastric and duodenal ulcers which are more common in blood group O individuals 
(O'Donnell and Laffan 2001), while gastric cancer is commonly seen in blood group 
A individuals (Reid and Bird 1990). Another observation is that individuals with blood 
type O have lower plasma levels of the von Willebrand factor and clotting factor VII, 
two essential proteins involved in the blood clotting cascade (O'Donnell and Laffan 




In malaria, several reports have proposed associations between the ABO blood group 
antigens and the development of severe or mild disease caused by P. falciparum 
(Pathirana et al. 2005, Beiguelman et al. 2003, Lell et al. 1999). The ABO blood group 
influences the susceptibility or resistance of an individual to developing severe malaria 
(Vigan-Womas et al. 2012, Fry et al. 2008, Rowe et al. 2007). Blood group O 
individuals have been reported to be significantly protected against the development 
of severe malaria through a mechanism of reduce rosetting compared with non-group 
O individuals (Rowe et al. 2007, Lowe et al. 1998). During rosetting, Plasmodium-
infected erythrocytes spontaneously bind to uninfected erythrocytes (Rowe et al. 
1995), leading to microvascular obstruction that results in severe malaria with its 
complications of hypoxia, acidosis, organ dysfunction and death (Kaul et al. 1991). 
This process is mediated by a sub-group of P. falciparum erythrocyte membrane 
protein 1 (PfEMP1) adhesins encoded by the large var gene family (Vigan-Womas et 
al. 2012, Rowe et al. 2009a).  
ABO blood group has been identified as the main receptor for rosetting parasites, with 
a higher rosetting preference for blood group A erythrocytes (Vigan-Womas et al. 
2012, Heddini et al. 2001, Barragan et al. 2000). This may possibly be due to the 
differential glycosylation on the surface of erythrocytes of the different blood group 
antigens (Fry et al. 2008). In vitro studies in support of the above showed that 
enzymatic removal of the A antigen on the erythrocytes and the introduction of soluble 
A antigen decreased P. falciparum rosette formation in blood group A erythrocytes 
(Barragan et al. 2000). Rosettes do form in blood group O erythrocytes but are smaller 
in size, easily disrupted compared to that formed in blood groups A and B, and involves 
receptors such as the complement receptor 1 (Rowe et al. 2009b) and increased 
phagocytosis of P. falciparum-infected type O erythrocytes (Wolofsky et al. 2012). 
Rosetting is more commonly seen in P. vivax than P. falciparum malaria (Lee et al. 
2014) and is associated with anaemia (Resende et al. 2017, Marin-Menendez et al. 
2013). Although P. vivax preferentially infects reticulocytes (Bruce and Day 2002), its 
rosetting complexes are commonly formed in mature erythrocytes (Lee et al. 2014). 
This has led to the suggestion that rosetting in P. vivax (Lee et al. 2014) or P. 





One of the host environmental challenges the schizont ruptured merozoite faces is the 
different red cell antigens when parasite infects individuals of different ABO blood 
groups. Whiles extensive research on the relationship between malaria and the ABO 
blood group have been done (as outlined above), there has been no study of the 
Plasmodium parasite gene expression changes when a single clone infects host of 



















1.10 Project aims and rationale 
Both parasite and host factors contribute to heterogeneity in the risk of developing 
malaria, clinical manifestation of the disease as well as the number of treatments 
required to clear parasites. This project endeavours to advance the knowledge and 
understanding behind host and parasite factors that drive heterogeneity in human 
malaria. Specifically, the project aims and rationale are as outlined below.  
Aim 1: To determine the seroepidemiology of the different Plasmodium species in 
two mesoendemic African populations in Zimbabwe and Sudan (Chapters 3 and 
4). 
The above aim is achieved by developing an enzyme-linked immunosorbent assay 
(ELISA) based on antigens derived from Plasmodium merozoite surface proteins, also 
known as MSP-119 from all four human Plasmodium species. 
Rationale: The ‘gold standard’ blood film microscopy for the diagnosis of malaria has 
several limitations (requirement of a high level of skilled personnel, subtle difference 
in the morphology of Plasmodium species, lack of functional microscopes or 
electricity to run them, lack of or sub-standard reagents such as stains) (Obare et al. 
2013, Payne 1988) that make the differentiation of the species of Plasmodium causing 
malaria very difficult, leading to under-reporting of mixed-species infections. There is 
therefore paucity of data on the epidemiology of the different Plasmodium species in 
many malaria endemic African populations, especially the non-falciparum species and 
their contribution to the overall malaria burden. This knowledge gap is the focus of 
using MSP-119 antigens derived from four human Plasmodium species as a diagnostic 
tool to characterize the prevalence of the different Plasmodium species in Zimbabwean 
and Sudanese populations. 
 
Aim 2: To determine if heterogeneity in clinical presentations of malaria (history 
of fever, body temperature and parasitaemia) and response to drug treatment is 
related to exposure to single vs. mixed-Plasmodium species infection (Chapter 4). 
Rationale: Phenotypic differences in the biology of the four human Plasmodium 
species that cause malaria include the duration of the pre-erythrocytic and erythrocytic 
schizogony and the number of merozoites produced per cycle, host erythrocyte 




erythrocytes. These differences in the developmental cycles and the biological 
interaction between different Plasmodium species in mixed-species infections may 
partly influence the clinical and treatment outcomes of diseases in the host. However, 
the dynamics and interactions of these phenotypes when the host is infected with more 
than one Plasmodium species is not fully understood. In view of this the clinical 
presentation and response to drug treatment when exposed to single vs. mixed-
Plasmodium species are not well documented, a knowledge gap this thesis hopes to 
address. 
Aim 3: To determine the spatial and temporal dynamics of malaria prevalence 
and Plasmodium species distribution in a mesoendemic village in eastern Sudan 
(Chapter 5). 
Rationale: Malaria risk can vary markedly between households within the same 
geographical area, but the determinants of variation in malaria risk remain poorly 
understood. Chemotherapy alone cannot reduce the burden of malaria even in a small 
geographical area. An understanding of the heterogeneity of malaria prevalence at a 
single village setting could have implications for designing small-area interventions 
targeted at eradicating disease at the local level. 
Aim 4: To determine gene expression changes in 3D7 P. falciparum parasites as 
they infect erythrocytes of different ABO blood group donors (Chapter 6). 
Rationale: The ABO blood group system is one of the red blood cell polymorphisms 
associated with a role in both infectious diseases and non-infectious diseases (Rummel 
and Ellsworth 2016, Reid and Bird 1990). The ABO blood group type of an infected 
host has an influence on the outcome of malaria, with the hosts of group O showing 
resistance to developing severe malaria, and the hosts of groups A and B being more 
susceptible to infection (Rowe et al. 2009b, Rowe et al. 2007). Moreover, malaria 
parasites have higher re-invasion rates in blood group A subtype A1 than in blood 
group B and O individuals (Chung et al. 2005). Gene expression in clonal parasites 
when these are transmitted to hosts of different ABO blood groups have not been 





1.11 Thesis chapter outline 
The study conducted in this thesis explored the seroepidemiology of Plasmodium 
species infections in two mesoendemic African countries (Zimbabwe and Sudan) using 
antigens derived from merozoite surface proteins from four human Plasmodium 
species. The reasons for choosing these two countries are discussed in Chapter 2. The 
clinical presentations and treatment requirement as well as the spatio-temporal 
dynamics of malaria are also studied in the Sudanese cohort. Finally, the gene 
expression profile of P. falciparum infection in different blood group erythrocytes is 
also examined. 
In Chapter 2 I provide an outline of the fieldwork carried out in Zimbabwe and Sudan 
that helped with sample collections and processing. I also outline the protein 
expression work done in the laboratory as well as the ELISA technique that was used 
for the seroepidemiological work described in this thesis. Statistical packages and tests 
used are also described. 
In Chapter 3 I determined the seroepidemiology of the different Plasmodium species 
in Zimbabwe. I used competition ELISA to explore the specificity of IgG antibody 
responses to Plasmodium MSP antigens (MSP-119). Based on this I developed an 
ELISA-based technique using MSP-119 from the four human Plasmodium species as a 
diagnostic tool for an immuno-epidemiological survey in three villages in Zimbabwe 
where Plasmodium transmission is described as mesoendemic (Hay et al. 2009, 
Mabaso et al. 2006).  
In Chapter 4 I extend the seroepidemiology work of Chapter 3 to a village in eastern 
Sudan, Daraweesh, where malaria epidemiology has been studied over a period of 
eleven years (Creasey et al. 2004). The antibody responses to MSP-119 antigens were 
categorised as single- or mixed-Plasmodium species and the clinical outcome (fever 
and parasitaemia) and the number of treatment required for parasite clearance 
compared between these two responder groups. 
In Chapter 5 I explore the space-time analysis of malaria epidemiology at the 





In Chapter 6 I investigate the gene expression changes when a single clone of P. 
falciparum 3D7 parasites infect erythrocytes of different ABO blood groups. Here I 
determined the growth rates of the parasite in the different blood group types as well 
as examining any differential expression of genes based on an individual’s blood group 
type. 
In Chapter 7 I discuss the major findings in this thesis against the body of scientific 
literature and summarise the key conclusions and the contribution of my work to 


































Chapter 2. Study design, sample collection 
and materials and methods 
2.1 Introduction  
The overall objective of this project was to determine the host and parasite factors that 
drive heterogeneity in human malaria. Although several factors are important in 
driving heterogeneity in human malaria the two factors I have focussed on in this thesis 
are the epidemiology of the different Plasmodium species and gene expression changes 
when a single clone of P. falciparum infects erythrocytes of different blood groups. 
 
Mixed-Plasmodium species infection can result in life-long chronic disease causing a 
wide range of morbidity such as nephropathy and chronic kidney diseases if 
undiagnosed and untreated (Badiane et al. 2014, Gilles and Hendrickse 1960). This 
has consequences on the health and general well-being of infected individuals. 
Although in malaria-endemic populations individuals may be infected with more than 
one species of Plasmodium the epidemiology of the non-P. falciparum species is 
poorly understood. This may be partly due to non-reporting of the type of infecting 
Plasmodium species diagnosed as the cause of malaria (Obare et al. 2013). Moreover, 
the conventional microscopy diagnosis of malaria has limitations (outlined previously 
in the general introduction) that do not allow the species to be properly reported, 
thereby attributing malaria to be solely caused by P. falciparum. Molecular methods 
such as PCR are not practicable in everyday diagnostic laboratories (Daniels et al. 
2017, Nkumama et al. 2017), whilst the available rapid diagnostic tests (RDTs) on the 
market are limited to detecting only P. falciparum and P. vivax infections (Wilson 
2012).  
 
The Plasmodium parasite’s developmental cycle in the human host involves a 
substantial amount of time in the host erythrocytes (Bannister and Mitchell 2003, 
Hawking et al. 1968). On the surfaces of the erythrocytes are blood group antigens, of 
which the ABO blood group is of much medical importance (Cooling 2015, Fung 




influences susceptibility and resistance to severe malaria (Rowe et al. 2009b, Rowe et 
al. 2007). In this thesis, an aspect of this interaction I have focussed on is the gene 
expression changes, if any, when a single clone of P. falciparum parasites infect 
erythrocytes of different ABO blood group donors. 
 
The study design outlined in this thesis uses quantitative analysis of epidemiological 
factors measured in the field associated with Plasmodium exposure and infection and 
compares the clinical outcomes (fever and parasitaemia) and treatment requirement of 
single- versus mixed-Plasmodium species anti-MSP-119 responders in three villages in 
Zimbabwe, and Daraweesh, a village in eastern Sudan. It also uses bioinformatic 
analysis of gene expression changes in Plasmodium falciparum infecting different 
ABO blood groups. In this chapter, I describe the study design and statistical methods 
applied to address the specific research aims. The participants’ selection criteria and 
epidemiological features of the study cohorts are also outlined.  
 
2.2 Study sites and fieldwork methods 
This project is made up of various studies that incorporate different populations for 
acquisition of data and analysis in addressing the specific aims outlined previously. 
Malaria parasite transmission i.e. endemicity is generally classified into four categories 
namely, holoendemic (transmission occurs all year long; disease affects a high 
proportion of the population at risk), hyperendemic (intense transmission, but with 
periods of no transmission during the dry season; disease affects a high proportion of 
the population at risk), mesoendemic (regular seasonal transmission that affects a 
moderate proportion of the population at risk) and hypoendemic (very intermittent 
transmission with disease affecting a small proportion of the population at risk) 
(Spencer 1963, Metselaar and Van Thiel 1959). These classifications are based on one 
of four indices, the entomological inoculation rate (EIR i.e. the number of infective 
bites per person per unit time), the spleen rate (number of palpable enlarged spleens 
per 100 individuals of similar ages, usually children aged 2-9 years), parasite rate 
(number of persons with parasitaemia per 100 individuals of similar ages) or annual 
parasite index (number of parasite infections in a well-defined geographical area; 




Table 2.2.1: Classification of malaria endemicity based on entomological inoculation rate, parasite rate and spleen rate. 
Indices of malaria transmission What is Measured Holoendemic Hyperendemic Mesoendemic Hypoendemic 
Entomological Inoculation Rate (EIR) The number of infectious mosquito bites 
per person per unit time. 
>500 250 - 499 50 - 249 0 - 49 
Parasite Rate (PR) (% of <5 years old 
children) 
Proportion of the population found to 
carry asexual parasites in RBCs; can also 
assess gametocyte rates; by age group. 
60-70  >50 <70  <20   0 - <10  
Spleen Rate (SR) (% of <5 years old 
children) 
The number of palpable enlarged spleens 
per 100 individuals of similar ages, 
usually children aged 2-9 years. 
>75  51 - 75  >20 <50  0 - <10  




2.2.1 Criteria for selecting study sites 
The blood samples for the seroepidemiology work described in Chapters 3 and 4 were 
collected from two African countries, Zimbabwe and Sudan, where malaria is 
endemic. The choice of these two countries as study sites for my research were based 
on the following reasons: 
 malaria parasite transmission as determined by the EIR is described as 
mesoendemic in Zimbabwe (Mabaso et al. 2006, Taylor and Mutambu 1986), 
whilst parasite transmission in the Daraweesh village of Sudan where blood 
samples for the work described in Chapters 4 and 5 is described as 
holoendemic, with a very low EIR of 1-3 infective bites per person per year 
(Hamad et al. 2002, Hamad et al. 2000, Arnot 1998). 
 although malaria epidemiology has been extensively studied in these two 
countries, there has been no focus on the epidemiology and disease burden of 
the non-falciparum species, as they are regarded as less frequent. The 
seroepidemiological data from this work highlights that the prevalence of the 
non-falciparum species is higher than has been reported in these two countries. 
 malaria control programmes (against P. falciparum) are ongoing in these 
countries. Similar to what has been reported elsewhere (Oliveira-Ferreira et al. 
2010), lack of knowledge of the epidemiology of the non-falciparum species 
has the potential to increase the prevalence and disease burdens of these minor 
species once P. falciparum infections decline.  
 samples for the study were readily available for me to commence my work. 
2.2.2 Zimbabwean samples 
The plasma samples for the work described in Chapter 3 were from a cross-sectional 
study conducted in three villages (Burma Valley, Chiredzi and Mutoko) in Zimbabwe 
as part of a larger project investigating the immunoepidemiology of schistosomiasis in 
villages with Plasmodium coinfection. This work was a collaboration involving groups 
from the University of Zimbabwe, the National Institutes of Health Research in 
Zimbabwe (formerly the Blair Research Institute) and the University of Edinburgh. 
Plasmodium parasite transmission in Zimbabwe is generally described as 




and Mutambu 1986). However, malaria endemicity has been shown to be markedly 
influenced by altitude varying from hyperendemic in the low altitude areas to 
hypoendemic or absent on the central watershed (Taylor and Mutambu 1986). The 
seasonal peak of transmission occurs during the onset of the rainfall season from mid-
February to May each year with very low transmission during the dry seasons of July 
to October (Taylor and Mutambu 1986).  
The study sites were Burma Valley in the eastern Highlands, Manicaland Province 
(31°30'E; 17°45'S), where samples were collected in 1994 (Mutapi et al. 2000, Mutapi 
et al. 1997, Hagan et al. 1994), Chiredzi in the south-eastern Masvingo Province 
(31°90'E; 17°45'S) where samples were collected in 1999 (Mutapi et al. 2005, Mutapi 
et al. 2003) and Mutoko in the north eastern Mashonaland Province of Zimbabwe 
(32°13′E; 17°20′S) , where samples were collected in 2003 (Mutapi et al. 2006). All 
blood sampling in the three study sites were undertaken in early February prior to the 
annual malaria parasite transmission season, i.e. before the onset of the rainfall. The 
importance of this in relation to using MSP-119 antigens as diagnostic tool (discussed 
in Chapter 3) is the demonstration that the levels of human IgG responses to MSP-119 
antigens are higher when blood samples are collected at the time of acute malaria and 
during malaria transmission seasons compared to lower levels observed when blood is 
taken from asymptomatic malaria patients outside of parasite transmission seasons 
(Braga et al. 2002, Cavanagh et al. 1998, Tolle et al. 1993) 
P. falciparum is the predominant species of malaria parasite in Zimbabwe, with malaria 
transmission described largely as unstable in nature, low and sporadic (Hay et al. 2009, 
Mabaso et al. 2006, Mharakurwa et al. 2004). The study cohort consisted of 100 
participants aged between five and 18 years (both males and females) in each study site 
(more details are given in Chapter 3). The study was school based, in which school 
children were recruited from the three villages. This is a common technique employed 
in epidemiological studies as it facilitates efficient recruitment and follow-up of school-
aged individuals. IgG antibody responses to Plasmodium merozoite surface proteins 







2.2.3 Sudanese samples 
Plasma samples for the work described in Chapters 4 and 5 are from an eleven year (1 
January 1990 and 31 December 2000) longitudinal study of malaria epidemiology in 
Daraweesh, in eastern Sudan (14.02° N, 35.36° E), in the Gedaref district, 80km north 
of the Sudanese capital, Khartoum (Creasey et al. 2004). The Daraweesh area has been 
extensively described in previous publications (Creasey et al. 2004, Cavanagh et al. 
1998, Elhassan et al. 1995). The principal activities in Daraweesh are farming of large 
scale sorghum and sesame. Daraweesh was founded by the Fulani grandfathers of 
many of the village elders (present at the time of the study) who migrated to Sudan 
from the Volta River region of present-day Burkina Faso in the 1880’s (Creasey et al. 
2004). The village is characterised by a long dry season (January to July) when malaria 
is rarely diagnosed, followed by a short rainfall season (August to October) after which 
the majority of malaria incidence is recorded (Creasey et al. 2004, Hamad et al. 2002). 
This seasonal pattern was observed to be the same over the 11 year study period. 
Vector-based measurements cannot absolutely establish the exact period of malaria 
parasite transmission in Daraweesh, (Arnot 1998), although malaria associated 
morbidities are always heavily concentrated between the months of September to 
November, with peak incidence in October (Hamad et al. 2000). Based on the EIR, 
malaria parasite transmission is described as holoendemic with an average infective 
bite per person per year estimated to be between 1 and 3 (Hamad et al. 2002, Hamad 
et al. 2000, Arnot 1998). The blood samples from Daraweesh for the work described 
in Chapters 4 and 5 were collected from individuals experiencing their first clinical 
malaria episode during the October to December transmission season years of 1991 to 
2000. 
Malaria was monitored by a village health team composed of doctors, malaria 
researchers and microscopists visiting from a permanent station in the nearby town of 
Gedaref. The team also included a health worker from Daraweesh who lived within a 
family compound in the village. The health team visited the village at least every 
second day during the malaria transmission season (September to November), and 2–
3 times per week outside that period. The residents reported to the team or attended 




suggestive of malaria warranted a blood smear to be made, and if found positive for 
malaria parasites, treatment was administered to the individual by the health team.  
The first line of treatment for uncomplicated malaria was with chloroquine (given as 
10-10.5 mg/kg/day), with sulfadoxine-pyrimethamine (Fansidar, given as 1.25 mg/kg 
body weight) treatment given in instances of chloroquine-resistant infections (A-
Elbasit et al. 2006, Creasey et al. 2004). Quinine was used as a third line of treatment 
and also given to patients allergic to sulfadoxine-pyrimethamine (Andrews et al. 
1990). Figure 2.4.1 on page 66 shows some photographs taken from the fieldwork in 
Daraweesh where the malaria experience of the residents was monitored. 
2.2.4 Edinburgh samples  
Samples used to generate data in Chapter 6 were collected from healthy adult volunteers 
from the University of Edinburgh King’s Buildings. More details about these volunteers 
are given in Chapter 6. 
 
2.3 Cohort selection  
Both the cohorts from Zimbabwe and Daraweesh, Sudan met the following inclusion 
criteria:  
1. Being lifelong residents of the study area 
2. Having provided a blood sample for plasma extraction. 
The volunteers who donated blood for the RNA work in Chapter 6 were all healthy 
Caucasian adults with no history of malaria and having undetectable plasma levels of 
IgG antibodies against MSP-119 antigens of the four Plasmodium species tested. 
2.4 Storage and transport of samples 
Plasma samples collected from the study sites in Zimbabwe and Sudan were kept at -
20°C and shipped to Edinburgh, UK on dry ice before placing at -80°C for long term 






Figure 2.4.1: Photographs from the fieldwork in Daraweesh. A: a typical 
household hut, B: vegetation of Daraweesh in a rainy season; C: Daraweesh in the dry 
season; D: a well that served as a source of drinking water; E and F are respectively 
residual water pool and a well that served as breeding site for mosquitoes. These pools 
were located outside the village of Asar, 4 km south of Daraweesh. (Pictures courtesy 





2.5 Ethical approval  
The study in the three Zimbabwean study sites (Chapter 3) received ethical approval 
from the University of Zimbabwe’s Ethics Review Board and the Medical Research 
Council of Zimbabwe. Permission to conduct the work in each of the three villages was 
obtained from the Provincial Medical Director, the District Educational Officer and 
Heads of schools in the study sites. Project aims and procedures were fully explained to 
the study participants and/or their guardian. Informed oral consent/assent in the local 
Shona language (if guardians could not read nor write) was obtained from 
parents/guardians, or participants if older than ten years, prior to enrolment of the 
participants into the study. The participants were recruited into the study on a voluntary 
basis and were free to withdraw with no further obligation.  
The study in Daraweesh, Sudan received ethical approval from the Ethical Committee 
of the University of Khartoum and national clearance from the Sudan Ministry of Health. 
The study protocol and objectives were explained in Arabic at regular village assemblies. 
Informed oral consent/assent was obtained from parents/guardians, or participants if 
older than 10 years, prior to enrolment of the participants into the study. Participation in 
activities such as finger-pricking for blood sampling was entirely voluntary for all ages.  
Finally, the study in healthy human volunteers in Edinburgh (Chapter 6) received ethical 
approval from the University of Edinburgh Ethics Committee. 
2.6 Recombinant protein expression and purification  
2.6.1 Overview of protein expression 
Protein expression in bacteria is a widely used technique in biotechnology. It involves 
a DNA encoding a target protein being cloned downstream of a promoter in an 
expression vector (Structural Genomics et al. 2008). This vector is subsequently 
introduced into a host cell, usually a bacterium, and the cell’s protein synthesis 
machinery produces the protein of interest. The cells are then lysed to extract the 
expressed protein for subsequent purification and quantification.  
 
Escherichia coli is a Gram negative bacterium that is widely used in protein expression 




shorter culturing or replication time, its ability to grow on low cost medium, and the 
relative ease of genetically manipulating it (Sorensen and Mortensen 2005). Within 
the realm of E. coli expression, the T7 system is the most popular approach for 
producing proteins. In this system, an expression vector containing a gene of interest 
cloned downstream of the T7 promoter is introduced into a T7 expression host. T7 
expression hosts such as DE3 strains or T7 Express strains carry a chromosomal copy 
of the phage T7 RNA polymerase gene (Structural Genomics et al. 2008, Sorensen and 
Mortensen 2005). When an inducer is added, T7 RNA polymerase is expressed and 
becomes dedicated to transcription of the protein of interest (Sorensen and Mortensen 
2005).  
 
2.6.2 Expression of recombinant merozoite surface proteins 
The four MSP-119 antigens (MSP-119 Wellcome sequence) used in this thesis were 
expressed by myself in E. coli as recombinant proteins fused to the C terminus of 
Schistosoma japonicum glutathione S-transferase (GST) using pGEX vectors, as 
previously described (Cavanagh and McBride 1997, Smith and Johnson 1988). MSP-
119 antigens can also be expressed in Saccharomyces cerevisiae, with 
baculovirus/insect cell culture being another example of commonly used expression 
system (al-Yaman et al. 1996, Riley et al. 1992).  
 
Plasmids of MSP-1 Block 2 antigens (3D7, MAD20, Wellcome, RO33), and MSP-2 
serogroups A and B antigens were kindly donated by my co-supervisor (Dr. David 
Cavanagh, University of Edinburgh), and expressed in E. coli as GST-fusion proteins 
(Cavanagh and McBride 1997). The different expression systems have been cited as 
contributing to variations in the prevalence of antibody response to MSP-119 antigen 
in immuno-epidemiological studies (Osier 2008). However, there is evidence from 
epidemiological studies showing that independent of the expression system used, 
strong correlations between human antibodies to the same MSP-l19 sequence are 
observed (Egan et al. 1995), although some correlations are seen to be weaker (John 
et al. 2004b).  
 
All the procedures described below were carried out aseptically. Plasmodium MSP 
antigens were expressed using freshly transformed BL21 (DE3) E. coli. BL21 cells 




mixed by flicking the tube. The cell-plasmid mixture was incubated on ice for 30 
minutes, and the mixture heat-shocked at 42°C for 1 minute in a water bath. The 
mixture was transferred onto ice for 2 minutes. 500 µL of Luria broth (LB) was 
added and incubated at 37°C for 1 hour in a water bath. Aliquot of the mixture was 
pipetted and inoculated on LB agar containing 100 µg/ml of kanamycin. Plates were 
incubated at 37°C overnight.  
 
After examination of bacteria growth, a single transformant colony was grown 
overnight at 37°C in 100 ml of LB supplemented with 100 μg/ml of kanamycin. 10 ml 
each of the overnight bacteria culture was dispensed into four 15 ml Cellstar tubes and 
centrifuged at 500g at 20°C for 10 minutes and resuspended in 10 ml of LB. Content 
of the resuspended culture was added to 1 L LB containing a final concentration of 
100 µg/ml of kanamycin, and incubated with shaking at 37°C until an optical density 
(OD at 600nm) of the culture reached a log phase of OD 0.6. In order to monitor 
growth, aliquots were taken at an hourly interval.  
 
Protein expression was induced with a final concentration of 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and culture incubated in a shaking incubator at 30°C 
for a further 4 hours. Cells were harvested by centrifugation at 500g for 10 minutes 
at 4C in a Sorvall SA3000 rotor. Cell paste was resuspended in 50 ml of 1X PBS 
(Sigma-Aldrich, P4417) and frozen down at -20°C until required. Cells were lysed 
by freeze-thawing and lysate treated with 1 µL/ml Benzonase (Novagen) and 
separated from cell debris by centrifugation at 1000g in GSA rotor at 4°C for 20 
minutes. Supernatant was filtered through a 0.45 µm filters (Acrodisc (R) Syringe 
Filters, Pall Corporation, USA).  
 
Protein purification was performed on the NGC-Chromatography machine using 
phosphate buffered saline (PBS) pre-equilibrated Glutathione Sepharose columns 
(GSTrap, GE Healthcare). After sample application, columns were washed with PBS 
and the GST fusion protein was then eluted with a buffer containing 1 M Tris pH8, 
100 mM reduced glutathione buffer. Eluted proteins were collected and analysed by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Fractions 
that contained purified product were investigated for purity by SDS-PAGE. Protein 




Scientific Pierce, USA). The fractions were then pooled, dialysed against PBS and 
concentrated to the desired concentration by centrifugal ultrafiltration Amicon 
concentrator (Milipore, UK). Table 2.6.1 on the next page shows the recombinant 






























Table 2.6.1: Recombinant Plasmodium merozoite surface proteins used for the 
study described. 
Recombinant antigen Amino acid 
position 
Description Reference 
P. falciparum MSP-119 1584-1620 Wellcome isolate (Burghaus and 
Holder 1994, 
Cavanagh et al. 
1998 
P. vivax MSP-119  1696-1728  Amanfo et al. 2016 
P. malariae MSP-119 1700-1732  Amanfo et al. 2016 
P. ovale MSP-119 1680-1711  Amanfo et al. 2016 
P. falciparum MSP-
1_B2_3D7 








54-144 RO33-like type (Cavanagh and 
McBride 1997) 
MSP-2_CH15019 1-184 Full length, allelic 
type A 
(Taylor et al. 1995) 
MSP-2_Dd2 22-247 Full length allelic 
type B 
(Taylor et al. 1995) 
Note: All the antigens were expressed in E. coli. P. falciparum MSP-1 Block 2 and 






2.6.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE)  
Protein samples were resolved by polyacrylamide gel apparatus using the BioRad 
mini Protein II system. Glass plates (0.75 mm or 1.5 mm spacer plate and short plate) 
were cleaned with detergent and 70% ethanol, then sandwiched together and 
clamped in place in a casting frame and stand. SDS-PAGE was performed using gels 
consisting of 12% resolving gel (1.5 ml 40% acrylamide, 1.3 ml 1.5 M Tris pH8.8, 
50 μl 10% SDS, 50 μl 10% APS, 2.1 ml dH2O, 4 μl TEMED), and 4.5% stacking gel 
(560 µL 40% acrylamide, 0.63 ml 1M Tris pH 6.8, 50μl 10% SDS, 50μl 10% APS, 
3.71 ml dH2O, 5μl TEMED), (protocol provided by my co-supervisor).  
The plates were filled to approximately 2 cm below the top of the short plate and the 
resolving gel was covered with isopropanol. After the gel was set the isopropanol was 
removed, the gel rinsed with distilled water and the stacking gel added. A 10 well 
comb was inserted and the gel allowed to set, after which it was rinsed with distilled 
water and the gel running apparatus assembled. The tank was filled with Tris-Glycine 
running buffer (7.55g Tris base, 47g glycine, 25 ml 10% SDS). 
Protein samples were heated-up at 70oC for 5 minutes and pipetted into wells (10 µL 
sample plus 5 µL sample buffer). Proteins were resolved alongside a protein size 
marker at a constant voltage of 200V for 45 minutes in the running buffer, until the 
bromophenol blue dye just ran off the bottom of the gel. Gels were then taken, rinsed 
with distilled water and stained with Coomassie blue (Life Technology) for 1 hour, 
followed by destaining with distilled water. 
Protein concentration was measured by bicinchoninic acid (BCA) assay (Pierce, UK) 
and calculated against standard curve of bovine serum albumin (BSA, Sigma-Aldrich: 
A0336) diluted in the same buffer used for the samples. 
2.6.4 Protein quantification by Bicinchoninic acid assay 
Bicinchoninic acid assay (BCA) is a colorimetric assay for the detection and 
quantitation of the total protein concentration (Noble and Bailey 2009, Smith et al. 
1985). Concentrations of the merozoite surface proteins from cell lysate were 




instruction. Duplicate test tubes containing 0.1 ml of protein standard, bovine serum 
albumin (BSA) or unknown samples were diluted in 2 ml of working reagent (50 part 
reagent A to 1 part reagent B) and incubated at 37oC for 30 minutes. The tubes were 
cooled at room temperature for 10 minutes. Sample absorbances were measured at 
OD562nm against blank. A standard curve of the average Blank-corrected OD562nm 
measurement for each BSA standard versus its concentration in µg/mL was prepared, 
from which protein concentration of each unknown sample was determined. 
2.7 Principles of Enzyme-Linked Immunosorbent 
Assay (ELISA) 
The underlining principle of the ELISA technique extensively used in this thesis is the 
concept of a Plasmodium-specific antibody binding to its corresponding antigen coated 
on a solid phase, thereby allowing for the detection of very small quantities of these 
antibodies in the plasma samples of malaria patients (Hornbeck 2015, Gan and Patel 
2013). There are three main types of ELISAs, namely; the direct, indirect, and 
sandwich ELISA all of which employ the basic steps illustrated in Appendix A.  
Plasmodium antigens diluted in a suitable buffer were passively absorbed unto a 96-
well polystyrene microtiter plate by hydrogen bonding and incubated for a specific 
time. These loose bonds allow for unbound reactants to be subsequently washed off 
the plate. The plates were washed and blocked with a non-specific protein (skimmed 
milk) to ensure the specific binding of the components added in the subsequent steps. 
Plasma samples diluted in the blocking buffer are added to the solid phase and 
incubated. An enzyme, horse radish peroxidase (HRP), for which hydrogen peroxide 
(H2O2) is a substrate, is covalently-linked to a secondary antibody that has a negligible 
effect on the binding properties of the primary antibody and acts as an amplifier of the 
signal is added (Hornbeck 2015). Unbound conjugates are washed and the action of 
the HRP enzyme on the H2O2 causes a colour change in the chromogen o-
phenylenediamine dihydrochloride (OPD) (Hornbeck 2015, Hornbeck et al. 2001). 
The intensity of the colour formed is proportional to the amount of Plasmodium-
specific antibody in the plasma. To ensure that the reaction does not proceed 




reaction. A spectrophotometer is used to quantify the amount of substance at a specific 
wavelength that is expressed in optical densities (OD). 
2.7.1 ELISA of MSP-1 and MSP-2 antigens 
In this thesis the ELISA technique used for the MSP antigens is as previously described 
(Cavanagh et al. 1998). Plasma samples were tested by ELISA for the presence of IgG 
antibodies able to recognize the recombinant merozoite surface proteins of the four 
Plasmodium species as an indication of recent or current exposure (Cavanagh et al. 
1998) as well as P. falciparum-specific MSP-1 Block 2 and MSP-2 antigens. 
96-well plates (Microlon, Greiner) were coated with 100 μL of 50 ng of each 
recombinant MSP-119 antigens of the four Plasmodium species in carbonate 
bicarbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.4) and incubated 
overnight at 4°C in a humidified atmosphere. Plates were washed four times in 
washing buffer [0.05% Tween-20 (Sigma-Aldrich: P9416) in PBS] using Skatron 
Skanwasher to remove unbound antigens and blotted on paper towels (Kimberley 
Clark 3-ply hand towels). Free binding sites in wells were blocked with 200 μL per 
well of blocking buffer (1% w/v skimmed milk powder in the PBS buffer) for 5 hrs at 
room temperature. The plates were further washed four times.  
Human plasma diluted 1:500 in the blocking buffer (100 μL per well) was added in 
duplicate to the MSP antigens-coated wells and incubated overnight at 4°C, in 
accordance with published protocols (Cavanagh et al. 1998). After four washes, the 
wells were incubated for 3 hrs at room temperature with 100 μL per well of horseradish 
peroxidase-conjugated rabbit antihuman IgG (1:5000) (Dako Ltd, High Wycombe, 
UK).  
Plates were washed four times to remove unbound secondary antibody before reaction 
development with 100 μL of substrate buffer [(0.04 mg/ml of o-phenylenediamine; 
Sigma, St Louis, MO, USA; 0.012% H2O2 in development buffer (24.5 mM citric acid 
monohydrate and 52 mM Na2HPO4, pH 5.0)] for 10-15 min at room temperature. An 
unstopped positive control plate was read at an optical density (OD) 450 nm, with an 
OD 450 nm of 0.7-0.8 taken to be equivalent to OD 492 nm of 2.5-3.0. The reaction 
was stopped by the addition of 25 μL of 2 M H2SO4 per well, and the OD measured at 




GST protein, purified from E. coli transfected with pGEX-2T alone, was used as a 
control to determine the non-specific (background reactivity) binding of human IgG 
to the GST. A well containing only coating buffer also served as an additional internal 
control. Corrected OD values for each plasma sample were calculated by subtracting 
the mean OD value of wells containing control GST protein from the mean OD value 
obtained with each test sample MSP-1 antigen. Cut-off values at which binding of 
antibody from malaria-exposed individuals was regarded as significantly above 
background were calculated as corrected OD above the mean plus 3 standard deviation 
of OD readings obtained with plasma samples from eight Scottish blood donors with 
no history of exposure to malaria. The cut-off OD values for each MSP-119 Ag were 
as follows: P. falciparum 0.217, P. malariae 0.114, P. vivax 0.110 and P. ovale 0.159. 
Day to day and plate to plate variability in ELISA outputs are common owing the 
factors such as variations in room and incubating temperatures. To account for this 
possible outcome, the same malaria positive control, pooled plasma sample from 
Brefet, The Gambia, was run in duplicate at four plasma dilutions (1:500, 1:1000, 
1:2000 and 1:4000), on each plate and on each day. Standard curves were plotted and 
the absorbances of the test samples calculated from it.  
2.8 Data entry 
Data such as a participant’s fever history and body temperature measurements were 
double entered into Microsoft Office Excel (Microsoft, USA) by two independent 
researchers and verified for accuracy. Malaria blood film and parasitaemia count 
results were entered into a separate spreadsheet at the time of diagnosis and double 
entered in Excel. Records of blood samples that were collected and processed were 
recorded each day and at the end of the fieldwork transferred to Excel. 
2.9 Statistical analysis  
This section provides an overview of the main statistical methods used in the project 
to test different hypotheses, with specific details according to each chapter expanded 





2.9.1 Parametric tests 
In parametric statistics the data are assumed to come from a known underlying 
distribution (e.g. normal distribution) and hypothesis testing is based on the 
assumptions made (Rosnar 2000). The following parametric techniques were used for 
exploratory data analysis and to test for associations: 
(i) Descriptive statistics was used to reveal the basic features of the data and 
provide summaries about the means, median and variability (standard 
deviations, SD and standard errors, SE) of the variables of interest.  
(ii) The Pearson's correlation coefficient (r) was used to estimate the strength 
of association between pairs of continuous variables. 
(iii) The logistic regression analysis was used to test relationships between 
variables while adjusting for the effects of other factors that can consist of 
discreet as well as continuous variables.  
2.9.2 Non-parametric tests 
When the assumptions of parametric test were not met, non-parametric tests were used 
instead. These tests work on the principle of ranking the data and thus the assumptions 
are less stringent than for parametric tests (Rosnar 2000). However, in making no 
assumptions about the data, the tests are sometimes considered less powerful. Non-
parametric tests do not require normally distributed data and the data were therefore 
not normally transformed prior to conducting the test, however the test does require 
data that has the same distribution (Sprent and Smeeton 2001). The non-parametric 
statistics used included: 
(i) The Chi-square (χ2) test, used to test for associations between independent 
categorical variables.  
(ii) The Spearman's rank correlation (p), used to measure the degree of association 
between two variables, appropriate for discrete data or when there were reasons 
to question the normality of the underlying data distribution. 






Chapter 3. Seroepidemiology of Plasmodium 
species in a Zimbabwean population  
Part of this work has been published I the Malaria Journal (Amanfo et al. 2016), and 
a copy of the publication is included in Appendix H. 
3.1 Introduction 
Malaria is a major public health problem in Sub-Saharan Africa, and is responsible for 
over half a million deaths annually, especially in children under the age of five years 
(WHO 2015, WHO 2013). Four major species of the protozoan parasite, Plasmodium, 
(P. falciparum, P. vivax, P. malariae, and P. ovale) cause human malaria in Sub-
Saharan Africa. In malaria-endemic countries, there is an overlap in the geographic 
distribution of the different Plasmodium species and the Anopheles mosquito vectors 
that transmit these parasites. Individuals may be exposed to, and harbour multiple 
Plasmodium species (Zimmerman et al. 2004). Generally, the epidemiology of the 
non-P. falciparum species in malaria-endemic human populations is not well 
documented (Howes et al. 2015), with only a few specific studies on the epidemiology 
and clinical outcomes of P. malariae and P. ovale infections that are largely based on 
clinical case reports and other hospital-based studies (Sutherland 2016, Hase et al. 
2013, Chadee et al. 2000). Diagnosis of malaria is important in enabling health 
practitioners to make informed decisions on treatment and management of malaria 
patients. Similarly, detection of mixed-species malaria infections helps to assess the 
prevalence and magnitude of the disease burden caused by these species in endemic 
populations. 
In malaria-endemic clinical settings, disease diagnosis is predominantly by the ‘gold 
standard’ blood film microscopic examination, and rapid diagnostic tests (RDT), both 
of which lack sensitivity and specificity in differentiating the species of Plasmodium 
causing malaria (Wilson 2012). Microscopic examination of Giemsa stained 
peripheral blood smears has limitations such as the inability to detect low levels of 
parasitaemia, and the difficulty in species differentiation owing to subtle differences 




species of Plasmodium causing disease being rarely reported (Obare et al. 2013, Ohrt 
et al. 2002). In view of this almost all cases of malaria are attributed to P. falciparum, 
the species responsible for life-threatening disease (Howes et al. 2015). This has led 
to underestimates of the prevalence of both mixed-species and non-P. falciparum 
species infections (Snounou and White 2004). These non-P. falciparum species are of 
significant clinical importance; for example, P. vivax and P. ovale which form latent 
liver stage ‘hypnozoites’ are capable of causing disease several months or years after 
the primary infection (Coldren et al. 2007). Systemic diseases such as nephrotic 
syndrome caused by P. malariae several months or years after people have returned 
from malaria-endemic regions have been reported (Vinetz et al. 1998). In some cases, 
drug treatment failure attributable to the misdiagnosis of primary infections caused by 
the non-P. falciparum species or as co-infecting species with P. falciparum have been 
observed (Smith et al. 2011), while P. malariae has been diagnosed following 
antimalarial treatment of uncomplicated P. falciparum infections (Franken et al. 
2012).  
Even though the WHO recommends that all RDTs should be capable of detecting all 
four species of malaria parasite that infect humans, there is currently no available kit 
that is able to detect and differentiate among all four species, with most RDTs unable 
to differentiate the non-P. falciparum species (Howes et al. 2015). There is therefore 
an urgent need for additional sensitive diagnostic tools capable of rapid detection and 
differentiation of all four infecting Plasmodium species for effective treatment, 
management and control of malaria (Howes et al. 2015, Mueller et al. 2007, 
Zimmerman et al. 2004). This is because diagnostic tools that can detect exposure to 
all four parasite species, which are easy to use and readily available in settings where 
they are most needed will help with targeted treatment of the infecting species, increase 
our understanding of the epidemiology of the different species as well as their 
contribution to the overall malaria burden. Employing MSP-119 antigens from the four 
human Plasmodium species may complement the existing tools for malaria diagnosis. 
In spite of the high sensitivity and specificity of PCR typing of infecting Plasmodium 
species the technique is not frequently available or applicable in many African clinical 
laboratory settings (Daniels et al. 2017), owing to its high cost and the requirement of 
qualified technical staff. These molecular surveys of parasite species have shown that 




malariae and/or P. ovale species are more common than previously reported (Daniels 
et al. 2017).  
The surface of the invasive merozoite is coated in MSP-1 which constitutes 31% of 
the GPI-anchored proteins on P. falciparum merozoites (Gilson et al. 2006). MSP-1 is 
expressed by all four human Plasmodium species (Birkenmeyer et al. 2010, Pizarro et 
al. 2003). In P. falciparum, MSP-1 undergoes two proteolytic cleavages resulting in a 
C-terminal MSP-119 fragment that is carried into the erythrocyte during merozoite 
invasion (Blackman et al. 1990, McBride and Heidrich 1987). Until recently, only the 
MSP-1 genes of P. falciparum and P. vivax had been characterized. In 2010, the 
sequences of the MSP-119 gene fragments for P. malariae and P. ovale were 
determined, but there has been limited characterization of the responses to these 
parasite proteins in human populations (Birkenmeyer et al. 2010, Muerhoff et al. 
2010). The authors found antibody detection assays of parasite exposure using 
recombinant MSP-119 proteins to be highly sensitive, but did not determine the species 
specificity of the antibody responses in their assay (Muerhoff et al. 2010). Although 
the gene sequences of MSP-119 antigens are unique to each of the four Plasmodium 
species, extensive homology can be found among them (Figure 3.1.1 on page 80).  
For example, the number and relative positions of the cysteine residues within the C-
terminal fragments of MSP-119 are comparable in all four Plasmodium species 
(Birkenmeyer et al. 2010). In addition, there are about 32 amino acid sites within the 
MSP-119 gene where all four parasite species share the same amino acid, and about 30 
sites where the same amino acid is conserved in two or three Plasmodium species 
(Figure 3.1.1). Comparative analysis of the amino acids using the Clustal Omega 
programme (Sievers et al. 2011) shows that between any two species there is between 






Figure 3.1.1: Sequence homology of Plasmodium MSP-119 antigens. Dots or semi-colons (. or :) indicate gene site where the same amino 
acid is shared between two or three Plasmodium species, while the asterisks (*) indicate conserved amino acid present in all four Plasmodium 





Table 3.1.1: Amino acid sequence comparison (%) of Plasmodium species MSP-
119. 
Plasmodium species P. falciparum P. ovale P. vivax P. malariae 
P. falciparum  100    
P. ovale 51.65 100   
P. vivax 53.26 59.78 100  
P. malariae 51.09 54.34 56.99 100 
 
The antigens for my work were chosen based on evidence that MSP-119 of P. 
falciparum and P. vivax are highly recognised by more than 90% of malaria-exposed 
individuals in different geographical areas in Africa, Brazil and South Korea (Park et 
al. 2001, Cavanagh et al. 1998, Soares et al. 1997, Riley 1992), and that these MSP-
119 antigens of P. falciparum and P. vivax are frequently used either alone or in 
combination in many seroepidemiological studies. Moreover, the P. falciparum and P. 
vivax MSP-119 antigens as well as P. falciparum-specific MSP-2 serogroups A and B 
antigens are components of Trinity Biotech’s CaptiaTM Malaria Total antibody EIA kit 
(formerly Newmarket Malaria EIA and marketed by Newmarket Laboratories Limited, 
UK) that is extensively used as a diagnostic kit for the screening of blood donors for 
malaria in many countries including the Scottish Blood Transfusion Services and other 
European and Australian Blood Banks (Seed et al. 2005a, Kitchen et al. 2004). 
Although this EIA kit’s sensitivity (99.2-100%) has been shown to be comparable to 
that of the indirect fluorescence test, and its specificity sufficient to screen ‘malaria-
risk’ donors, it still depends on antibody cross reactivity to identify recent P. malariae 
and P. ovale exposure (Seed et al. 2005a, Kitchen et al. 2004). Ideally, a pan-
Plasmodium specific antibody test capable of detecting human exposure to all four 
major Plasmodium parasites is needed (Hemingway et al. 2016), and recombinant 
MSP-119 antigens show promise in this regard (Amanfo et al. 2016, Muerhoff et al. 




In Zimbabwe over half of the population are exposed to malaria, with P. falciparum 
being the predominant species, accounting for almost all cases of the disease (Hay et 
al. 2009, Mabaso et al. 2006, Taylor and Mutambu 1986). There is little or no 
epidemiological data of exposure to the non-P. falciparum species and/or mixed-
Plasmodium infections in Zimbabwe. To date, there is no commercial kit available in 
the market that incorporates MSP-119 antigens of all four human Plasmodium species, 
and there has been no field study using all four recombinant MSP-119 antigens to 
characterize the seroepidemiology of exposure to Plasmodium in any African 
population. This knowledge gap is addressed in this chapter with samples from 
Zimbabwe. 
 
3.2 Study aim 
To determine the seroepidemiology of the different Plasmodium species in a 
Zimbabwean population.  
This was done by developing an ELISA based on antigens derived from merozoite 
surface proteins, also known as MSP-119, from four human Plasmodium species. This 
assay is capable of detecting exposure to all four human Plasmodium species, based 
on serum antibody responses to the C-terminal merozoite surface protein 1 (MSP-119). 
The assay is a relatively simple and inexpensive technique that could be of great 
applicability for epidemiological studies, the screening of blood donors and the 
serological diagnosis of the infecting Plasmodium species causing malaria if it is 
developed fully as a rapid diagnostic test. 
 
3.3 Hypotheses 
1. IgG antibody responses to Plasmodium MSP-119 antigens will show species 
specificity. 






3.4 Materials and methods  
3.4.1 Study populations 
Plasma samples were collected in three Zimbabwean villages where malaria parasite 
transmission is described as mesoendemic (Taylor and Mutambu 1986), as part of a 
broader study investigating the immuno-epidemiology of schistosomiasis in villages 
with Plasmodium co-infection. The study sites were Burma Valley in the Eastern 
Highlands, Manicaland Province, where samples were collected in 1994 (Mutapi et al. 
1997, Hagan et al. 1994), Chiredzi in the south eastern Masvingo Province, where 
samples were collected in 1999 (Mutapi et al. 2003), and Mutoko in the north eastern 
Mashonaland Province of Zimbabwe, where samples were collected in 2003 (Mutapi et 
al. 2006). The study cohort in each village consisted of 100 participants aged between 
five and 18 years (both males and females). Details of the age distribution of this cohort 
are shown in Table 3.4.1. Antibody responses to merozoite surface proteins from four 
human Plasmodium species were detected using enzyme-linked immunosorbent assays 
(ELISA). 
 
Table 3.4.1: Age (in years) of study population from the three villages according 
to gender. 
Study area Age 
range 
Mean age Median age Male (%) Female (%) 
Burma Valley 6-15 11.00 10 49 51 
Mutoko 5-18 16.86 9.5 36 64 
Chiredzi 7-16 15.06 11 52 48 
 
3.4.2 Recombinant antigens 
MSP-119 antigens used in the ELISAs were expressed in E. coli transformed with 
pGEX-derived plasmid constructs (Polley et al. 2006, Cavanagh et al. 1998, Cavanagh 
and McBride 1997, Burghaus and Holder 1994) as recombinant proteins fused to 




purified by affinity chromatography using HiTrap glutathione Sepharose columns on 
an AKTAprime system and quantified by the Bicinchoninic acid assay. 
 
3.4.3 ELISA procedure 
The ELISA protocol has already been described in the materials and methods, in 
section 2.7.1.  
3.4.4 Competition ELISA 
Given that MSP-119 antigens from the four human Plasmodium species share some but 
not all antibody epitopes, competition ELISA was performed to determine the 
contribution of shared or antigen-specific epitopes to antibody reactivity in plasma. 
Competition ELISA was performed on plasma samples from individuals with antibody 
reactivity (optical densities ≥1.0) to more than one MSP-119 antigen, to assess whether 
human anti-MSP-119 IgG antibodies specific for MSP-119 were species-specific or 
cross-reacted with each other. 
Each pre-diluted plasma sample was incubated with different concentrations of soluble 
MSP-119 antigen, and then added to the wells of microtitre plates coated with either the 
homologous or heterologous MSP-119 antigen. In this context, a homologous antigen 
is defined as identical to the competing antigen pre-incubated with the plasma sample, 
whereas a heterologous antigen is from a different Plasmodium species than the 
competitor antigen. The rationale of the competition ELISA is that shared epitopes 
between the competing and plate-bound antigens alleles will be blocked in the pre-
incubation step and that appropriate antigen epitopes will react with their 
corresponding paratopes in the plasma, so that with increasing antigen concentration, 
all paratopes in the plasma react with the antigen, leaving none available to bind to 
antigen on the solid-phase microtitre plate (Gan and Patel 2013, Cavanagh and 
McBride 1997). In the case of antigens without corresponding paratopes in the plasma, 
there will be no prior reactivity between the antibodies and antigens, regardless of the 
antigen concentration, and binding to heterologous antigens will be unaffected.  
The same ELISA protocol described in section 2.7.1 was followed with slight 
modification. Plates were coated with recombinant MSP-119 Ag and incubated 




concentrations (0 to 10 μg/ml) of soluble competing homologous or heterologous Ag, 
i.e., with up to 20-fold excess over the 0.50 μg/ml immobilized Ag to allow sera to 
bind to the antigen before reacting with the antigen bound on the plate, then tested on 
the plate-bound Ag overnight. This was followed by washing and incubation with a 
horseradish peroxidase-conjugated second Ab, as described previously in the indirect 
ELISA in section 2.7.1.  
3.4.5 Statistical analyses 
To determine if exposure prevalence derived from single species data differed from 
that based on mixed-species, Chi-square (χ2) test was used. Data were analysed and 
graphs constructed with GraphPad Prism 7® software (San Diego, CA, USA). All 




3.5 Results  
3.5.1 Specificity of IgG antibodies reactivity to Plasmodium MSP-119 
antigens 
300 plasma samples from the three study sites were screened by ELISA for antibody 
responses to MSP-119 antigens. 140 of these had mixed-species responses of varying 
optical densities. Competition ELISA was performed on 30 plasma samples with 
antibody reactivity (of at least optical density ≥1.0) to more than one Plasmodium 
species MSP-119 antigen. Competition ELISA showed that in plasma samples reactive 
against recombinant MSP-119 antigens from more than one parasite species, anti-MSP-
119 IgG antibody responses were species-specific and did not cross-react. In positive 
control wells, for example, where P. falciparum MSP-119 antigen was coated onto the 
microtitre plates (as capture antigen), plasma pre-incubated with P. falciparum MSP-
119 (competing homologous antigen), were inhibited from binding in a dose-dependent 
manner (e.g. Figure 3.5.1, red solid line). This inhibition occurred at competing 
homologous Ag concentration as low as 0.1 μg/ml with some plasma samples. Similar 
results were observed when the homologous competitor antigens were either P. 
malariae MSP-119 (Figure 3.5.1., blue solid line), or P. ovale, or P. vivax (Appendix 
C).  
 
To assess anti-MSP-119 cross-reactivity, P. falciparum MSP-119 antigen was coated 
onto microtitre plates and dual specificity sera were pre-incubated with increasing 
concentrations of the heterologous P. malariae or P. ovale or P. vivax MSP-119 
antigens. IgG binding to P. falciparum MSP-119 antigen was not inhibited by soluble 
heterologous P. malariae or P. ovale or P. vivax MSP-119, even at concentration 20 
times the capture antigen. This was also true when the coating and competing antigens 
were reversed in the assay (Figure 3.5.1 blue and red dashed lines, and Appendix C). 
The pattern of complete inhibition observed between homologous antigens and the 
lack of inhibition between heterologous antigens as shown in Figure 3.5.1 was typical 
in all the 30 plasma samples tested. The corrected absorbance readings for the 100 






Figure 3.5.1: IgG antibodies to recombinant Plasmodium MSP-119 antigens are 
species specific. Plasma samples were tested at 1 in 500 dilution. Legends indicate the 
pairs of competing antigens used, with the well-bound capture antigen listed first and 
the competing homologous (control) or heterologous (test) antigen second. The 
capture antigens were coated at 50 ng/well. In each panel the red and blue solid lines 
with open circle symbols represent competition reactions involving homologous 
antigens, while the red and blue dashed lines with open triangle symbols represent 
reactions involving heterologous antigens. The y-axis indicates antibody absorbance 
measured at 492nm whiles the x-axis shows a titration with increasing concentrations 
of the competitor homologous or heterologous antigen added to the diluted plasma 
sample. The figure shows reactions between P. falciparum (Pf), and P. malariae (Pm). 
Ag is antigen. The reactions between other pairs of Plasmodium species are shown in 
Appendix C.  
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3.5.2 Different plasma dilutions do not affect antibody response  
My co-supervisor’s laboratory (Dr. David Cavanagh) previously used checkerboard 
titrations to standardise its ELISA protocols and had determined an optimal serum or 
plasma dilution of 1:500 for immuno-epidemiological studies involving MSP-119 
antigens, and this has been used in previous epidemiological studies (Cavanagh et al. 
2004, Cavanagh et al. 1998, Egan et al. 1995). This plasma dilution was chosen as 
optimal because it was the best compromise between sensitivity and specificity in the 
assay. The lack of standardized ELISA protocols with respect to serum or plasma 
dilution for determining antibody response to blood-stage antigens of Plasmodium 
parasites has been highlighted as a factor that accounts for variations observed in the 
reported prevalence of antibodies to MSP-119 in different epidemiological studies 
(Osier 2008, John et al. 2005). For example, Osier highlighted in her PhD thesis two 
independent studies (Cavanagh et al. 2004, Dodoo et al. 1999) conducted on the same 
Ghanaian cohort measuring serum IgG response to the same P. falciparum MSP-119 
antigens. These studies reported different prevalence to the protein, partly due to the 
different serum dilutions used (Osier 2008). In these studies, while Dodoo et al. 
reported anti-MSP-119 prevalence of approximately 30% at a serum dilution of 1:1000, 
Cavanagh et al. reported a higher prevalence of 56% at a serum dilution of 1:500. The 
higher serum dilutions used in the work by Dodoo et al. might partly account for the 
differences in the two reported prevalences, assuming the levels of antibodies present 
in the serum were low. 
With the above differences in mind and to ensure that low concentrations of antibody 
responses to parasite antigens were not missed, or mixed-species responses were not 
misclassified as single response as a result of the plasma dilution of 1:500, individual 
plasma samples and a pooled plasma sample with high reactivity to single species 
MSP-119 as well as samples with no reactivity to any parasite antigens (i.e. negative 
samples) were re-tested at two different dilutions, the original 1:500 and a lower 
dilution of 1:50 (high concentration, i.e. being only a 10th of the original dilution).  
As seen in Figure 3.5.3, in plasma samples with single species anti-MSP-119 
responses to either P. falciparum (panels A and B), P. malariae (panel C) or P. ovale 
(panel D) antigens, there was a marginal change in the absorbance at the two 




absorbance of the non-reacting species at the two different dilutions, indicating that 
mixed-species responses were not missed at the 1:500 plasma dilution. I did not use 
neat plasma, as this had the potential of giving a lot of background interference 
owing to high antibody reactivity, and also considering plasma volume of 100 µL 
required to perform the test. There is no plot for P. vivax as there was no individual 
with a response to this parasite antigen alone. 
 
 
Figure 3.5.3: Plasma dilution has no effect on the specificity of IgG antibodies to 
MSP-119 antigens. Plasma samples with responses to single species were assayed by 
ELISA at two different dilutions (1:50 and 1:500) to determine whether the original 1 
in 500 dilution did not underestimate mixed-species responses. The figure shows four 
independent plasma samples with single species responses to P. falciparum only (A), 
pooled samples of P. falciparum only (B), P. malariae only (C) and P. ovale only (D). 
The y-axis indicates antibody absorbance measured at 492nm whiles the x-axis shows 
the two dilutions of 50 and 500.  
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3.5.3 Prevalence of human IgG antibodies to recombinant MSP-119 
from four Plasmodium species 
Antibody recognition of the panel of four Plasmodium recombinant MSP-119 antigens 
was tested by ELISA against 100 plasma from each of the three study sites (Burma 
Valley, Mutoko and Chiredzi). Overall prevalence of IgG responses to MSP-119 
antigens in the three villages was 41.3% (95%CI: 31.6-50.9). The observed prevalence 
of IgG response to all recombinant MSP-119 antigens was 61% (95%CI: 51.4-70.6), 
31 (95%CI: 21.9-40.1) and 32% (95%CI: 22.9-41.1) in the Burma Valley, Mutoko and 
Chiredzi villages, respectively (Figure 3.5.4). There were no significant differences 
between the exposure prevalence between the villages (Burma Valley vs Mutoko: 
χ2=0.002, df=1, P=0.97), (Burma Valley vs Chiredzi: χ2=0.423, df=1, P=0.52) and 
(Mutoko vs Chiredzi: χ2=0.001, df=1, P=0.97). 
 
 
Figure 3.5.4: Prevalence of IgG response to MSP-119 antigens in three 
Zimbabwean population. Comparisons by study village on a population of 100 
participants in each study village. The error bars indicate 95% confidence intervals. 
 


































3.5.4 Single vs. mixed-Plasmodium species anti-MSP-119 responses 
Taking the three Zimbabwean villages as a single population, mixed-species IgG 
response to MSP-119 accounted for nearly 50% of individuals in the study. Of the 
individuals with anti-MSP-119 responses in all three study areas, Burma Valley (n=61), 
Mutoko (n=31) and Chiredzi (n=32), the prevalence of single- and mixed-species 
responses at a plasma dilution of 1:500 in Burma Valley and Mutoko were comparable, 
whiles in Chiredzi the proportion with single species responses were higher than mixed 
species responders (Table 3.5.1). In the single species response category, IgG 
antibodies were predominantly against P. falciparum MSP-119 antigens (80, 68.8 and 
78.3%) in Burma Valley, Mutoko and Chiredzi respectively. Antibody responses to P. 
malariae or P. ovale ranged between zero and 31.2% (Table 3.5.1). In responders with 
antibodies to mixed-Plasmodium species, antibody responses to the non-P. falciparum 
species were almost always accompanied by responses against P. falciparum MSP-119 
antigens in all three study areas (Table 3.5.1). 
Mixed-Plasmodium species antibody responses were very common. IgG responses to 
P. falciparum and P. malariae MSP-119 accounted for 78-87%, with responses 
between P. falciparum and P. ovale MSP-119 accounting for ~50%. The high exposure 
prevalence of IgG responses to P. malariae MSP-119 antigens suggests that infection 
with this parasite species is at a higher frequency in these populations than has been 
previously reported, and that co-infection, or co-exposure is predominantly associated 
with the main, usually stronger response to P. falciparum MSP-119.  
While there were no single species responders to P. malariae MSP-119 in Mutoko, a 
much higher proportion of this cohort (31.2%) responded to three parasite antigens (P. 
malariae, P. falciparum, and P. ovale) compared to the other two villages. Only one 
individual in Chiredzi had an antibody response to P. vivax antigen in addition to a 


















Single species anti-MSP-119 responders Mixed-species anti-MSP-119  
responders 








P. ovale only 
P. 
falciparum/ 








& P. ovale 
Burma 
Valley  
39 30 31  24 (80) 3 (10) 3 (10) 26 (83.9) 2 (6.5) 0 1 (3.1) 2 (6.5) 
Mutoko  69 15  16  11 (68.8) 0 4 
(31.2) 
6 (37.5) 2 (12.5) 0 3 (18.8) 5 (31.2) 
Chiredzi  68 23  9  18 (78.3) 3 (13) 2 
(8.7) 
6 (66.7) 0 1 (11.1) 0 2 (22.2) 
Note: Values indicate the number of responders while those in parenthesis are expressed as percentage (%) of responders in the respective 







When single species IgG responses to only P. falciparum were compared to mixed-
species responses involving P. falciparum with P. malariae and/or P. ovale, no 
significant differences were observed in any of the three villages. When the cohort was 
divided into two age groups, based on the median age (i.e., those below ten years and 
those ten years and above), it was observed that the overall exposure prevalence in the 
two age groups was comparable in both Burma Valley (χ2=3.5, df=1, P=0.06) and 
Mutoko (χ2=0.05, df=1, P=0.83). However, in Chiredzi a significantly higher exposure 
prevalence was observed in responders aged ten years and above compared to those 
below ten years (χ2=6.13, df=1, P=0.01) (Table 3.5.2). Differences between the two 
age groups in responders to single- and mixed-Plasmodium species in all three study 
areas were not compared because of the smaller sample sizes involved. An important 
observation was the consistent higher absolute ELISA absorbance of P. falciparum 
responses compared to the non-falciparum species in the context of co-infection, while 
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(86.7) 
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(6.6) 
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(33.3) 
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(22.2) 
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(22.2) 
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3                 
(42.8) 
0 1              
(14.4) 
3                    
(42.8) 
Chiredzi <10 (25) 3                    
(12) 
2   
(66.7) 
1   
(33.3) 
2           
(100) 
0 0 1                     
(100) 
0 0 0 




8    
(27.6) 
16         
(76.2) 




5                 
(62.5) 
0 0 2                
(25) 
Note: Values in parenthesis are expressed as percentage (%) of responders in the respective categories. One hundred individuals were 





In this current study, IgG responses to recombinant MSP-119 antigens (an indication of 
prior exposure to Plasmodium antigens) were determined by ELISA, from the four 
major human Plasmodium species in three Zimbabwean villages.  
 
In the current study, the antibody response to individual Plasmodium recombinant 
MSP-119 antigens in humans was seen to be highly species-specific. Furthermore, the 
study showed that naturally acquired human antibodies to individual species variants 
of MSP-119 were not cross-reactive, despite the significant amino acid sequence 
similarities between the four Plasmodium MSP-119 antigens. Specificity of antibody 
binding to its target antigen is a cardinal characteristic feature, often described as the 
lock and key system (Abbas 2011). This is because antibodies possess a highly 
complementary site structure to that of their target antigens. In experimental monkey 
and human studies utilizing all four Plasmodium species MSP-119 antigens, a superior 
sensitivity was seen when compared to commercially available antibody assays 
(Muerhoff et al. 2010). The only commercially available kit (Malaria EIA) that 
incorporates MSP-119 antigens is marketed by the Newmarket Laboratories, and 
mainly used for screening of blood donors (Seed et al. 2005a, Seed et al. 2005b). The 
assay is designed to detect antibodies in individuals infected with the four major 
Plasmodium species but incorporates only the MSP-119 antigens of P. falciparum and 
P. vivax and depends on cross-reactivity in detecting the other two species (Kitchen et 
al. 2004). The package insert of this assay states that “the antigenic similarity between 
Plasmodium species means that antibodies to all species can be detected”. Although 
the assay shows a high sensitivity and specificity against P. falciparum and P. vivax, 
these are lower in P. malariae and P. ovale infections (Kitchen et al. 2004, Chiodini 
et al. 1997), possibly due to its dependence on cross-reactivity as opposed to having 
the antigens of these two parasites incorporated in the assay.  
 
As previously shown in this chapter (Figure 3.1.1 and Table 3.1.1), the sequence and 
phylogenetic analysis of the amino acid sequences of four Plasmodium MSP-119 
clearly shows that each parasite’s sequence is unique and not simply a variant of each 




have a diagnostic tool that incorporates all four antigens to improve and increase the 
specificity and sensitivity of detecting the other two species. The specificity of IgG 
antibodies to these MSP-119 antigens observed in this current study supports the 
evidence that these antigens could be used in pan-malaria diagnostic assay to enable 
the rapid detection of the type of Plasmodium species causing malaria (Muerhoff et al. 
2010).  
 
The overall antibody prevalence in the three villages was 41.3% ranging from 31 to 
61% in the three study areas. In malaria endemic areas the prevalence of IgG antibody 
responses to MSP-119 antigens are influenced by various factors and have been 
variedly reported to range from 4 to 96% (Dodoo et al. 1999, Hogh et al. 1995). Some 
of the factors implicated as contributing to increasing prevalence antibody response to 
MSP-119 antigens are increasing age, (Cavanagh et al. 2004, Dodoo et al. 1999, Egan 
et al. 1995), the health status of the study population (Branch et al. 2000), when 
populations have documented clinical episodes of malaria (Dobano et al. 2008, 
Cavanagh et al. 1998) and when study populations are parasitaemic at the time of 
sampling (Osier et al. 2007, Polley et al. 2004, Tolle et al. 1993). The study population 
in Zimbabwe were of younger age group, and in ‘good health’ at the time of sampling, 
as none was hospitalised. The variation in the prevalence between Burma valley and 
the two villages might be accounted for by differences in the different transmission 
years when samples were taken in each of the villages, although all samples were 
collected just before the malaria transmission season.  
 
In many malaria-endemic countries in Sub-Saharan Africa, P. falciparum is the 
predominant species that causes malaria, thus it was not surprising that the antibody 
response to P. falciparum MSP-119 antigens was predominant in all three study sites. 
Since P. falciparum infections have higher parasitaemias than the other malaria 
parasite species (Oguike et al. 2011, Bruce et al. 2008), it is likely that individuals will 
have a stronger immune response to P. falciparum infection. One of the novel findings 
from this study was the indication that the exposure prevalence of P. malariae and P. 
ovale is higher than expected, as previous reports have attributed about 98% of all 




al. 2006). More importantly, the observed higher exposure prevalence of P. malariae 
in the Burma Valley district was striking, as reports suggest that this species only 
accounts for between 1 and 2.6% of all malaria cases diagnosed by light microscopy 
(Langford et al. 2015, Scopel et al. 2004, Al-Maktari and Bassiouny 2003). 
Microscopy has long been known to underestimate the prevalence of the non-P. 
falciparum species owing to difficulties in distinguishing the subtle differences in the 
morphology of the different species as well as the challenge posed in detecting 
minority species in a blood film with high density P. falciparum parasitaemia. It is 
therefore not surprising that these assays detected a higher sero-prevalence of these 
species, as this also reflects recent and concurrent parasite exposure. Studies 
employing nucleic acid based techniques for Plasmodium parasite detection and 
species identification in some African countries have reported prevalence of the non-
P. falciparum species to be between 1 and 17% (Oguike et al. 2011, Bruce et al. 2008).  
 
While antibody responses to single species P. falciparum antigens were common, 
single species responses to P. malariae and P. ovale antigens were infrequently 
detected. A significant proportion of individuals with IgG responses to P. malariae 
and/or P. ovale MSP-119 almost always had responses to P. falciparum MSP-119. This 
results support the findings of a recent study in Ghana that reported frequent detection 
of P. malariae and P. ovale in individuals who were also PCR positive for P. 
falciparum (Dinko et al. 2013), and a previous findings in Ivory Coast in which P. 
malariae infections were always seen in mixed-infections with P. falciparum (Black 
et al. 1994). The plasma dilution (concentration of plasma IgG antibody) used did not 
affect the responses generated, with single species responders at both 1:50 and 1:500 
plasma dilutions giving the same antibody response type. Existing kit uses undiluted 
plasma or serum (Kitchen et al. 2004), and would likely pick up much higher amounts 
of antibodies if adapted for the four antigens. My assay was not compared to any of 
the existing kits which could have added extra value to my claim of species specificity. 
However, the laboratory of my co-supervisor is undertaking a comparative study 
between the four Plasmodium MSP-119 antigens and the Malaria EIA kit from the 
Newmarket Laboratory using the Zimbabwean and Daraweesh blood samples I used 




Gambia), and malaria positive blood samples from the Scottish Blood Transfusion 
Services. The outcome of this comparative study would further demonstrate the 
sensitivity and specificity of these MSP-119 antigens as potential diagnostic tools for 
accurate detection of the species of Plasmodium responsible for malaria. 
 
The reasons for this co-occurrence of the non-P. falciparum species with P. falciparum 
may be both epidemiological and biological. Of the epidemiological reasons, it has 
been suggested that the same Anopheles mosquito circulating in a population might be 
responsible for the simultaneous or sequential inoculation of the different species 
(Snounou and White 2004), thereby increasing the likelihood of multiple species 
infections. Biological reasons may include selective advantages for these minor 
species when co-infecting with P. falciparum. For example, due to density-dependent 
regulation of immune responses directed against the majority species (P. falciparum), 
these non-P. falciparum species may be able to evade host immune responses and 
establish disease (Bruce and Day 2002, Bruce et al. 2000). There are also parallels in 
other infectious diseases, such as the obligate satellite virus hepatitis D, which is 
unable to establish disease independent of hepatitis B virus (Pascarella and Negro 
2011). Hepatitis D virus co-infection in Hepatitis B-infected individuals worsens 
hepatic damage and inflammation, and is more likely to lead to hepatocellular 
carcinoma (Ho et al. 2013, Yurdaydin et al. 2010). The results show some single 
species P. malariae responses, indicating that this species is capable of establishing 
infection independent of other Plasmodium species. However, the significant 
proportion of individuals with co-occurrence of antibody responses to P. falciparum 
suggests a possible dependency on P. falciparum receptors or proteins for successful 
disease by P. malariae. These non-P. falciparum species, which usually exist as part 
of a complex mixed-infections with P. falciparum (Kasehagen et al. 2006, Zimmerman 
et al. 2004) may cause chronic, sub-clinical disease with potential health 
consequences, including treatment failure, disease relapse and long-term systemic 
consequences (Smith et al. 2011, Coldren et al. 2007, Vinetz et al. 1998). A recent 
study in Indonesia found P. malariae to be associated with a lower mean haemoglobin, 





In mixed-species responders the absorbance of antibody responses to P. falciparum 
was always higher than the co-infecting species. This may be explained by the fact that 
malaria caused by P. falciparum is more common in malaria endemic areas and hence 
individuals may be more likely to be first exposed or infected with this species and 
subsequently with the non-falciparum species. Additionally, repeated exposure to this 
predominant P. falciparum species may result in boosting the antibody responses 
individuals make against this species compared to the non-falciparum species which 
are less frequently encountered. 
 
Antibody responses to P. vivax MSP-119 were rarely observed in this study population. 
Plasmodium vivax requires the presence of Duffy antigen on host erythrocytes to 
establish a successful infection (Miller et al. 1976). P vivax is predominantly endemic 
in Asian and Latin American countries where this Duffy antigen is prevalent on the 
surfaces of host erythrocytes. It has long been reported that the Duffy antigen is absent 
in most African populations (Miller et al. 1976) and this confers some protection 
against P. vivax malaria (Carter and Mendis 2002). It was therefore not surprising to 
observe a low frequency of responses to P. vivax MSP-119, which is consistent with a 
report obtained from nine African countries where no P. vivax was found despite 
extensive PCR screening (Culleton et al. 2008). In recent years however, there have 
been reports of P. vivax infections in both Duffy positive and negative individuals in 
Cameroon, suggesting that this species might have evolved and adapted to using other 
receptors to invade erythrocytes and establish disease (Fru-Cho et al. 2014). 
 
Serological responses have generally been reported to increase with age (Perraut et al. 
2005, Perraut et al. 2003, Egan et al. 1996, Egan et al. 1995). In this present study, age 
was not a confounding factor in Burma Valley and Mutoko, while in Chiredzi 
responders ten years old and above had higher overall frequencies of IgG antibodies 
to MSP-119 antigens. Although all three villages are described as mesoendemic, the 
observed differences in age responses could be explained by the respective 
transmission dynamics of the different seasons in which sampling was done. In very 
low and unstable malaria transmission areas such as Daraweesh in eastern Sudan, 




responses are not apparent, as malaria affects all age groups (Giha et al. 1998, Roper 
et al. 1996). 
 
This assay utilised IgG antibodies to detect both recent and long-term exposure (at 
least within 2-3 months after exposure) to Plasmodium parasite MSP-119 antigens. 
Since antibodies to these antigens often wane in the absence of continuous exposure 
to parasite antigens (Cavanagh et al. 1998), its use in detecting exposure in individuals 
whose blood samples are taken long (more than six months) after they have cleared 
parasites by drug treatment may be of limited value. This however excludes blood 
samples taken at the acute phase of infection and stored appropriately until use, such 
as is the case of these Zimbabwean samples. The importance of this in malaria control 
is that when this assay is used in epidemiological surveys during the peak of malaria 
transmission seasons, there is the potential of detecting a higher prevalence of 
responses in a population compared to when it is used for surveys long after the 
transmission season when most individuals would have cleared their infections leading 
to reduced levels of antibody to parasite antigens. The assay can also be modified to 
detect IgM antibodies which are the first antibodies detectable following acute 
infections.  
Enzyme labels in immunoassays have been significant and sensitive techniques since 
their introduction over four decades ago (Engvall and Perlmann 1971). The technique 
has become a standard procedure that is widely used in studying serological responses 
to parasitic infections and as diagnostic tool to demonstrate the appearance of antibody 
or to detect parasite antigens. One major advantage of the ELISA test is the ability to 
use this technique for large-scale batch testing in epidemiological studies 
(Rajasekariah et al. 1991). In spite of these, methodological issues with regards to 
ELISA standardisation are cited as contributing to variations observed in antibody 
prevalence in populations (Osier 2008, John et al. 2005).  
 
The sensitivity and specificity of an ELISA test are influenced by almost every stage 
of the assay protocol. Being the major technique I used in this thesis, I ensured that 
internal quality controls were adhered to, to ensure the reliability and reproducibility 




effect’ resulting in the cooler, outer wells of the microtitre plates binding less antigen 
than the inner wells (Venkatesan and Wakelin 1993, Oliver et al. 1981). To overcome 
this, I ensured that plates were incubated overnight in wrapped wet towels ensuring a 
humidified environment to minimise the ‘edge effect’. It has been reported that, when 
microtitre plates are stacked, variations are usually observed between the lower and 
upper plates and the middle plates when incubation steps involve changes in 
temperature, such as from room temperature to 4°C or 37°C (Venkatesan and Wakelin 
1993). Since my work involved working on many plates at a time, plates had to be 
stacked during incubation periods. To minimise any variations, a maximum of four 
plates were stacked at a time. Maximising specific antigen to antibody binding while 
minimising nonspecific binding are essential to improving the sensitivity and 
specificity of ELISA test. These were achieved through thorough washing steps using 
the detergent Tween 20 in phosphate-buffered saline (PBS) (Gardas and Lewartowska 
1988), the use of skimmed milk as a blocking agent which is regarded as superior to 
others such as casein or bovine serum albumin (Venkatesan and Wakelin 1993), and 
diluting plasma samples in PBS containing skimmed milk. Protein bound to these 
antibody then reduces the nonspecific binding of the antibody. 
 
The sensitivity of an ELISA is also affected by the plasma or serum dilution used 
(Venkatesan and Wakelin 1993). In my study, I used a plasma dilution of 1:500, as 
previously established by my co-supervisor’s laboratory as the optimal dilution that 
gives the best compromise between sensitivity and specificity for MSP-119 antigens 
(Cavanagh et al. 1998). To confirm this, plasma samples from single- and mixed-
species responders were tested at two different dilutions (the standard 1:500, and 1:50 
dilutions). It is reasonable to speculate that assays at 1:50 dilution should permit 
detection of a tenfold increase in antibody binding, compared to the original 1:500 
dilution. However, the results showed no change in the outcomes of the response 
between the initial 1:500 plasma dilution and the increased antibody concentration at 
plasma dilution of 1:50. This confirms that the previously established plasma or serum 
dilution of 1:500 for serological work involving P. falciparum MSP-119 antigens 
(Cavanagh et al. 1998) is applicable for these four antigens. It must be noted, however, 




increasing background binding. While the sensitivity of the ELISA test may be 
affected by sample dilution, with a lower dilution favouring this (Venkatesan and 
Wakelin 1993), sample economy and nonspecific reactions may also influence the 
dilution taken to achieve the required endpoint (Venkatesan and Wakelin 1993). One 
of the main problem with ELISA is that of batch-to-batch, and within-batch variability 
owing to the type of plates used (Pruslin et al. 1986, Wreghitt and Nagington 1983). 
To overcome this I used high binding plates and included controls (positive malaria 
plasma samples from Brefet, The Gambia, and negative samples from the Scottish 
Blood Transfusion Services) in each batch to ensure that these variations were kept to 
a minimal, if any (Venkatesan and Wakelin 1993).  
 
3.6 Conclusions 
This study has shown for the first time, that IgG antibodies to recombinant MSP-119 
antigens of the four major human Plasmodium species are species-specific and that 
there is no cross reactivity to this antigen between the different Plasmodium species. 
This makes these antigens a good diagnostic tool for detecting the species of 
Plasmodium parasites a host has been exposed to. The study demonstrates that in 
Zimbabwean populations exposed to Plasmodium infections, the prevalence of the 
non-P. falciparum species responses is higher than previously reported in many other 
cross-sectional studies [reviewed by (Mueller et al. 2007)].  
 
Finally, the study has demonstrated that a high proportion of individuals with antibody 
responses to non-P. falciparum MSP-119 antigens also had antibodies to P. falciparum 
MSP-119. MSP-119 antigens from all four major species of human malaria parasite 
offer a potential diagnostic tool for the rapid detection of exposure to the different 
Plasmodium species such as in blood transfusion screening services. It remains to be 
established if these exposure responses to mixed-Plasmodium species indicated by the 
serological survey correspond to concurrent or sequential exposure to previous or 





In the next chapter I have extended this seroepidemiology work in Daraweesh, a 
village in eastern Sudan with a very low entomological inoculation rate of 1-3 
infectious bites per person per year. I investigated some observable clinical outcomes 
(fever and parasitaemia) and the number of treatment requirement in individuals with 






















Chapter 4. Clinical and therapeutic impact of 
mixed-Plasmodium species infections in 
Daraweesh, Sudan 
4.1 Introduction 
In malaria endemic countries, there is heterogeneity in the clinical manifestation of 
malaria and the number of drug treatments needed to clear parasites. How infection 
with multiple Plasmodium species affects this heterogeneity remains poorly 
understood. Several phenotypic differences in the biology of the four human infecting 
Plasmodium species that commonly cause malaria in Sub-Saharan Africa (Bruce and 
Day 2002) may account for heterogeneity in malaria. These phenotypic differences 
include the duration of the pre-erythrocytic and erythrocytic schizogony (Garnham 
1966) and the number of merozoites produced per cycle (Bruce and Day 2002, 
Garnham 1966), host erythrocyte preference (Garnham 1966), and the ability to form 
dormant liver-stages (Markus 2015, Markus 2011a, Markus 2011b) or sequester 
infected erythrocytes (Rowe et al. 2009a). 
For example, P. falciparum has a shorter pre-erythrocytic cycle of 5.5-7 days 
(Garnham 1966) and produces more merozoites in the schizont (up to 30,000) 
compared to 6-16 days duration and the 10,000 to 15,000 merozoites produced by the 
non-P. falciparum species (Bruce and Day 2002, Garnham 1966, Fairley 1947). While 
P. falciparum, P. vivax and P. ovale have a 48-hour intra-erythrocytic developmental 
cycle resulting in tertian fever (fever occurring every two days), P. malariae completes 
its development in 72-hours and produces quartan fever (fever occurring every third 
day) (Collins and Jeffery 2007, Collins and Jeffery 2005, McKenzie and Bossert 
1999). The host cell tropism in these species also differs; P. falciparum invades all 
ages of erythrocytes, P. malariae prefers older erythrocytes, while P. vivax and P. 
ovale establish infections in reticulocytes (Bruce and Day 2002, Garnham 1988b). 




positive erythrocytes (Miller et al. 1976), although several recent reports from some 
Sub-Saharan African countries revise this view and suggest that Duffy-negative 
individuals may in fact be equally susceptible to this species (Fru-Cho et al. 2014, 
Mbenda and Das 2014, Mendes et al. 2011, Wurtz et al. 2011, Menard et al. 2010, 
Ryan et al. 2006). Quiescent liver stage forms (hypnozoites) which serve as a chronic 
parasite reservoir that promotes disease relapse in P. vivax and P. ovale (Markus 
2011b, Markus 2011a, Krotoski et al. 1980) are absent in P. falciparum and P. 
malariae (Garnham 1988a, Bray and Garnham 1982), although there is evidence of re-
emergence of blood-stage infection by P. malariae after many years of blood-smear 
negativity (Garnham 1966, Kitchen 1939).  
Morbidity and mortality associated with P. falciparum infections are usually higher 
than in P. vivax, P. ovale and P. malariae (Langford et al. 2015, Gilles 1993), although 
these non-P. falciparum species contribute significantly to morbidity (Langford et al. 
2015). Severe anaemia is associated with both P. falciparum and P. vivax, but only P. 
falciparum causes cerebral malaria, and the metabolic and respiratory complications 
associated with malaria (Weatherall et al. 2002). Plasmodium malariae infections are 
characterised by prolonged chronicity that can persist for months or years after the 
primary infection (Franken et al. 2012, Vinetz et al. 1998). 
The dynamics and interactions of these phenotypes when the host is infected with more 
than one Plasmodium species are not fully understood, especially in areas of very low 
and seasonal transmission, such as Daraweesh in Sudan. There are limited, and 
conflicting, reports on the clinical outcome of single- versus mixed-Plasmodium 
species infections. There are both reports of exacerbation and amelioration of disease 
severity in mixed-species infections (McKenzie et al. 2006, Black et al. 1994). Fever, 
although nonspecific, is a cardinal symptom associated with malaria, and in low-
resource regions, it is often used as a surrogate indicator of presumptive malaria 
diagnosis (Singh and Sharma 2014). However, mixed species infections have been 
both negatively and positively associated with fever. In Thailand, higher body 
temperatures were reported in patients with mixed P. vivax–P. falciparum infections 




relationship between fever and mixed-species infections involving P. falciparum and 
P. malariae was found in a village in Ivory Coast (Black et al. 1994).  
Malaria in the village of Daraweesh, in the Sub-Saharan savannah of eastern Sudan 
has been extensively studied in terms of parasitology, immunology and entomology of 
the disease (Creasey et al. 2004, Cavanagh et al. 1998, Roper et al. 1996, Elhassan et 
al. 1995). Malaria parasite transmission in this village is seasonal, following the 
rainfall that starts in June, peaks in August and ends by mid-late September. More than 
95% of malaria cases occur between September and November, with the peak of 
clinical malaria cases in October each year (Hamad et al. 2000, Theander 1998). 
Entomological data reveal that there are perhaps 1-3 infectious bites per person per 
year, making this area a very low transmission zone by African standards (Hamad et 
al. 2002, Hamad et al. 2000, Arnot 1998). Some of the observed age-related dynamics 
of malaria in other high transmission areas are absent in Daraweesh (Roper et al. 
1996).  
To date, there has been no study in this village, or any African low malaria 
transmission area, comparing observable clinical outcomes (fever, body temperature, 
parasitaemia) and the drug treatment requirements associated with single- vs. mixed-
Plasmodium species infections diagnosed using the four MSP-119 antigens. In Chapter 
3, I demonstrated that human antibodies to the recombinant MSP-119 antigens from 
malaria-exposed donors show no cross-reactivity between the different Plasmodium 
species (Amanfo et al. 2016). Thus detection of anti-MSP-119 antibodies is a robust 
diagnostic tool for detecting recent infection by each species of Plasmodium parasite. 
In this chapter I have extended the seroepidemiology work in the village of Daraweesh 
and compared the clinical manifestations (fever and parasitaemia) and treatment 







4.2 Study aims 
1. To determine the seroepidemiology of the different Plasmodium species in a 
mesoendemic Sudanese population. 
 
2. To determine if heterogeneity in the clinical presentations of malaria (history 
of fever, body temperature and parasitaemia) and response to drug treatment 
is related to exposure to single vs. mixed-Plasmodium species infection. This 
was by comparing observable clinical manifestation (fever and parasitaemia) 
and the number of treatments required (single chloroquine or repeated 
chloroquine/sulfadoxine-pyrimethamine) between infections with single- vs 
mixed- Plasmodium species antibody response to MSP-119 antigens in 
Daraweesh. 
 
3.  To determine whether the number of recognisable P. falciparum MSP-1 
Block 2 and MSP-2 antigens differed in single and mixed-species responders 
and whether these influence the clinical outcome and the number of treatments 
required for effective parasite clearance.  
4.3 Hypotheses 
1. Clinical presentations of malaria (history of fever, body temperature and 
parasitaemia) would be differentially affected in individuals infected with P. 
falciparum alone versus those with mixed-Plasmodium species infections. 
 
2. The number of drug treatments required for parasite clearance in malaria 
patients would be different in individuals infected with P. falciparum alone 






4.4 Materials and methods 
4.4.1 Study area and population 
The malaria experience of the residents of Daraweesh village (14.0243° N, 35.3686° E) 
in eastern Sudan was monitored between 1 January 1990 and 31 December 2000. The 
study area has been extensively described in previous publications (Creasey et al. 2004, 
Cavanagh et al. 1998, Elhassan et al. 1995). Briefly, Daraweesh village is located 15-18 
km from Gedaref town in Eastern Sudan (14.0243° N, 35.3686° E). Vector-based 
measurements cannot absolutely establish the exact period of malaria parasite 
transmission in Daraweesh (Arnot 1998), although, malaria associated morbidities are 
always heavily concentrated between September to November, with peak incidence in 
October (Cavanagh et al. 1998, Elhassan et al. 1995). Daraweesh is characterised by a 
long dry season (January to July) when malaria is rarely diagnosed, followed by a short 
raining season (August to October) after which the majority of malaria incidence is 
recorded (Creasey et al. 2004, Hamad et al. 2002). Malaria case incidence in Daraweesh 
in relation to rainfall pattern between 1990 and 2000 is shown in Figure 4.4.1 on page 
110 (Creasey et al. 2004).  
95% of malaria in Daraweesh has been reported to be caused by P. falciparum with 
Anopheles arabiensis being the only mosquito vector implicated in parasite transmission 
(Elhassan et al. 1993, Haridi 1972). Malaria was monitored by a village health team 
composed of doctors, malaria researchers and microscopists visiting from a permanent 
station in the nearby town of Gedaref. The team also included a health worker from 
Daraweesh who lived in his family compound in the village. The health team visited the 
village at least every second day during the malaria transmission season (September to 
November), and 2–3 times per week outside that period. The residents reported to the 
team or attended the village clinic if they had any medical complaint. Complaints or 
symptoms suggestive of malaria warranted making a finger-prick blood smear, and if 
found positive for malaria parasites, treatment was administered to the individual by the 
health team.  
The Sudanese government’s policy on malaria treatment at the time of the study, and 




treatment for uncomplicated malaria (El Sayed et al. 2000), with sulfadoxine-
pyrimethamine (SP, commonly called Fansidar) treatment given in instances of 
chloroquine-resistant infections (Creasey et al. 2004). Quinine was used as third line of 
treatment and also given to patients allergic to sulfadoxine-pyrimethamine (Creasey et 
al. 2004). 
 
Figure 4.4.1: Malaria cases in relation to the Normalised Difference Vegetative 
Index (NDVI) in Daraweesh village between January 1990 and December 2000. 
Cases are expressed per 1000 inhabitants. The NDVI represents a measure of 
vegetative growth and is a reliable surrogate for rainfall. Both the NDVI and the 
number of cases per 1000 are expressed per dekad or 10-day period. Figure taken with 
permission from (Creasey et al. 2004). 
In the Daraweesh study an individual was categorised as requiring single treatment when 
there was no evidence of parasitaemia 7 days post standard chloroquine treatment, while 
requirement for repeated treatment was defined as the presence of parasites in blood 7 
days post initial treatment and therefore requiring another dose of chloroquine and/or 
sulfadoxine-pyrimethamine treatment for effective parasite clearance. This latter group 
is usually considered as patients with late parasitological failure, defined as the presence 




up (usually 28 days) with axillary temperature < 37.5°C (WWARN 2012, Price et al. 
2007). 
The population of Daraweesh grew from 396 in the first quarter of 1990 to 560 at the 
end of 2000, with the birth of 164 children during the study period (Creasey et al. 2004). 
Over an eleven year period, 802 single clinical episodes of malaria were recorded in the 
village (Creasey et al. 2004). Individuals in the village rarely had more than one clinical 
malaria episode per year, however, the number of malaria episodes any single individual 
experienced varied between zero and eight throughout the eleven year study period 
(Creasey et al. 2004). A third of the village population did not experience any clinical 
malaria episodes, nor reported of signs and symptoms of malaria throughout the study 
period. The reasons underlying this striking finding are not fully understood (Creasey et 
al. 2004).  
4.4.2 Malaria case definition 
There was no age-specific criteria for defining clinical episodes of malaria with an 
individual defined as having malaria if both these two criteria were met; (a) febrile 
(body temperature measured with an oral probe at clinical examination was >37.5oC), 
or reported fever in the preceding 48 hrs prior to attending the clinic, and (b) had slide 
detectable malaria parasites, evaluated by examining 200 fields under oil immersion 
(Giha et al. 2000, Roper et al. 1998, Roper et al. 1996). Parasites were counted per 300 
leukocytes and standardized as parasites/µL (Bruce et al. 2008). Thick and thin blood 
smears were stained with Giemsa and examined for Plasmodium parasites under a 
magnification of ×1000 (Fleischer 2004, Giemsa 1904). Blood films were considered 
negative after the examination of 200 thick smear fields without detection of asexual 
parasites. Treatment for those with malaria was initiated immediately after diagnosis.  
4.4.3 Study cohort 
Three-hundred and thirty-three (333) individuals, aged 1 to 78 years (median age 11 
years) with first clinical episode of malaria were recruited into this current study (see 





Figure 4.4.2: Flow chart of Daraweesh study participants’ indicating the number 
of individuals recruited in each transmission year. 
Between October 1989 and June 1990, there was severe drought in Daraweesh and the 
Gedaref plain (Roper et al. 1996), during which only one clinical malaria case was 
diagnosed in the 1990 transmission season (Creasey et al. 2004). This drought-clearance 
of patent parasitaemia and clinical malaria served as an informative baseline for patient 
anti-malarial antibody responses in the village (Cavanagh et al. 1998). All samples were 
from the first documented clinical malaria episode of individuals, confirmed by Giemsa-
stained microscopy of asexual Plasmodium parasites, with complete information on 
history of fever, temperature, parasitaemia and treatment. These samples were collected 
during the malaria parasite transmission seasons of September to November (1991-




















Population at the start of study in 1990: 396 
164 births during study period 
Population at the end of the study in 2000: 560  
381 individuals with first time 
clinical malaria  
333 individuals with 
first time malaria 
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6 26 46 48 41 94 38 10 23 1 
48 individuals excluded from 
study for non-availability of 
plasma sample  
 179 individuals never 
reported malaria 





malaria episode was more of a statistical consideration than biological, in order to avoid 
repeated measures on the same individual, and to exclude the temporary protective 
effects of chloroquine treatment and acquired immunity developed after malaria (van 
der Hoek et al. 1998). It has been hypothesised that individuals with previous clinical 
malaria episodes, may often carry parasites which have certain genotype(s) within which 
might be epitopes identical to a conserved antigen in a subsequent infection (Cavanagh 
et al. 1998). Thus using blood samples of the first malaria episode will help rule out 
possible memory responses to MSP-119 antigens in previously infected individuals. 
Details of the characteristics of the study cohort are shown in Table 4.4.1.  
Table 4.4.1: Study cohort and description (ages are in years). 
Gender Number of individuals Mean age Median age Age range  
Male 162 (48.6%) 18 12 1-78  
Female  171 (51.4%) 19 16 4-68  
 
4.4.4 Serological analysis 
Plasma samples were screened by ELISA for IgG responses to MSP-119 antigens from 
the four Plasmodium species and responders grouped as having antibody response to 
either single-Plasmodium or mixed-Plasmodium species antigens. Additionally, plasma 
samples were also screened for P. falciparum MSP-1 Block 2 antigens (the K-1 type, 
MAD20-type and RO33-type) as well as MSP-2 serogroups A and B antigens. 
4.4.5 Blood sampling and blood film preparation 
The malaria morbidity in Daraweesh was monitored throughout the malaria seasons 
(September-January) from September 1990 to December 2000 by a surveillance team 
that visited the village at least every second day. The malaria case detection was done 
by both passive and active case detection. In the passive case detection, the people of the 
village were instructed to report to the study team if they had complaints or symptoms 
suggestive of malaria. Actively, the village was visited by the study team every second 




temperature measured. A blood smear was obtained from individuals with symptoms 
suggestive of malaria and/or a body temperature higher than 37.5°C. Three millilitres 
(3mL) of venous blood was obtained from participants into heparinized vacutainers 
(Becton Dickinson, Rutherford, NJ, USA). Plasma was separated from the blood by 
centrifugation and transferred into cryotubes, then stored at -20oC in the study site. 
Aliquots of plasma samples were transported to Edinburgh and stored at -80 oC until 
used. 
Thick blood smears were prepared at the time of blood collection with a drop of blood 
smeared within an area of 3 cm on a glass slide and allowed to air dry. Thin blood 
films were prepared by using approximately 1 µL of blood and spreading it thinly of a 
microscope slide with a cover glass or a glass spreader. This was allowed to air dry, 
and fixed with absolute methanol and air-dried. Both thick and thin slides were stained 
with 10% v/v Giemsa (TCS Biosciences, HS295) in Giemsa buffer made up of PBS 
pH 7.2. Thick blood films were examined for the presence of asexual Plasmodium 
parasites under a magnification of ×1000 as is routine (Fleischer 2004, Giemsa 1904). 
Blood films were considered negative after the examination of 200 smear fields 
without detection of asexual parasites. Thin films were used for species identification 
where practicable. 
4.4.6 Recombinant proteins and ELISA testing 
The MSP-119 antigens from the four Plasmodium species and the P. falciparum MSP-
1 Block 2 and MSP-2 serogroups A and B antigens are as shown previously in Table 
2.6.1. The ELISA protocol for detection of IgG to MSP-119 is as described in section 
2.7.1 and is based on assays developed in earlier studies (Cavanagh et al. 1998). 
Briefly, plasma samples were tested at a dilution of 1 in 500 for the presence of IgG 
antibodies able to recognize recombinant MSP-119 proteins. 96-well plates (Microlon, 
Greiner) were coated with 100 μL of 0.5 μg/mL of recombinant antigen in coating 






4.4.7 Statistical Analyses 
Parasitaemia data were log-transformed in order to reduce the skewness of the data 
distribution. The Chi-square (χ2) test, binary logistic regression and the Mann-Whitney 
U test and Spearman’s rank correlation coefficient were used to determine if history 
of fever, body temperature, parasitaemia and the need for repeated drug treatment 
differed between single-P. falciparum species versus mixed-species responders. The 




4.5 Results  
4.5.1 Antibody response to MSP-119 antigens in Daraweesh 
IgG antibody recognition of the panel of four Plasmodium recombinant MSP-119 
antigens (P. falciparum, P. malariae, P. vivax and P. ovale) was tested by ELISA 
against three-hundred and thirty (333) plasma samples from individuals from 
Daraweesh who had been diagnosed as having malaria. Responders were grouped as 
either having antibodies to MSP-119 from a single species, or with IgG responses to 
more than one MSP-119 antigen defined as mixed-species responders. Serological 
responses correlated with microscopy, with all plasma samples tested showing 
reactivity to at least one recombinant MSP-119 antigen. The mean level of IgG response 
(measured as OD at 492nm) to MSP-119 of P. falciparum, P. malariae, P. vivax and P. 
ovale were 1.60, 0.34, 0.18 and 0.24 respectively. 
Antibody responses to single-species MSP-119 antigens accounted for 63.1% of all 
responses, and were almost exclusively against P. falciparum (Figure 4.5.1). Only 
three individuals had single species antibodies to P. ovale or P. vivax antigens. With 
the exception of four individuals, all mixed-species responses (36.9% of total) always 
involved responses to the P. falciparum MSP-119 antigen. Dual responses against P. 
falciparum and P. malariae antigens (40.6%) were the predominant observation in the 
mixed-species category, although 22.8% of mixed-species responders had responses 
against all four Plasmodium species antigens. The median age of single and mixed-
species responders was not significantly different (14 vs. 16 years, P=0.23, t-test). 
Three individuals had single-species responses to P. ovale (2) and P. vivax (1). All 
three individuals were from different households (D, F and V; the detail of the 
Daraweesh household structure is described in Chapter 4). They were all males aged 
7 years (individuals F13 and V14) and 12 years old (individual D9) at the time of their 
first clinical malaria episode and reported of a history of fever in the preceding 48hr 
before blood sampling. The P. ovale antibody responses of individuals D9 and V14 
were observed in their first and only documented malaria episode in the malaria 
transmission seasons of 1995 and 1998 respectively. Individual F13 who was the only 




the 1994 transmission season) subsequently had four additional clinical malaria 
episodes in the 1995, 1997, 1998 and 1999 transmission seasons. These subsequent 
infections showed antibody responses to more than one parasite antigen including P. 
falciparum. These individuals were excluded from further analysis involving antibody 
responses to single-species. Only the single-species P. falciparum responses were used 







Figure 4.5.1: Single-species responses are almost exclusively against P. falciparum MSP-119 antigens. Note: With the exception of three 
individuals all single-species responses were against P. falciparum MSP-119 antigens. The predominant mixed-species responses were against 
P. falciparum and P. malariae MSP-119 antigens. F: P. falciparum, M: P. malariae, V: P. vivax, O: P. ovale. n is the total number of 
individuals represented in each panel.
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4.5.2 Body temperature and reported fever in single-P. falciparum 
versus mixed-species responders 
Body temperature data was normally distributed in the study population, and ranged 
between 35.0 and 41oC. There was no significant difference (P=0.23, by Fisher’s exact 
2-tailed test.) in the median temperatures recorded for infections with P. falciparum 
only (37.9oC, 95%CI 37.8-38.1) and mixed-species anti-MSP-119 responders (37.8
oC 
95%CI 37.5-38.5) (Figure 4.5.2A). Of the individuals with antibody response to P. 
falciparum antigens only, there was a significant difference (Pearson’s Chi-square 4.7, 
DF=1, P=0.01) between the proportion with body temperature ≥37.5oC and those 
below 37.5oC (65.7% vs. 34.3%), however this was not so in mixed-species responders 
(P=0.62). When body temperature ≥37.5oC was considered between the two antibody 
responder groups, there was a significant difference (P=0.03) between the proportion 
with responses to only P. falciparum (67.3%), who were approximately 1.7 times more 
likely to have body temperature ≥37.5oC (OR: 1.65, 95%CI 1.04 – 2.62) than mixed-
species responders (32.7%) (Figure 4.5.2B).  
The proportion of individuals presenting with a history of fever (in the previous 48 hrs 
prior to attending clinic) was significantly higher (P=0.001) in both P. falciparum only 
and mixed-species responders (77.3 vs 22.7%, and 74.0 vs 26% respectively) 
compared to those who did not have a history of fever. Of responders with a history of 
fever, however, there was no significant difference between the proportion with P. 
falciparum only and mixed-species responders (P=0.50) (Figure 4.5.2C). Moreover, 
the relative risk of having a history of fever when an individual has an antibody 
response to P. falciparum only or mixed-Plasmodium species was the same (RR: 1.0, 





Figure 4.5.2: Median body temperature between P. falciparum vs mixed-species 
anti-MSP-119 responders is similar. Panel A: Dot plot of body temperature 
measurement showing no significant difference in the median body temperature, panel 
B: proportion of individuals with fever (body temperature ≥37.5oC), panel C: 
proportion of individuals who reported a history of fever in the preceeding 48hr prior 
to blood sampling. n is the number of individuals represented in each panel. Error bars 































) P = 0 .2 3
A . D o t p lo t  o f  b o d y  te m p e ra tu re  m e a s u re m e n ts  (n = 3 3 0 )
















P = 0 .0 3
 B . B o d y  te m p e ra tu re  3 7 .5
o
C  (n = 2 0 2 )
















P = 0 .5 0




4.5.3 Parasitaemia in single-P. falciparum versus mixed-species anti-
MSP-119 responders 
The World Health Organization defines hyperparasitaemia in low transmission areas 
such as Daraweesh as >2% of infected erythrocytes or >100,000 parasites/µL of 
blood (WHO 2011). In this study, the median parasitaemia was not significantly 
different (P=0.36, by the Mann-Whitney U test) between P. falciparum only and 
mixed-species anti-MSP-119 responders (Figure 4.5.3A). The proportion of 
responders with low parasitaemia was significantly higher (P<0.001) compared to 
those with high parasitaemia in both the P. falciparum only (82.6%) and mixed-
species (78.9%) groups. Among those with high parasitaemia, there was no 
significant difference between P. falciparum only and mixed-species responders 
(P=0.47) (Figure 4.5.3B). The odds of having a high parasitaemia in responders with 
P. falciparum only was only 1.3 times that of mixed-species responders (OR: 1.3, 
95%CI 0.73 – 2.2).  
A significant positive correlation (P<0.0001) was observed between parasitaemia and 
body temperature in the overall study population regardless of whether the patient has 





Figure 4.5.3: Median parasitaemia count in P. falciparum vs mixed-species anti-MSP-119 responders is similar. Panel A: Dot plot of 
parasite count showing no significant difference in the median parasitaemia, panel B: proportion of individuals with high parasitaemia 
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Figure 4.5.4: Parasitaemia correlates positively with body temperature. There is 
a positive association between body temperature and parasitaemia. Parasitaemia 









4.5.4 Treatment requirement in single-P. falciparum versus mixed-
species anti-MSP-119 responders 
In this study, 78% of those with antibodies to P. falciparum MSP-119, effectively 
cleared their infections with a single chloroquine treatment over the course of three 
days. By contrast, only 15% of those with antibodies to more than one species 
responded favourably to the same treatment. A significant proportion of individuals 
with antibodies to mixed-species (75%, P=0.001) required repeated treatment with 
chloroquine and/or sulfadoxine-pyrimethamine for effective clearance of parasites. In 
this study, repeated treatment is defined as the administration of chloroquine and/or 
sulfadoxine-pyrimethamine following the detection of asexual parasites in blood films 
three days after the initial chloroquine treatment of a malaria patient. There was no 
statistically significant difference in the mean age of those who required repeated 
treatment in either group (P=0.08). Of individuals requiring repeated treatment, the 
proportion of mixed-species responders was higher than those with antibodies to only 
P. falciparum MSP-119 (66 vs 33.3%, P=0.001) (Figure 4.5.5). This was reflected in 
the odds of requiring repeated treatment in mixed-species responders, which was 10 






Figure 4.5.5: Significant proportion of mixed-species anti-MSP-119 responders 
require repeated treatment for parasite clearance. Repeated treatment is defined as 
the administration of chloroquine and/or sulfadoxine-pyrimethamine 3 days post-
treatment owing to the presence of asexual parasites in blood smears. Error bars 
represent the 95% confidence intervals; n is the number of individuals.  
4.5.5 Relationship between the number of recognized P. falciparum 
MSP-1 Block 2 antigens and clinical outcomes and treatment 
requirement 
Humoral responses have been suggested to play a role in the efficacy of amodiaquine 
for the treatment of malaria (Mawili-Mboumba et al. 2003), with a significantly higher 
proportion of malaria patients with antibody response to more than one variant MSP-
1 Block 2 antigen having a higher cure rate compared to those with responses to only 
one antigen (Mawili-Mboumba et al. 2003). With almost all mixed-species responses 




treatment outcomes observed in this population had any correlation with the number 
of P. falciparum–specific MSP-1 Block 2 and MSP-2 serogroup A and B antigens an 
individual recognises.  
Of the 330 individuals with clinical malaria screened and included in the preceding 
analysis, 64.2% had detectable antibody response to at least one P. falciparum MSP-1 
Block 2 antigen (Table 4.5.1). Of the MSP-1 Block 2 responders, 41.0 and 59% 
respectively had a response to either one, or more than one Block 2 antigen. Antibody 
response prevalence to the K1-type, MAD20-type and RO33-type were 78.3, 63.2 and 
62.7% respectively. In individuals with antibody response to only P. falciparum MSP-
119 antigen (single species responders) the proportion who recognised only one Block 
2 antigen and those with responses to more than one Block 2 antigens were similar 
(49.1 vs. 51.9%). However, in mixed-species anti-MSP-119 responders the proportions 
of individuals who recognised more than one Block 2 antigen was significantly higher 
than those who recognised only one antigen (68.4 vs. 31.6%, χ2=6.66, P=0.01) (Table 
4.5.1 on page 127).  
Of individuals with antibody response to only P. falciparum MSP-119 antigen, 
independent of the type of response to Block 2 antigens, the proportions with a history 
of fever, body temperature above 37.5oC, low parasitaemia and requiring single 
treatment with chloroquine were higher than those with no history of fever, body 
temperature below 37.5oC, high parasitaemia and requiring repeated treatment for 
parasite clearance. In all the above parameters, the proportion of individuals with 
responses to one Block 2 and more than one Block 2 antigens were comparable (Table 
4.5.2 on page 128).  
Of mixed-species anti-MSP-119 responders the proportion with a history of fever, low 
parasitaemia and requiring repeated treatment were higher than those with no history 
of fever, high parasitaemia and requiring single treatment, and was independent of 
Block 2 response an individual had. The proportions with body temperature above and 




Table 4.5.1: Prevalence of antibody response to P. falciparum MSP-1 Block 2 antigens. 
 No response Block 2 response 1 Block 2 Ag >1 Block 2 Ag 
All population (n=330) 118 (35.8%) 212 (64.2%) 87 (41.0%) 125 (59.0%) 
P. falciparum-only responders (n=207) 93 (44.9%) 114 (55.1%) 56 (49.1%) 58 (51.9%) 
Mixed-species responders (n=123) 25 (20.3%) 98 (79.7%) 31 (31.6%) 67 (68.4%) 




Table 4.5.2: Block 2 response type and its relationship with clinical and treatment data in P. falciparum-only anti-MSP-119 
responders. 
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Table 4.5.3: Block 2 response type and its relationship with clinical and treatment data in mixed-Plasmodium species anti-MSP-119 
responders. 
Mixed-species anti-MSP-119 responders (n=123) 
MSP-1 Block 2      
response 
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4.5.6 Relationship between the number of recognized P. falciparum 
MSP-2 antigens and clinical outcomes and treatment requirement 
85.5% of the study population included in the analysis had an antibody response to 
MSP-2 antigens. Of these responders, a significant proportion (75.2%) had antibody 
response to both MSP-2A and MSP-2B serogroups compared to those with responses 
to only MSP-2A (11.3%) and MSP-2B (13.5%) antigens. When the population is 
divided into P. falciparum-only and mixed-Plasmodium species anti-MSP-119 
antibody responders, the pattern was the same with a high proportion recognising both 
MSP-2A and MSP-2B serogroups (70 and 83% respectively) (Table 4.5.4 on page 
131). The proportion with antibody response to only MSP-2A or MSP-2B antigen was 
similar in both P. falciparum-only and mixed-Plasmodium species MSP-119 response 
groups. 
In P. falciparum anti-MSP-119 responders, independent of an individual’s IgG 
response to MSP-2 antigens, the patterns of fever history, body temperature, 
parasitaemia and treatment requirement were similar to that observed in Block 2 
responders, with a higher proportion of individuals having a history of fever, body 
temperature above 37.5oC, lower parasitaemia and requiring single treatment for 
parasite clearance (Table 4.5.5 on page 132). In mixed-Plasmodium species anti-MSP-
119 responders, the above pattern was the same except in treatment requirement in 
which all individuals with no antibody response to MSP-2 antigens as well as a higher 
proportion of individuals with responses to both MSP-2A and MSP-2B required 
repeated treatment (Table 4.5.6 on page 133). While in single-species responders a 
lack of antibody response to MSP-2 antigens is seen in a higher proportion of 
individuals clearing their infections with single treatment (Table 4.5.5), all mixed-
species responders who had no antibody response to MSP-2 antigens required repeated 






Table 4.5.4: Prevalence of antibody response to P. falciparum MSP-2 antigens. 
 No response MSP-2 response MSP-2A  MSP-2 B  MSP-2A and 2B 
All population (n=330) 48 (14.5%) 282 (85.5%) 32 (11.3%) 38 (13.5%) 212 (75.2%) 
P. falciparum-only responders (n=207) 37 (17.9%) 170 (82.1%) 25 (14.7%) 26 (15.3%) 119 (70%) 
Mixed-species responders (n=123) 11 (9.0%) 112 (91.0%) 7 (6.3%) 12 (10.7%) 93 (83%) 




Table 4.5.5: MSP-2 response type and its relationship with clinical and treatment data in responders to P. falciparum-only antigens. 
P. falciparum-only anti-MSP-119 responders (n=207) 












No response 37   
(17.9) 








28           
(75.7) 
9                    
(24.3) 
34     
(91.9) 
3          
(8.1) 
MSP-2A only 25    
(12.1) 
9       
(36.0) 
16             
(64.0) 
11         
(44.0) 
14         
(56.0) 
21                   
(84.0) 
4                         
(16.0) 
21                  
(84.0) 
4                     
(16.0) 
MSP-2B only 26    
(12.6) 
6                    
(23.1) 
20                 
(76.9) 
4          
(15.4) 
22                 
(84.6) 
21                             
(80.8) 
5                         
(19.2) 
17                   
(65.4) 
9                  
(34.6) 
MSP-2 A & B 119 
(57.4) 
22                      
(18.5) 
97               
(81.5) 
43                 
(36.1) 
76                  
(63.9) 
99                  
(83.2) 
20                               
(16.8) 
89                       
(74.8) 
30                          
(25.2) 




Table 4.5.6: MSP-2 response type and its relationship with clinical and treatment data in responders to mixed-Plasmodium species 
antigens. 
Mixed-species anti-MSP-119 responders (n=123) 












No response 11          
(8.9) 
5                  
(45.5) 
6                      
(54.5) 
5                
(45.5)     
6                    
(54.5) 
6                              
(54.5) 
5                            
(45.5) 
0                        
(0.0) 
11                    
(100.0) 
MSP-2A only 7                    
(5.7) 
1                        
(14.3) 
6                     
(85.7) 
3                
(42.9) 
4                  
(57.1) 
6                                 
(85.7) 
1                        
(14.3) 
2                           
(28.6) 
5                          
(71.4) 
MSP-2B only 12               
(9.8) 
3                     
(25.0) 
9                 
(75.0) 
6                  
(50.0) 
6                        
(50.0) 
10                    
(83.3) 
2                                    
(16.7) 
5                     
(41.7) 
7                       
(58.3) 
MSP-2 A & B 93                        
(75.6) 
23                    
(24.7) 
70                      
(75.3) 
43                
(46.2) 
50                  
(53.8) 
72                     
(46.2) 
21                             
(22.6) 
24                           
(25.8) 
69                   
(74.1) 





While individuals living in malaria endemic regions are exposed to the different 
Plasmodium species, it is important to understand the drivers, if any, that exist of the 
clinical outcomes and treatment requirement of these individuals when infected with 
single or mixed-Plasmodium species. Clinical outcomes of single- and mixed-
Plasmodium species infections have been variedly reported as being advantageous 
(Mohapatra et al. 2012, Lorenzetti et al. 2008, Black et al. 1994) and sometimes as 
detrimental (McKenzie et al. 2006) to the host. In the previous chapter I established 
the specificity of IgG antibodies to MSP-119 antigens and used these to characterise 
the epidemiology of the four human Plasmodium species in three Zimbabwean villages 
(Amanfo et al. 2016). In this current chapter I extended the seroepidemiology work to 
characterise the full range of infecting Plasmodium species and strain variants of P. 
falciparum i.e. MSP-1 Block 2 and MSP2 in Daraweesh and asked if heterogeneity in 
clinical presentation and response to drug treatment was related to exposure to single 
vs. mixed-Plasmodium species. This was achieved by comparing fever and 
parasitaemia, and the number of treatments required for parasite clearance in malaria 
patients with P. falciparum only versus mixed-Plasmodium infections. The most 
significant findings were the higher response of mixed-species infections than have 
been previously reported by microscopy, and the associated drug treatment failure in 
a significant proportion of the population with mixed-species infections.  
In this study all plasma samples tested (taken from first documented clinical episodes 
of malaria patients) had detectable antibody responses to MSP-119 antigen of at least 
one Plasmodium species. This is consistent with observations by others that antibody 
responses to Plasmodium MSP-1 antigens are higher when plasma samples are taken 
at, or shortly after, the acute stage of malaria, or when blood films are positive for 
asexual-stage parasites and when patients are relatively highly parasitaemic (Osier et 
al. 2008, Osier et al. 2007, Polley et al. 2004, Tami et al. 2002, Cavanagh et al. 1998, 
Tolle et al. 1993). About 96% of all malaria cases in Daraweesh have been attributed, 
by optical microscopy of Giemsa-stained slides, to P. falciparum infections (Hamad 
et al. 2000). This is essentially confirmed here, as the great majority of plasma samples 




119 antigens, similar to the observations made in the Zimbabwean study described in 
Chapter 3. A previous study in this Daraweesh population showed the frequency of 
antibody recognition to MSP-119 of P. falciparum of approximately 90% (Cavanagh et 
al. 1998). This is probably attributable to the close clinical monitoring and blood 
sampling in the Daraweesh study. As previously mentioned (in Section 4.4.1 of this 
chapter), in addition to the resident health worker in the village, the external health 
team visited the village at least every second day during malaria transmission seasons, 
and 2–3 times per week outside that period, with those found to be having malaria 
parasites, promptly treated. 
One of two novel and striking observations made in this study is the higher than 
expected frequency of antibody responses to the non-falciparum species, especially 
responses against P. malariae in the context of mixed-species responses. This level of 
mixed species antibody responses (which in the context of malaria epidemiology in 
Daraweesh correlates with infection) was not detected by light microscopy (Hamad et 
al. 2000). This reveals the limitations of Plasmodium species detection and 
differentiation by microscopy alone (Barber et al. 2013, Mueller et al. 2007, McKenzie 
et al. 2003). With the exception of four individuals, all mixed-species antibody 
responses in Daraweesh always involved responses to P. falciparum antigens. This is 
similar to serological observations in Zimbabwe (Amanfo et al. 2016), and in Memni, 
a village in the Ivory Coast, where P. malariae infections were always found in 
association with P. falciparum by light microscopy (Black et al. 1994). P. falciparum 
is confirmed as indeed the heavily predominant human malaria parasite in Africa, but 
equally clearly, African malaria is far from being a monospecies problem. Using these 
new antigens as tools, has demonstrated that previous studies in this village have 
clearly underestimated the prevalence of P. vivax, P. malariae and P. ovale in this part 
of eastern Sudan. 
Entomological surveys in Daraweesh and other northern Sudanese sites have found 
Anopheles arabiensis to be the sole vector responsible for Plasmodium transmission 
(Hamad et al. 2000). It is possible that the intrinsic vectorial capacity of this mosquito 
species might be higher for P. falciparum than the non-falciparum species, or that P. 




mixed-species infections are caused by the simultaneous or sequential inoculation of 
parasites by the same or different mosquitoes (Snounou and White 2004, McKenzie 
and Bossert 1997), it seems highly likely that these mixed-species infections, are also 
being transmitted by the An. arabiensis vector. The preponderance of P. falciparum 
infections could be a function of the intrinsic vectorial capacity of the Anopheles 
mosquitoes being higher for P. falciparum than the non-falciparum species. 
Alternatively, P. falciparum may be out competing its rivals in capacity to produce 
infectious gametes. The very low EIR and the short transmission season of September 
to November in Daraweesh suggest these infections may have been initiated 
concurrently. This tentative assumption is supported by the observation that rising IgG 
responses to P. falciparum MSP-119 antigens are only seen in Daraweesh when 
individuals are actually having clinical episodes of malaria (or, less commonly, have 
become PCR positive but remain asymptomatic) (Cavanagh et al. 1998). Antibodies 
to any species MSP1 antigen remain at undetectable levels in the absence of disease 
during the long dry seasons (December to August) when malaria is very rarely 
diagnosed in the population (Giha et al. 2000, Cavanagh et al. 1998). 
Febrile episodes are the cardinal symptoms of malaria and usually coincide with the 
cyclical release of merozoites during schizont rupture of erythrocyte (Gazzinelli et al. 
2014, Golgi 1889). Fever may alter the clinical course of the disease by influencing 
parasite replication, survival and virulence (reviewed by (Oakley et al. 2011)). In 
mixed-species infections a less defined ‘non-classical’ pattern of fever may be 
observed owing to differences in parasite synchronization, parasitaemia and the host 
immune response (reviewed by (Oakley et al. 2011)), as well as density dependent 
regulatory mechanisms (Bruce and Day 2002, Bruce et al. 2000). In this study, 
although a significantly high proportion of both monospecies-P. falciparum and 
mixed-species responders had a history of fever or with a body temperature above 
37.5oC, the median body temperature was not significantly different between the two 
groups. This observation is different to that reported in patients from western Thailand 
in which mixed P. falciparum-P. vivax infected patients presented with higher fevers 
than those with single-P. falciparum or single-P. vivax infections (McKenzie et al. 




and mixed-infection epidemiology. Fever involves a cascade of events involving 
parasite toxins and cytokine induction. The host immune response directed against one 
Plasmodium species has the potential to dampen the severity of malaria in the context 
of mixed-species infection (Chuangchaiya et al. 2010). Since these non-P. falciparum 
species are capable of establishing chronic, asymptomatic, low-level parasitaemia in 
the human host, antibody directed against parasite toxins in mixed-species infections 
may play a role in down-regulating the cytokine cascade and thereby dampening fever 
episodes (Black et al. 1994).  
P. falciparum is capable of establishing infection in all stages of erythrocytes and 
generally causes higher parasitaemia than the non-P. falciparum species which have 
erythrocyte-stage restrictions (Bruce and Day 2003, Bruce and Day 2002). However, 
in the Daraweesh population a significantly higher proportion of both single- and 
mixed-species responders had lower parasitaemia levels. With a low EIR and the 
presence of accessible health care/team for the people to visit (i.e. close monitoring 
over the study period) it is possible that the compliance of the people in seeking 
accessible health care from the team as well as natural control of infection through 
immunity might have played a part in individuals having lower parasitaemia. Since 
almost every mixed-species response in Daraweesh involved P. falciparum, it is 
reasonable to assume that the contribution of the non-P. falciparum species to 
parasitaemia may be minimal, resulting in no significant difference in the parasitaemia 
of single-P. falciparum versus mixed-species responders. This assumption is 
supported by evidence that fever induced by the low density parasitaemic-P. vivax may 
protect against severe disease and limit P. falciparum parasitaemia (Smith et al. 2001, 
Luxemburger et al. 1997). Although co-infection with two rodent Plasmodium species 
have been reported to be highly virulent to the host (Ramiro et al. 2016), this was 
obviously not the case in this human population with respect to the parasitaemia data. 
In a recent mouse model study of malaria infection, the authors observed that when 
the rodent parasite species P. chabaudi, capable of infecting all stages of erythrocytes 
(similar to P. falciparum in humans) is inoculated first and establishes an infection, it 
facilitates the growth of P. yoelii species that have erythrocyte restriction (similar to 




either control infections or when both species were simultaneous inoculated in the 
mouse host, although the timing of infection is also critical (Ramiro et al. 2016).  
Although in the Daraweesh study the certainty of which parasite species was first to 
infect cannot be deduced, what is certain is that the mixed-infections occurred within 
the tight transmission period of September to November of each years when samples 
were collected from patients with clinical episodes, as pre-transmission samples of 
these donors did not show detectable levels of antibody responses to the parasite 
antigens. Of the individuals with high parasitaemia in Daraweesh, there was no 
significant difference observed in the proportion of single- versus mixed-species 
responders. This finding is in agreement with a recent report that suggested that 
competition in mixed-strain P. falciparum infections does not increase the overall 
parasite density and that in the presence of competitors, densities of individual parasite 
strains are reduced (Bushman et al. 2016). Parasitaemia did not generally correlate 
with the level of antibody as measured by ELISA absorbance. It might be expected 
that the onset of an acute infection and the rising parasite density prior to treatment 
might correlate with the level of immune response against an infecting pathogen. The 
contrary observation in the Daraweesh population might be explained by the close 
monitoring of the population by the study team which included prompt treatment of 
all malaria cases diagnosed. In view of presence of a resident research team member 
in the village, the residents who presented with symptoms of malaria reported these to 
the team early and were diagnosed and treated before parasite densities could rise to 
levels often seen when disease is not diagnosed and left untreated for a longer duration. 
In most Sub-Saharan African countries artemisinin-based combination therapy 
(ACTs) have currently been adopted as first-line treatment for uncomplicated malaria 
due to the widespread chloroquine resistance in most malaria endemic areas (Menard 
et al. 2016). Chloroquine was still an effective first line drug for treatment of 
uncomplicated malaria according to the Sudanese Ministry of Health guidelines, and 
was used extensively during the 1990s, with sulfadoxine-pyrimethamine treatment for 
chloroquine resistant cases (El Sayed et al. 2000). Self-medication in the Daraweesh 
population did not occur as the villagers had free health advice, drug treatment and 




treatment requirements were significantly different between those with single- and 
mixed-species antibody responses, with a significantly higher frequency of multiple 
drug administration in those with mixed-species infections. Most single P. falciparum 
infections were cleared by single course of the chloroquine treatment. By contrast, I 
observed that a significantly higher proportion of mixed-species infections required 
repeated treatment with sulfadoxine-pyrimethamine. This is in agreement with other 
studies, where co-infections with P. falciparum- and P. malariae (Smith et al. 2011) 
and P. ovale (Senn et al. 2014), resulted in artemether-lumefantrine, and oral 
atovaquone-proguanil treatment failures respectively, with patients requiring repeated 
treatment for full parasite clearance.  
Furthermore, P. malariae infections have been reported to occur after antimalarial 
treatment in the absence of re-exposure of patient to the parasites (Franken et al. 2012, 
Muller-Stover et al. 2008, Hess et al. 1993). In a study of monoinfection of P. knowlesi 
(including microscopy result of P. malariae) in Malaysia, the authors reported a faster 
parasite clearance and fever resolution, and lower risk of anaemia within 28 days in 
patients treated with artesunate-mefloquine compared to those who received 
chloroquine alone (Grigg et al. 2016). However, what is not clear in the above study 
is the possible influence of the P. malariae species on the treatment outcome of the 
two groups. 
Although there is widespread chloroquine resistance to P. falciparum in most malaria-
endemic countries, P. vivax treatment in Ethiopia where this species is co-endemic 
with P. falciparum remained largely based on effective chloroquine monotherapy 
(Seifu et al. 2017). However, data is lacking on the susceptibility of P. malariae and 
P. ovale to chloroquine treatment. Some studies have reported recrudescent infection 
of these species, especially P. malariae infection months or years after P. falciparum 
treatment with chloroquine (Franken et al. 2012, Muller-Stover et al. 2008). In my 
study, the three individuals with single-species antibody response to P. vivax or P. 
ovale MSP-119 antigens (who were excluded from further analysis) all cleared their 
infection with a three-day course of chloroquine treatment. Although this number is 
not of any statistical significance it probably shows the effectiveness of chloroquine 




In the current study the proportion of individuals with antibody response to MSP-1 
Block 2 antigens was 64.2%, with about 38% having a response to more than one 
variant antigen. These prevalences were higher than that observed in 77 post-
transmission season samples collected from the same population between 1991 and 
1995, in which 43% had a response to Block 2 antigens, with a lower prevalence of 
24% responding to more than one Block 2 antigen (Cavanagh et al. 1998). This 
difference could be explained by the larger sample size and the fact that this current 
study sampling was until the year 2000, and included only those with documented 
evidence of clinical malaria as oppose to both symptomatic and asymptomatic patients 
screened by Cavanagh and colleagues. IgG response to MSP-1 Block 2 antigens in 
African population is of the IgG3 subclass, which are short-lived (half-life of 7 days) 
compared to response to the conserved MSP-119 which is of the IgG1 subclass (half-
life of 21 days) (Cavanagh et al. 2004, Cavanagh et al. 2001). This short half-life of 
IgG3 means that antibody responses might not be detectable in asymptomatic patients 
who have cleared their infections weeks or months prior to sampling. The Block 2 
antigens are highly polymorphic and P. falciparum specific and therefore it is of 
interest to note that a higher proportion of mixed-Plasmodium species anti-MSP-119 
responders recognised more Block 2 antigens than those with responses to only P. 
falciparum antigens.  
While the patterns of a history of fever, body temperature above 37.5oC and having a 
lower parasitaemia was similar in P. falciparum only and mixed-Plasmodium species 
anti-MSP-119 responders irrespective of the response type to, or the number of Block 
2 antigens recognised, treatment requirement differed with a higher proportion of those 
with mixed-Plasmodium species responses requiring repeated treatment as against a 
higher proportion of P. falciparum only responders clearing their parasite with only 
single treatment. This suggests that the type or number of recognisable MSP-1 Block 
2 antigens (i.e. a surrogate measure of the number of P. falciparum clones infecting an 
individual) is not as important in determining the treatment requirement as of the 
number of Plasmodium species an individual is exposed to. This is in contrast to what 
was observed in amodiaquine efficacy in Gabon, in which a significantly higher cure 




one variant MSP-1 Block 2 antigen compared to those with responses to only one 
Block 2 antigen (Mawili-Mboumba et al. 2003). However, that study did not 
investigate the presence or exposure of individuals to the non-P. falciparum species, 
as is the case with my thesis.  
Antibody responses to P. falciparum-specific MSP-2 antigens in the study population 
was higher in the overall population (85%), as well as in both single- and mixed-
species responders. In both responders, the acquisition of antibodies to MSP-2 antigens 
correlated with lower parasitaemia and higher body temperature. While in single-
species responders, anti-MSP-2 responses were associated with parasite clearance with 
single treatment, the opposite effect was seen in mixed-species responders who 
required repeated treatment independent of the number of MSP-2 antigens recognised. 
It has been shown that under natural exposure, the number of Plasmodium antigens an 
individual recognises (i.e. exposed to), and the level of antibody response (antibody 
titre) against these antigens confers a degree of protection, with children having high 
antibody levels to five or more antigens experiencing no clinical episode of malaria 
(Osier et al. 2008). In my study, recognition of Block-2 and MSP-2 antigens were 
associated with lower parasitaemia in a higher proportion of both single- and mixed-
species responders. It would have been expected that an accumulation of Block 2 and 
MSP-2 antibodies would influence drug treatment, i.e. those recognising more of these 
antigens would be more likely to clear their infections with a single course of 
treatment. However, treatment outcomes seem to be more dependent on the 
Plasmodium species than the number of polymorphic MSP antigens an individual 
recognised. This study did not consider protection from malaria (as all individuals 
sampled had malaria), however, the dynamics of malaria epidemiology in Daraweesh 
may be unique, in that, although people had antibody responses to a diverse range of 
antigens, individuals experienced between zero and 8 malaria episodes throughout the 
study period (Creasey et al. 2004). 
In the serological work of both Chapters 3 and 4, I could have further explored 
correlating the serological results obtained with PCR data from the samples I worked 
on. However, the limitation was that the plasma samples from the two study cohorts 




characterisation of the Plasmodium species. However, in validating the use of these 
recombinant MSP-119 antigens of the four Plasmodium species, work from others in 
my co-supervisor’s laboratory has compared the plasma antibody responses to MSP-
119 antigens with immunofluorescence antibody test (IFAT) and PCR data of positive 
malaria blood samples collected from the Scottish Blood Transfusion Services. A clear 
correlation of the serology using MSP-119 antigens with the IFAT and PCR results 
were obtained (D. Cavanagh, personal communication). 
Anaemia is an important feature usually associated with malaria (Haldar and 
Mohandas 2009). Comparison of anaemia status in single- versus mixed-species 
infections would have added value to the current literature especially having a well 
characterised cohort like the Daraweesh population. Unfortunately, at the time of the 
Daraweesh study, measurement of haemoglobin was not included in the study design. 
4.7 Conclusion  
The study of malaria epidemiology in Daraweesh based on antibody response to 
Plasmodium MSP-119 antigens has demonstrated for the first time that exposure to 
mixed-Plasmodium species are higher than previously reported in this village (Hamad 
et al. 2000). Similar to the observation in the Zimbabwean study (Chapter 3), this 
finding confirms the need for a standard and sensitive method of detecting mixed-
infections to be implemented, as there are important clinical and therapeutic 
implications if minority species go undetected, or parasitaemia becomes sub-clinical 
without full cure. The requirement for multiple drug treatments was significantly 
higher in multi-species Plasmodium infections. Whilst a much higher proportion of P. 
falciparum infected individuals cleared their infections with a single chloroquine 
treatment course, two-thirds of mixed-species infections failed to clear their infection 
after one chloroquine course.  
This significant finding of an associated drug treatment failure with mixed-species 
infections has potential health implications such as the development of drug-resistant 
strains. Treatment failure or partial parasite clearance has the potential to allow onward 




understanding of the ecology and epidemiology of all the human Plasmodium species 
being transmitted in Africa would certainly contribute to designing more effective 
malaria treatment, control and elimination programmes in African populations.  
I propose that this work should be replicated in other malaria epidemiological settings 
in light of the current shift to treating uncomplicated malaria with ACTs. This would 
confirm whether the observation in Daraweesh of the requirement of repeated 
treatment with chloroquine seen in mixed-species responders is similar or differs when 
































Chapter 5. Household-level spatiotemporal 
dynamics of malaria prevalence in Daraweesh, 
Sudan  
5.1 Introduction 
The epidemiology of malaria is very complex, and involves infected mosquito vectors 
that spread Plasmodium parasites locally and typically over short distances to 
susceptible human hosts. In malaria, heterogeneity in parasite transmission within a 
defined geographical location is common (Bousema et al. 2012, Bousema et al. 
2010a). This variation is also seen in parasitic diseases such as schistosomiasis 
(Manning et al. 1995) and other infectious diseases (Woolhouse et al. 1997), in what 
is described as the 20/80 rule (Woolhouse et al. 1997), in which about 20% of the 
population experience the heaviest burden of disease (about 80%), while the majority 
of the population carry only a few or no infections (Woolhouse et al. 1997). However, 
villages or towns with higher malaria incidence are usually targeted as a whole in 
malaria control programmes until such a time that individual episodes of malaria 
remain and become the focus of control (WHO 2007). 
Variation in malaria risk are seen in both low to moderate transmission areas, where a 
considerable proportion of the population experience only little or no disease, while 
others experience multiple episodes of malaria over several years (Bousema et al. 
2010a, Clark et al. 2008, Creasey et al. 2004, Woolhouse et al. 1997), and in high 
transmission intensity settings, where the majority of the population experience at least 
one malaria episode per year (Kreuels et al. 2008, Carter et al. 2000). This variation 
may be due to heterogeneity in contact rate between infected mosquitoes and the 
susceptible host (Acevedo et al. 2015, Smith et al. 1995b), which has the potential to 
alter the prevalence of malaria as well as the immunological response of the host to 
the parasite antigens (Smith et al. 1995b). In a single village there can be very marked 




al. 2017), but population-level analysis of malaria risk and epidemiology usually 
obscures these fine variations at the individual or household level. Factors underlying 
the variations in malaria risk may include the ecological characteristics facilitating 
breeding sites of mosquitoes (Reinbold-Wasson et al. 2012), household structural 
features and household size (Seyoum et al. 2017, Hulden et al. 2014), human 
behaviour such as outdoor sleeping at night (Clark et al. 2008) and economic activities 
that may increase exposure to infectious mosquito bites (Chuquiyauri et al. 2012). 
Although individuals may be infected or challenged with the same strain of 
Plasmodium parasite, the host susceptibility to disease may vary owing to within and 
between host variations in immune responses. Malaria parasite transmission usually 
originates from a ‘hot spot’ within a geographical location (Bousema et al. 2012, 
Bousema et al. 2010a). A hot spot of malaria parasite transmission is defined as a 
“geographical part of a focus of malaria transmission where transmission intensity 
exceeds the average level” (Bousema et al. 2012). Hot spots are often more stable over 
time (Seyoum et al. 2017) and may serve as both sources of infection during 
transmission seasons as well as supporting continuing parasite transmission during the 
dry seasons (Bousema et al. 2012) when vector numbers are low. Identifying malaria 
hot spots within villages can help to predict areas of high risk of disease transmission 
and serve as a focal point of target in malaria control and elimination programmes 
(Bousema et al. 2012, Bousema et al. 2010a). It can also help focus health control 
measures and epidemiological surveillance in endemic areas where resources are 
inadequate (Bousema et al. 2010a). 
The village of Daraweesh in eastern Sudan is considered a single homogeneous area, 
for which the malaria experience of its residents was closely monitored over time 
(Creasey et al. 2004). Although many studies in Daraweesh have looked at the malaria 
immunoepidemiology at the population level, there has been no study in this village 
looking at the household level dynamics of malaria epidemiology and mixed-
Plasmodium species infections. The use of spatial-temporal tools to identify groups of 
households within this single village who are at increased risk of developing clinical 
episode of malaria has not been applied to analyse malaria transmission in this unique 




Knowledge of the biological, environmental and socioeconomic risk factors associated 
with malaria are important in implementing intervention programmes targeted at 
malaria control. A better understanding of malaria epidemiology at the household 
level, in relation to the population level, would provide important metrics for 
understanding the factors that contribute to variations in malaria incidence in a local 
area. 
5.2 Study aim 
To determine the spatial and temporal dynamics of malaria prevalence and 
Plasmodium species distribution in a mesoendemic village in eastern Sudan. 
5.3 Hypothesis 
The risk of having clinical malaria or being infected with a species of Plasmodium 
parasite is the same in all Daraweesh households and the same over time. 
5.4 Materials and methods 
5.4.1 The setting of the Daraweesh village 
There were 52 families living in Daraweesh during the study period (1990-2000) with 
household sizes ranging from 2 to 26 occupants (mean household size 10.9 
individuals). Families lived together in compounds comprising of a group of circular 
mud walled dwellings with thatched roofs (called tukul in the local Daraweesh 
community). Several families lived within compounds surrounded by woven sorghum-
stalk fencing (designated in Figure 5.4.1 by solid lines on the next page). The yard 
spaces, locally called the hawsh, were used for outdoor sleeping except on rainy and 
cold nights in autumn and winter (Hamad et al. 2002). Traditional subsistence 
agriculture is centred around sorghum cultivation, which depends on the seasonal 
rains. There were also a number of market gardens irrigated by water pumps joined to 
deep-bore wells. No form of mosquito control was implemented during the study 
period, but during the early rainy season some local farmers used Malathion and other 




There were either metal or concrete storage tanks of drinking water fed from a well, 
which were used throughout the year. Spillages, particularly from the larger tanks 
create small water pools and fill animal hoof prints that may provide breeding sites for 
mosquitoes (Hamad et al. 2002). The village lies on a flatter surface covered by black 
soil that allows rainwater to stay on the surface longer. These local environment 
characteristics may influence the presence of mosquito breeding sites. 
For simplicity, families were designated with letters of the alphabet (e.g. families A to 
Z) or alphanumeric (e.g. family 2A, 2B etc.) for identification purposes. For this study, 
I labeled the compounds containing the family huts numerically. There was a mosque 
located between compounds 8 and 11, and a deep well closest to compound 10, that 
served as the source of water for the village (Figure 5.4.1 on page 149). A schematic 
outline of the village and the settings of the families or households and compounds at 
the time of the study is illustrated in Figure 5.4.1. It must be noted that the village has 
gone through a lot of remodelling and development in recent times compared to the 






Figure 5.4.1: Schematic layout of Daraweesh village indicating households and 
compounds. Families or households are designated by letters of the alphabet or 
alphanumeric combinations, with the numbers in red representing the different 
compounds. Solid lines indicate the woven sorghum-stalk fencing which separates 
compounds. Huts with no identification served as storage for agricultural materials and 
produce, as well as shelter for livestock. This schematic figure was provided by Prof. 
David E. Arnot (University of Edinburgh). 
5.4.2 Study participants 
The relationship between household and clinical malaria episodes included all 52 
families and took into account the 802 single clinical malaria episodes diagnosed by 
microscopy in Daraweesh, which represented 1902600 person-days (i.e. an estimate 
of the actual time-at risk in days that all persons contributed to a study) over the eleven 
year study period (January 1990 to December 2000) (Creasey et al. 2004). Subsequent 
analysis of the spatiotemporal distribution of malaria included these 802 single 











































































antigens of the 333 individuals whose first clinical episode of malaria was discussed 
previously in Chapter 4. These individuals represented 49 of the 52 families in the 
village.  
5.4.3 Antigens and ELISA 
Antigens used for the ELISA included the MSP-119 of the four Plasmodium species as 
well as P. falciparum–specific MSP-1 Block 2 antigens and the full-length and 
species-specific MSP-2A and MSP-2B serogroups (Table 2.6.1). ELISAs were 
performed as described in Section 2.7.1 
5.4.4 Mapping of spatial data by QGIS 
Maps showing year by year malaria prevalence and its distribution within the village 
were generated using QGISTM v.2.186 (QGIS developer team, Open Source 
Geospatial Foundation).  
 
5.4.5 Statistical analysis  
Space-time analysis of malaria prevalence and species of Plasmodium was done using 
a discrete Poisson model, with a generalised linear mixed model performed to identify 
differences in Plasmodium species between different households over time. 
5.4.5.1 Discrete Poisson model  
The discrete Poisson model was used as the number of cases in each household was 
known and the nature of the data were counts (Kulldorff 2015, Kulldorff 1997). 
Households with malaria were taken as cases, and the population as the combined 
number of person-years used to fit the Poisson model. Then, the Poisson data were 
analysed with the space-time scan statistics.  
 
5.4.5.2 Cluster analysis 
The scan statistics developed by Kulldorff and SaTScan™ software version 9.4 
(Kulldorff 2015) were used to identify the presence of space-time malaria clusters. The 
scan statistics did scanning gradually across time and/or space to identify the number 




scanning window was an interval (in time), a circle (in space) or a cylinder with a 
circular base (in space-time) to which window sizes were determined, and the window 
with the maximum likelihood was the most likely cluster, and a P-value was assigned 







5.5.1 Trends in population and malaria prevalence in Daraweesh 
Within the 11-year study of malaria epidemiology in Daraweesh, there were 802 single 
episodes of clinical malaria, with a third of the village population not experiencing a 
clinical malaria episode (Creasey et al. 2004). After the long dry season of 1988-1990, 
the first and only clinical episode of malaria case in the village was recorded in 1990. 
There was a steady rise in malaria incidence from 1992 peaking in 1994 following the 
rainfall in 1993 (Figure 5.5.1 on page 153). Following this there was a steady fall in 
malaria episodes until 1997. Malaria incidence peaked again in 1998 with the number 
of cases being about four times that observed in the previous year. The rainfall 
recorded in Daraweesh and across the entire Sudan was higher in 1998 compared to 
that of previous years. There was a decline in the number of malaria cases in both 1999 
and 2000, with the cases recorded in 2000 being similar to levels observed in 1992 
(Figure 5.5.1). It is obvious in Daraweesh that rainfall patterns influence the number 
of malaria cases in each transmission season, as it has a direct effect on the number of 
adult mosquitoes. In the dry seasons the annual rain-dependent expansion of the 
Anopheles population is not observed, reducing parasite transmission and malaria 
cases, as observed with only one documented clinical malaria case during the 1990 
transmission season, when drought occurred. 
The population of Daraweesh increased steadily throughout the study period. The 
mean malaria positive prevalence, which is the fraction of clinical malaria episodes to 
the population of the village, for the 11 year study period was 1.36 ± 0.068SD (range 
0-3) and varied markedly between households. The number of households 
experiencing clinical malaria correlated positively with the number of cases in each 
transmission year, with more households experiencing clinical malaria in transmission 






Figure 5.5.1: Incidence of malaria correlates positively with increasing household size in the Daraweesh village. 
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5.5.2 Overview of clinical malaria cases in Daraweesh households  
The 802 individual clinical infections diagnosed in Daraweesh were treated over 
63420 person-months, giving an overall 11-year average malaria case rate of 12.6 
episodes/1000 person/months (Creasey et al. 2004). This average, however, conceals 
possible household to household variation in clinical disease incidence, which is 
addressed in this chapter. The single clinical malaria episode in 1990 (representing 0.2 
malaria cases/1000 person months) was identified in an individual (aged 16 years) 
from family R in compound 7 (Figure 5.5.2 and Figure 5.5.3 on page 155 and 156 
respectively). The location of the hut in which this individual resided is important in 
terms of the ecology of mosquitoes and parasite transmission. Family R is one of the 
families closest to the vegetation on the southeast part of the village.  
In 1991, there were six new cases of clinical malaria. These were randomly distributed 
in the village within five households 2B, 2N, G, J, and V, residing in four different 
compounds (Figure 5.5.2). No member of family R experienced a malaria episode in 
that year, suggesting that the episodes seen in 1991 were not from any identifiable foci. 
This dispersed pattern may be indicative of the unusual biting behaviour of the 
mosquitoes. During the 1992 transmission season, there was a north and south divide 
of the incidence of malaria and this spread was both seen within and between 
households. The increased rainfall between 1993 and 1998 (Creasey et al. 2004) 
correlated positively with a corresponding rise in malaria episodes and this was 
uniformly distributed throughout the village, until 1997 when the north and south 
divide became similar to that observed in 1992.  
Whiles some families (A, B, F, G, H, O, V, X, 2A, 2H, 2L, 2M, 2O and 2P) 
experienced higher incidence of malaria over the study period, there were two families 
(Y and 2U) with household sizes of 2 and 10 members respectively, who did not 
experience any clinical malaria episodes over the course of the eleven year study 
period (see previous Figure 5.5.2 and Figure 5.5.3). One, five and thirteen households 
experienced malaria in 1990, 1991 and 1992 respectively. Between 1993 and 2000, 






Figure 5.5.2: Malaria incidence is focal in Daraweesh households. The pie charts show the year by year episodes of malaria, with the sizes representative 
of the number of malaria cases. Households are defined by letters of the alphabet and alphanumeric combinations, while compounds are defined by the numbers in red. 





Figure 5.5.3: Malaria incidence occurs most frequently in certain households. Households are defined by letters of the alphabet and 




5.5.3 Malaria cases and household size 
Malaria transmission is generally within households and compounds and the 
propagation of the disease depends on the transmission that occurs between individuals 
and family members. A third of the Daraweesh population did not experience clinical 
malaria episode for the duration of the study, although some of these people were 
found to be PCR positive for malaria. The malaria experience ranged from 1 to 8 
episodes, with two individuals experiencing 7 and 8 clinical malaria episodes over the 
course of 11 years. Family or household size has been reported to be proportional to 
the incidence and prevalence of malaria in communities where the disease is endemic 
(Hulden et al. 2014). As shown in Figure 5.5.4 on the next page, there was a direct 
relationship between household size and the incidence of malaria episodes in 
Daraweesh, with household level variations in the incidence of clinical malaria 
explained by variation in household size. Smaller family sizes (less than 5 individuals) 
experienced fewer episodes of disease (0-13, mean 4.75 malaria episodes) compared 
to families with more than 5 members in a household where between 0 and 52 clinical 
malaria episodes (mean 17.4 cases) were recorded over 11 years. The number of 
households experiencing clinical malaria in each transmission season correlated with 
the number of malaria cases diagnosed in that transmission season. 
There was a general trend of a higher proportion of residents in households 
experiencing a clinical episode of malaria (Figure 5.5.5). Excluding the two 
households (families Y and 2U) where no clinical malaria was documented, the 
proportion of individuals experiencing clinical malaria per household ranged from 
16.66 to 100% with a mean of 55.69%. The lower range was observed in family U 
where only one individual (out of a 6 household members) experienced one clinical 
malaria. Two households (family 2G, household size 2 and family 2A, household size 
13) had all the residents experiencing at least one clinical malaria episode over the 11 
year study period. The proportion of individuals per household who experienced a 






Figure 5.5.4: Household size correlates with the incidence of malaria in Daraweesh. Households are defined by letters of the alphabet 
and alphanumeric combinations and labelled in blue. Straight line indicates a regression line. 













































































Figure 5.5.5: A higher proportion of residents of households experienced clinical malaria episodes. The proportion of individuals 
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5.5.4 Space-time analysis of clinical malaria cases in Daraweesh 
households 
Knowing the number of individuals and the number of clinical malaria cases recorded 
for each household in each transmission season, a retrospective space-time analysis 
was performed using the discrete Poisson model. This model confirmed that malaria 
episodes in Daraweesh were not randomly distributed within households. Two 
significant space-time clusters, and one temporal cluster were identified in the village. 
These clusters span different time periods and included different households in 
different geographical locations in the village. The first space-time cluster (cluster 1) 
was a 0.23 km radius area that spanned a longer time period between 1993 and 1999. 
It was largely concentrated in the southwest and central area of the village and included 
23 households, with a population of 272 individuals experiencing 407 clinical malaria 
episodes over seven transmission seasons (Figure 5.5.6 on page 161). The observed 
number of malaria cases was higher than expected (1.66) (Figure 5.5.7 and Table 5.5.1; 
pages 162 and 163 respectively). Households and individuals within this cluster were 
2.33 times more likely to be at risk of having a clinical malaria episode than households 
outside of this cluster (RR =2.33, P <10 x 10-15) (Table 5.5.1). 
The second cluster (cluster 2) occurred within a shorter time period between the 1998 
and 1999 transmission seasons. It covered a 0.25 km radius area and included 22 
households mainly in the northeast part of the village. Cluster 2 included 214 
individuals experiencing 100 clinical malaria episodes in two years. Similar to cluster 
1, the observed/expected ratio of malaria cases was higher (1.81). Households and 
individuals within cluster 2 were 1.93 times more likely at risk of having a clinical 









Figure 5.5.6: Two clusters of malaria incidence were identified in Daraweesh 
between 1991 and 2000. The red ovals in the large pink circle represents households 
in cluster 1, southwest and central area of the village (1993-1999), and the blue ovals 
in the large blue circle represent households in cluster 2, northeast part of the village 
(1998-1999). Households outside the pink and blue circles were outside the two 






Figure 5.5.7: The first significant cluster of clinical malaria episodes covered 
seven transmission seasons (1993-1999). Cluster 1 covered the southwest and central 
area of the village and included 23 households, with a population of 272 individuals 
experiencing 407 clinical malaria episodes between 1993 and 1998. The observed 
number of malaria cases was higher than expected (1.66). Households and individuals 
within this cluster were 2.33 times more likely to be at risk of having a clinical malaria 














Cluster 1 Cluster 2 
 
Coordinates (N, E) 
 
 
13.903490 N, 35.408406 E 
 






Jan 1993 to Dec 1999 Jan 1998 to Dec 1999 


























10x10-15 3.2 x 10-4 
Household in cluster (A, B, C, D, E, F, G, H, I, J, 
K, L, T, U, V, X, 2G, 2H, 
2I, 2K, 2N, 2P and 2Q) 
(P, Q, R, S, V, Y, Z, 2A, 
2B, 2C, 2D, 2E, 2F, 2R, 2S, 
2T, 2X, 2Y, AA, and AE) 
Note: Households are defined by letters of the alphabet and alphanumeric 
combinations. 
The start years of both cluster 1 (1993) and cluster 2 (1998) corresponded to the 
transmission seasons when heavy rainfalls were recorded in Daraweesh (Creasey et al. 
2004). The two clusters were also found next to each other suggesting that for a while, 
and over a longer period of time the population in cluster 1 were continually being 
infected with Plasmodium parasites until an overlap in 1998 when the population in 




cluster was observed from 1993 to 1999, with an overlap of the 1998 transmission 
season. 
5.5.5 Space-time analysis of Plasmodium species in households 
As previously discussed in Chapter 4, antibody response to MSP-119 antigens of the 
four Plasmodium species were tested for 333 individuals who had experience a first 
malaria episode. Similar to the model used above for the total clinical malaria episodes 
over the course of eleven years, a retrospective space-time analysis was performed 
using the discrete Poisson model for all first time malaria diagnosed to understand if 
there were any significant clustering of the species in space and time.  
This model confirmed that infection by the four Plasmodium species were not 
randomly distributed within the village. Multiple significant clusters were identified 
for the parasite species; three for P. falciparum, two for P. vivax and P. malariae, and 
one for P. ovale (Figure 5.5.8 on page 165). These clusters had overlapping time 
frames, with some of the species significantly infecting the same households. 
For example, P. falciparum and P. vivax had two overlapping significant clusters 
spanning between 1992 to 1996 in the same household of 2A, with relative risk of 3.69 
(P=4.4 x 10-5) and 4.65 (P=1.5 x 10-2) respectively, and between 1996 to 1999 in which 
these two species increasingly caused malaria in the same 9 households (RR=1.93, 
P=2.2x10-6 for P. falciparum and RR=3.94, P=1.7 x 10-15 for P. vivax) (Table 5.5.2 on 
page 166). The third significant cluster of malaria caused by P. falciparum was from 
1995 to 1998 and was concentrated in six households located in the southeast of the 
village. Residents of these household were 1.7 times more likely to be infected with 
this species than households outside of this cluster (P=1.4 x 10-2).  
Similarly, between 1995 and 1999, residents of household 2P were significantly at risk 
of increasing malaria caused by P. malariae (RR=8.63, P=4.4 x 10-16) and P. ovale 
(RR=7.74, P=1.7 x 10-15) than other households (Table 5.5.2). The second cluster of 
malaria caused by P. malariae was seen during the 1996 to 1999 transmission seasons, 
with four households located in northeast of the village at significantly increased risk 





Figure 5.5.8: Multiple significant clusters identified for the parasite species. Multiple significant clusters were identified for the 




Table 5.5.2: Retrospective space-time analysis of the most likely Plasmodium species infecting households. 
 P. falciparum P. vivax P. malariae P. ovale 
Variables  
 








































3.68 1.70 1.93 4.65 3.94 8.63 4.23 7.74 
LLR 
 
16.9 10.4 20.2 11.1 44.1 48.2 10.6 45.8 
P-value 
 
4.4 x 10-5 1.4 x 10-2 2.2x10-6 1.5 x 10-2 1.7 x 10-15 4.4 x 10-16 1.7 x 10-2 1.7 x 10-15 
Household 
in cluster 
(2A) (A, B, C, 
D, F, and 
G) 





(2A) (J, 2G, 2I, 
2K, 2L, 
2M, 2N, 
2P, 2U and 
2V) 
(2P) (O, Y, 2B 
and 2C) 
(2P) 




5.5.6 Variation in Plasmodium species within households and over 
time 
Of the 333 individuals experiencing a first clinical episode of malaria (samples used 
in Chapter 4) the year by year proportion of the four different Plasmodium species was 
stable from 1991 to 1999 in the order of P. falciparum, P. malariae, P. vivax and P. 
ovale (Figure 5.5.9 on page 168). Of the 49 families in which blood samples were 
available and screened for IgG response to MSP-119 antigens from the four 
Plasmodium species, mixed-Plasmodium infections-only were seen in three families 
(2K, 2X, 2Y) (Figure 5.5.10). Families 2X and 2Y lived in the same compound in the 
north of the village while family 2K lived alone in a compound in the western part of 
the village. Infections caused by single species only were seen in six families (families 
E, I, P, Q, R and U), all of whom lived in different compounds in the village. All other 
families experienced malaria comprising of both single and mixed-species infections 







Figure 5.5.9: Plasmodium species are relatively stable over time. The proportions 





Figure 5.5.10: Single- and mixed-Plasmodium infection prevalence in Daraweesh 
households. Households are defined by letters of the alphabet and alphanumeric 
combinations. 
5.5.7 Heterogeneity in antibody responses to Plasmodium MSP 
antigens  
There was no plasma sample available from the individual who contracted malaria in 
1990 to determine the type of Plasmodium species or the genotype of P. falciparum 
antigens he carried. The first episodes of malaria with available plasma sample were 
from the 1991 transmission season. Plasma IgG antibody responses from these six 
individuals showed heterogeneous responses to MSP-119 antigens of the four 
Plasmodium species as well as P. falciparum-specific MSP-1 Block 2 and MSP-2A 
and -2B antigens. P. falciparum MSP-119 antigen was recognised by the plasma 
antibodies of all individuals, while two MSP-1 Block-2 antigen types, K-1 and 
MAD20 Block 2, were detectable by the plasma of five of these six individuals. RO33 
Block 2 was detectable by only one individual, 2N, who also had antibody responses 
to all other antigens tested (Table 5.5.3, page 170). Two members of the same family 




119 antigens, only individual V4 had additional responses to two MSP-1 Block-2 
antigens. The antibody responses observed in these individuals in the 1991 
transmission season illustrate no clear compound- or family-specific responses. This 
observation was also very common in subsequent transmission seasons. 
Table 5.5.3: Antibody responses to Plasmodium MSP antigens are 
heterogeneous in Daraweesh (1991 transmission season). 















2B2 + + - - + + - + - 
2N4 + + + + + + + + + 
G7 + - + - + + - + + 
J2 + - - - + + - + + 
V4 + - - - + + - - - 
V5 + - - - - - - - - 
Note: The letters of the alphabet and alphanumeric combinations represent each 
individual’s identity within a family. The + and - symbols represent detectable and 
undetectable antibody response respectively to the various Plasmodium antigens. 
In the Daraweesh population, a previous study reported that a minority of the 
population often responded well to P. falciparum MSP-119 antigen, but failed to 
response to the polymorphic MSP-1 Block 2 antigens (Cavanagh et al. 1998). In view 
of this I wanted to determine the patterns of antibody responses to P. falciparum MSP-
119 antigen and the polymorphic MSP-2 antigens in individuals who had more than one 
documented clinical malaria episode. A subset of the study population (136 




years had their plasma (from the second episode) tested to determine changes, if any, 
of antibody responses to P. falciparum MSP antigens between the first and subsequent 
malaria episodes. Selective non-responsiveness was observed in 11.03% of the 
population studied, with three different patterns of anti-MSP response to P. 
falciparum-specific antigens seen.  
The first and the most common pattern (which was expected), consisted of individuals 
who had antibody responses to P. falciparum MSP-119, and at least one MSP-2 antigen 
in both the first and subsequent infections (121 of 136 individuals, Figure 5.5.11 panel 
A). The second pattern was observed in 11 individuals who made antibodies responses 
against P. falciparum MSP-119 antigen, but not MSP-2 antigens, in the first infection, 
but responded to the other more polymorphic MSP-2 antigens in subsequent 
infection(s). An example of this pattern is illustrated in panel B of Figure 5.5.11. The 
final pattern is represented by a minority of individuals (4 of 136 cases) who responded 
well to both the conserved MSP-119 and the polymorphic MSP-2 antigens at the first 
infection, but then failed to recognise MSP-2 antigens in subsequent infection(s). An 
example is illustrated in panel C of Figure 5.5.11. In this example, an individual having 
a malaria episode in October 1994 made an antibody response to both P. falciparum 
MSP-119 and MSP-2A and 2B antigens, but then failed to make responses to the MSP-
2 antigens during subsequent malaria episodes in August 1996 and October 1997, in 






Figure 5.5.11: Selective non-responsiveness to P. falciparum polymorphic 
antigens is common in Daraweesh. A: individual X7 represents the majority of the 
population (121 individuals) who had antibody response to the polymorphic MSP-2 
antigens at both the first and subsequent clinical malaria episode (October 1992 and 
1994); B: individual 2E5 represents a smaller population (8 individuals) who only had 
a response to MSP-2 antigens at their second infection (January 1998 but not in the 
1994 transmission season); C: individual 2I3 represents the minority group (4 
individuals) who made a response to MSP-2 antigen at their first infection (October 
1994), but failed to respond to these polymorphic antigens at subsequent clinical 
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In this chapter, a retrospective analysis of malaria incidence in Daraweesh allowed an 
in-depth characterisation of some fine scale details of malaria epidemiology in the 
village, including significant space-time clustering of malaria incidence, and 
identifying variations in malaria incidence between households and over time. 
The epidemiology of malaria in the village showed a rainfall-dependent pattern in 
which higher number of clinical malaria cases were diagnosed in transmission seasons 
where there was heavy rainfall, and lower number of cases in the dry season periods. 
During the dry seasons the village continued to depend on the deep well as a source of 
water for domestic and vegetative purposes. This did not seem to play any role in 
creating breeding sites for adult mosquitoes, suggesting that drought has the capacity 
to break malaria parasite transmission in the village. The diagnosis of one case of 
malaria in 1990, however, suggests that blood feeding mosquitoes were not entirely 
absent in the village during the dry seasons, although the vector to human population 
ratio might have been very low. It has been shown that during the dry season, female 
Anopheles mosquitoes partially feed on human blood while undergoing an incomplete 
reproductive diapause (i.e. a period of suspended development in an insect) (Yaro et 
al. 2012, Lehmann et al. 2010). In this case malaria parasite transmission in the village 
could be described as endogenous, meaning the malaria cases originate within the 
village with a resident population of mosquitoes that are not being wind-dispersed over 
long distances into the village. This is supported by the fact that mosquitoes that breed 
around houses fly locally and do not have the capacity to fly longer distances (Biggs 
and Brown 2001, Gilles 1993).  
Considering that the closest village to Daraweesh, Asar, was 4 km away it is possible 
the mosquitoes were inhabiting local vegetation during the time of drought, but had 
limited water source for breeding. It is worth noting that within this same period, low 
but significantly higher number of malaria cases were recorded in Asar, possibly due 
to there being more water sources and mosquito breeding sites in Asar relative to that 
in Daraweesh. (Hamad et al. 2002). The rainfall measurements in Daraweesh were 




indicative of levels of actively growing vegetation. This measure is a surrogate for 
rainfall in and around the plains within a 10 km square area, in which Daraweesh sits. 
Rainfall patterns can influence the ecology of the mosquito population and their 
breeding sites (Billingsley et al. 2005, Hamad et al. 2002). Mosquito population size 
and sporozoite rates have been shown to fluctuate between seasons and over years, 
increasing shortly after the onset of rainfall, and declining during long dry seasons as 
sources of water for breeding become scarce (Billingsley et al. 2005, Charlwood et al. 
1995). This might have contributed to the fluctuating number of malaria cases seen 
during rainy and dry seasons.  
In Daraweesh, household sizes correlated with malaria cases with larger family sizes 
experiencing higher numbers of malaria cases. In areas where malaria has been 
eradicated or prevalence has reduced over many years, it has been shown that declining 
household sizes play a key role in malaria case decline (Bannister-Tyrrell et al. 2017, 
Hulden et al. 2014, Hulden and Hulden 2009). Decreasing household size may result 
in fewer interactions between families, and accordingly decreasing contacts between 
the host and mosquito vectors (Hulden and Hulden 2009). However, in larger 
household in Daraweesh and other neighbouring villages, individuals are likely to 
sleep outdoors during the night (Hamad et al. 2002), thereby increasing the likelihood 
of being bitten by mosquitoes. The outdoor biting capacity of An. arabiensis has been 
shown to be significantly higher in Daraweesh than its indoor biting rate (Hamad et al. 
2002), which may partly explain the higher number of malaria episodes observed in 
larger households where occupants are likely to sleep outdoors. Mosquito control 
complemented with other factors such as effective drug treatment and surveillance are 
important steps towards malaria eradication. The finding of my study of an apparent 
correlation between household size and decline in malaria cases is significant for both 
short and long term control of malaria in endemic regions. For example, malaria 
control agencies in Ministries of Health working in collaboration with other 
departments and stakeholders could ensure that land development, settlement planning 
and the planning of exploration of natural resources (Hulden et al. 2014) are taken into 
consideration when designing programmes for malaria eradication. Evidence of this is 




the provision of individual bed nets and effective antimalarial drug distribution and 
surveillance in smaller household size (average of 5.6 individuals) (Kaneko 2010, 
Kaneko et al. 2000). Such coordinated efforts through inter-ministerial collaboration 
would contribute significantly to reducing the burden of malaria.  
The risk of having a clinical malaria episode in Daraweesh were significantly clustered 
in two geographical locations, herein referred to as ‘hotspots’. These clusters spanned 
different transmission seasons and included different households in two geographical 
locations in the village, mainly the southwest and central, and the northeast of the 
village. These clusters were more stable at these locations and over time. In this study, 
the discrete Poisson model confirmed both the existence of clustering of households 
with clinical malaria episodes, and demonstrated that households with malaria 
episodes were more aggregated than those not experiencing clinical malaria, consistent 
with other observations of malaria clustering elsewhere (Alemu et al. 2013). The 
concentration of the heaviest burden of malaria in households which fell under cluster 
1 over a long period of time (1993-1999), and cluster 2 for two years (1998-1999), 
both being within a radius of 0.25 km suggests a focal nature of Plasmodium parasite 
transmission in the village. Similar observations have been reported with Dengue 
fever, another mosquito-borne viral disease causes by Dengue virus, in which certain 
populations within a hotspot area are seen to be heavily infected over time and account 
for the transmission of the disease to other neighborhoods (Vincenti-Gonzalez et al. 
2017).  
The clustering of malaria incidence (cluster 1) suggests a higher exposure to infectious 
mosquitoes in the 23 households in the southwest and central areas of the village for a 
longer period of time (1993-1999), especially after the two heavy rainfalls in 1993 and 
1998 (peak of cases in 1994 and 1998 according to the space-time analysis). It has 
been shown that mosquitoes have the tendency to feed and return to the first household 
they encounter (Smith et al. 1995b), with female mosquitoes visiting no more than 3 
houses in their lifetime (Gubler 1998) and flying shorter distances of between 10 and 
30 meters away from breeding or water sources (Getis et al. 2003). This may suggest 
that infectious mosquitoes were closer to these households than other parts of the 




of pools, as well as the greener vegetation may serve as potential breeding sites for the 
female mosquitoes (Seyoum et al. 2017). This may contribute to an increase in vector 
density as well as increased contact with the human host, leading to a greater number 
of clinical malaria episodes (Seyoum et al. 2016, Abate et al. 2013). Households which 
fell under cluster 1 had larger family sizes. As is the case in this village, members of 
larger households usually use the yard spaces in the compounds for outdoor sleeping 
(Hamad et al. 2002) which may explain their vulnerability to infectious bites. Although 
this study assumes that all malaria cases were occurring within households, 
occupation-related mobility and multiple residence system (Bannister-Tyrrell et al. 
2017) such as household member(s) moving to other properties, or children staying 
overnight with relatives in other households could not be accounted for as these are 
challenging to assess. 
The onset of the 1993 rainfall resulted in the cluster not randomly distributed over the 
entire village, but limited to only the 23 households in the southeast and central part 
of the village. This cannot be explained by some of the common factors associated 
with malaria clustering such as landscape, building structure or house construction 
(Bannister-Tyrrell et al. 2017). The characteristics of the local environment (e.g. the 
flat surface covered by black soil that allows rainwater to stay on the surface longer) 
which may influence the presence of mosquito breeding sites, was similar throughout 
the village (Hamad et al. 2002). Furthermore, the materials use for the construction of 
the household huts were the same for all the residents. What is known is that the deep 
well in the village was located at the southwest of the village, and may have 
contributed as a breeding site during both the rainy and dry seasons, culminating in 
households closest to it being more susceptible to infectious bites from mosquitoes. 
Genetic traits such as ABO blood group, and red blood cell haemoglobinopathies have 
also been suggested to influence clustering of malaria incidence in certain households 
within a population (Bannister-Tyrrell et al. 2017). These may not explain these 
differences in space-time analysis between the two geographical locations in 
Daraweesh where malaria cases clustered. This is because the people of the village are 




been found to contribute to increased susceptibility of malaria in some groups more 
than others (Creasey et al. 2004).  
The northeast households in the village were a consistent and significant secondary 
cluster for malaria incidence (1998-1999), that corresponded to the start of heavy 
rainfall recorded in 1998. Although this cluster overlapped in time with cluster 1, the 
shift of malaria burden to another part of the village was dramatic and intense over a 
shorter period. Shift in malaria hotspots are common when control interventions are 
implemented in areas under intense transmission (Dhimal et al. 2014). However, apart 
from chemotherapy which was promptly administered to people who were diagnosed 
of having clinical malaria, no specific malaria control interventions were implemented 
in this village during the study period that could account for this shift (Creasey et al. 
2004, Hamad et al. 2002). This shift may be explained in part, by some acquired 
immunity by households in cluster 1, who had been intensely exposed to parasites and 
infected over a longer period. Sterile immunity to malaria is rarely achieved 
(Langhorne et al. 2008, Marsh and Kinyanjui 2006), however, over many years of 
exposure, individuals develop a certain level of immunity against severe disease and 
the development of clinical malaria (Langhorne et al. 2008, Marsh and Kinyanjui 
2006). It is possible that most individuals in households which fell under cluster 2 were 
‘non-immune’ to disease owing to fewer exposure to parasite over a long periods, and 
therefore the new wave of disease in the 1998 and 1999 transmission seasons made 
them more susceptible to disease. 
I also confirmed that infection by the four Plasmodium species were not randomly 
distributed within the village. Multiple significant clusters were identified for the 
parasite species; three for P. falciparum, two for P. vivax and P. malariae, and one for 
P. ovale. The significant observation was the overlap of clusters in time and space 
between the different Plasmodium species. P. falciparum and P. vivax infections 
overlapped in time and in the same households, with a similar trend observed with P. 
malariae and P. ovale infections. A biological reason for this interaction might be 
related to the erythrocyte preferences of each species (Bruce and Day 2002). Since P. 
falciparum can infect all stages of red cells (Bruce and Day 2002, Gilles 1993), the 




infections. The cluster of P. vivax infections in focal households may also suggest that 
residents of such households may either be Duffy positive (a measurement beyond the 
scope of this thesis) or may have unidentified erythrocyte receptors which this species 
binds to establish infection. Duffy antigens are relatively rare in the population of Sub-
Saharan Africa, making them refractory to P. vivax infection (Miller et al. 1976). 
However, recent work has shown that P. vivax infections are increasingly being 
identified in Sub-Saharan African populations who are Duffy negative (Mbenda and 
Das 2014, Fru-Cho et al. 2014, Wurtz et al. 2011, Mendes et al. 2011), and perhaps 
this antigen is no longer a barrier to the ability of P. vivax to establish a successful 
infection. It is of interest for future research to explore the mechanism of these cluster 
interactions between the different species. 
Following the long dry season in Daraweesh between 1988 and 1990, the first clinical 
episode of malaria was diagnosed in 1990. Unfortunately, the Plasmodium species and 
genotypes of the individual from family R who was infected in that year could not be 
identified owing to the non-availability of plasma sample for testing. Using the 1991 
season as a case study, I observed heterogeneity in the parasite structure with reference 
to the type of antibody response to Plasmodium MSP antigens of the six individuals 
who were infected in that transmission season. Although the origin of these parasites 
is unknown, there is evidence from molecular studies showing that between 19-24% 
asymptomatic individuals in this village who carry some parasites during the long dry 
seasons when clinical malaria episodes are rare (Roper et al. 1996). This may also 
suggest the intrinsic capacity of the Plasmodium parasite to persist as chronic sub-
clinical asymptomatic infections in some of the population over time. These 
individuals may serve as reservoirs for onward parasite transmission in subsequent 
seasons when environmental conditions are favourable for the mosquito vector 
(Bousema et al. 2012, Bousema et al. 2010a). In the preceding drought years where 
only one clinical malaria case was diagnosed in 1990 it was expected that the new 
infections of 1991 would arise from a limited number of sources and that antibody 
responses to these limited antigens in the population would reflect this. The 
heterogeneity in antibody response to MSP antigens in these six infections of 1991 




mosquito population may have been low. This assumption is supported by evidence 
that P. falciparum parasites isolated from clinical samples in both Daraweesh (Arnot 
et al. 1994) and its neighbouring villages (Babiker et al. 1991a, Babiker et al. 1991b) 
show extremely high genetic variability. This may further suggest that although the 
malaria episodes in Daraweesh may originate from identifiable foci, as seen in the 
clusters analysis, the parasite population is very diverse. 
 
Selective non-responsiveness of individuals to parasite antigens between different 
seasons was observed in 11% of the subset of the Daraweesh population who had more 
than one malaria episode at different transmission seasons. It has been suggested that 
the phenomenon of “clonal imprinting,” or “original antigenic sin” (Francis 1960) may 
be responsible for selective non-responsiveness of some individuals to certain parasite 
antigens during infection. This hypothesis suggests that an individual’s B cell 
repertoire against parasite antigens might become fixed by his or her first or early 
exposure to a particular parasite antigenic variant, thereby preventing the recognition 
of other variant antigens in subsequent infections (Riley 1996, Taylor et al. 1996). This 
phenomenon is very much evident in viral diseases caused by the influenza virus (Kim 
et al. 2009) and dengue virus (Rothman et al. 2014, Halstead et al. 1983). However, 
the patterns of selective non-responsiveness to merozoite surface proteins in the 
Daraweesh population do not support this hypothesis as individuals do not show a 
fixation of their antibody response to any particular MSP antigen. Although a possible 
transitory antibody response to these polymorphic antigens could be argued (owing to 
the short half-life of IgG3 to these polymorphic antigens), this may not be the case as 
blood samples were collected at the acute phase of the disease, and not as might be the 
case with antibody responses to these antigens when blood sample is collected many 
months after illness (Cavanagh et al. 1998). A possible explanation to this observation 
in Daraweesh might be the limited number of variant antigens in the panel of 
polymorphic antigens used in this study that were unable to detect the presence of 
variant-specific antibodies that individuals might have been exposed to at different 
transmission seasons. There is the possibility of the full range of allelic variants in the 
MSP-2 antigens of the parasite population in Daraweesh being more than the 




polymorphic MSP antigens might be as a result of the repertoire of parasite antigens 
an individual is exposed to at different transmission season, owing to the diversity of 
parasite population present at each season.  
 
5.7 Conclusions 
I have demonstrated in this chapter that malaria parasite transmission is more focal in 
Daraweesh and that hotspots of clinical malaria episodes were more stable at the 
geographical level and over time. Two space-time clusters of significantly increased 
malaria risk were identified (1993-1999, and 1998-1999) with marked variation 
between households, but little or no variation in the species of Plasmodium over time. 
This may suggest that even in a small geographic area malaria transmission shows 
heterogeneity, and that such data can provide useful information to guide malaria 
control efforts.  
An important finding in this chapter is the correlation of household sizes with the 
incidence of malaria cases in Daraweesh. This finding provides new information that 
would be important in the long term planning and implementation of optimal control 















Chapter 6. Identifying gene expression 
signatures in P. falciparum infecting different 
ABO blood group donors 
6.1 Introduction 
A substantial part of the development of P. falciparum in humans takes place within 
the host erythrocyte where it replicates in a 48-hour cycle of intracellular growth, 
lysis and re-invasion (Bannister and Mitchell 2003, Hawking et al. 1968). This 
stage of the parasite’s life cycle is responsible for the pathology of the disease, 
mediated by the parasite’s rapid expansion in numbers (Simpson et al. 2002), the 
release of toxic by-products of erythrocyte lysis (White et al. 2013a), and the 
sequestration of infected erythrocytes within the microvasculature of the host’s 
organs (Rowe et al. 2009a), leading to severe forms of malaria which have high 
rates of morbidity and mortality. Disease severity is related to parasite virulence 
factors, which interact with host parasite resistance factors, including the ABO 
blood groups.  
It has been known for some years that the ABO blood group type of the infected 
host has an influence on the outcome of infectious diseases (Cooling 2015) and 
cancers (Rummel and Ellsworth 2016, Aird et al. 1953). The hosts of blood group 
O show resistance to severe malaria, possibly due to reduced parasite rosetting and 
sequestration than the non-O groups (Rowe et al. 2009b, Barragan et al. 2000). 
Group O is also far more common in areas of present day and historical malaria 
endemicity than elsewhere (Cserti and Dzik 2007). For example, in Sub-Saharan 
Africa and Central and Southern America where P. falciparum is endemic, a higher 
prevalence ratio of group O to group A is documented, whereas in the Western 
hemisphere and other temperate regions of the world with no malaria, a higher 
prevalence of blood group A individuals is observed (Fung 2014, Cserti and Dzik 




invasion rates in blood group A subtype A1 compared to other ABO types (Chung 
et al. 2005).  
What is not clear from any of these studies is the change, if any, in gene expression 
in clonal parasites when they are transmitted to hosts of different ABO blood 
groups. In bacteria, spontaneous switching between active and repressed states for 
a large number of genes generates transcriptional diversity within a clonal bacterial 
population before any environmental change is encountered, thus representing a 
risk-spreading strategy (Veening et al. 2008). Thus, upon a change in the 
environment, transcriptional heterogeneity provides the grounds for natural 
selection of pre-existing parasites, which have transcriptional patterns that confer 
maximum fitness under the new conditions. This form of epigenetic inheritance is 
likely to be important for malaria parasites encountering a new host, where 
environmental conditions will likely be different from those in the previous host.  
I speculated that the transcriptional variability in P. falciparum might result not 
only in antigenic variation, but also in functional variation in the parasite’s growth 
capabilities, which could be selected for or against by changes in the host 
environment that occur when parasites are transmitted between genetically different 
hosts. To date, no study of parasite gene expression profiling has been done to 
identify changes in parasite gene expression induced by changes in host ABO blood 
group. I hypothesised that there will be changes in the parasite’s gene expression 
patterns when P. falciparum 3D7 clones infect erythrocytes of different ABO blood 
groups. 
To test the above hypothesis, I cultured a single clonal isolate of P. falciparum 
(3D7, for which the complete genome sequence is known) in blood groups A, B 
and O erythrocytes, harvesting total mRNA at mid-trophozoite stage (Bunnik et al. 
2013, Lacsina et al. 2011). The reason for harvesting at mid-trophozoite stage is 
because it is the stage where the parasite’s metabolism is highest (Bunnik et al. 
2013). I subsequently applied high-throughput transcriptome sequencing (RNA-
seq) using previously described bioinformatic methods (Rovira-Graells et al. 2012, 
Vignali et al. 2011) to characterise the gene expression changes between different 




6.2 Study aim 
To determine gene expression changes in 3D7 P. falciparum parasites as 
they infect erythrocytes of different ABO blood group donors. 
 
6.3 Hypothesis 
P. falciparum infection will change the parasite’s gene expression patterns in 
erythrocytes of different ABO blood group donors. 
6.4 Materials and methods 
6.4.1 Donor recruitment 
15 adult Caucasians (5 each of known blood groups A, B and O) with no previous 
clinical history of malaria were recruited into this study. The blood collection 
procedure was carefully explained to them and each volunteer could leave the study 
at any time.  
6.4.2 ABO blood group typing 
To confirm the ABO blood group type of the donors finger prick blood was 
collected from each donor, and donor red blood cells (RBCs) evaluated for 
reactivity with commercial anti-A, and anti-B sera (Bio-Rad Medical Diagnostics, 
Germany), in what is described as the forward reaction (unknown donor ABO 
antigens against known anti-sera) (Khan et al. 2013, Cooling 2008). Two 50 µL 
aliquots of each donor’s blood were placed on a white tile and a corresponding 50 
µL of either anti-A or anti-B serum added to each drop of donor blood (Cooling 
2008). Donors belonging to blood group A had the presence of the A antigens on 
their erythrocyte surface agglutinated by the anti-A serum, while the erythrocytes 
of blood group B individuals agglutinated upon the addition of anti-B serum. Blood 
group O individuals, having neither A nor B antigens on the RBCs showed no 






6.4.3 Blood collection and processing 
18 ml of whole blood from each donor was collected weekly for 2 weeks into Acid 
Citrate Dextrose tubes (Sigma-Aldrich, UK) (Carter et al. 1993). White cells/buffy 
coat was removed after centrifuging blood at 200g for 5 mins. Plasma and as much 
of the buffy coat layer on the surface of the red cells were removed as possible by 
aspiration. Erythrocytes were washed 3 times in Incomplete RPMI medium (RPMI 
1640, 25 mM HEPES, 2 mM glutamine, 20% glucose, 25 μg/ml gentamicin, 1 M 
NaOH, 100 μM hypoxanthine, 20 mM NaHCO3) (Thermo Fisher Scientific, UK), 
aspirating, re-suspending and mixing between each wash. An equal volume of the 
incomplete RPMI medium to the volume of cells was used for each round of wash. 
After the third wash, red cells were re-suspended at 50% haematocrit in complete 
medium (RPMI 1640, 25 mM HEPES, 2 mM glutamine, 20% glucose, 25 μg/ml 
gentamicin, 1 M NaOH, 100 μM hypoxanthine, 20 mM NaHCO3, 10% of human 
AB negative serum) and stored at 4oC for a week from the date of drawing. 
6.4.4 Thawing of deep-frozen 3D7 P. falciparum 
All work involving 3D7 P. falciparum was done in a biosafety level 3 laboratory. 
Parasite culturing was done in a Class II biological safety cabinet under sterile 
conditions. All materials used for culturing were sterile and the solutions were warmed 
up to 37°C for use. 
Three thawing solutions (A -12% NaCl, B - 1.6% NaCl, and C - 0.9% NaCl + 0.2% 
dextrose) were freshly prepared and sterilised by filtration through 0.22 micron filters 
(Carter et al. 1993). An ampoule of P. falciparum 3D7 parasites were removed from 
liquid nitrogen, placed in water bath at 37oC for 2-3 minutes until fully thawed (Carter 
et al. 1993). The sample was transferred to a sterile tube and the volume of blood 
measured. Using 0.2 ml solution A for every 1 ml of thawed blood, solution A was 
added drop by drop, with constant mixing. The tube was allowed to stand for 3 
minutes. Solution B was added drop by drop with constant mixing, using 10ml for 
each 1ml of original thawed blood. Finally, solution C was added drop by drop using 




minutes. Supernatant was removed and cells re-suspended slowly in complete medium 
to a 5% haematocrit in a T-25cm2 culture flask (Greiner Bio-One, UK).  
6.4.5 Maintaining parasite cultures 
The culture was then maintained at 37oC overnight in a humidified tissue culture 
incubator at 5% CO2. A 50µL drop of freshly washed, 50% haematocrit blood group 
O positive erythrocytes obtained from the Scottish National Blood Transfusion Service 
was added on the second day after thawing, when rings were preparing to burst and re-
invade new erythrocytes. The culture was re-incubated at 37oC overnight. On the third 
day, an aliquot of the culture was taken and a thin blood film prepared and examined 
for parasites by the Giemsa staining technique. A second preparation was made to 
estimate parasitaemia by staining parasite DNA with Hoechst 33342 and measuring 
by flow cytometry (Crowley et al. 2016). For RNAseq, these cultures were initially 
expanded to a parasitaemia of 1-10% in a 25 ml culture volume. 
6.4.6 Parasitaemia count by Giemsa and Hoechst 33342 staining 
Parasitaemia was monitored by both the Giemsa staining of thin blood films (Fleischer 
2004, Giemsa 1904) and by the Hoechst staining technique for flow cytometry 
(Crowley et al. 2016, Chazotte 2011). For Giemsa staining, a 2 µL aliquot of the 
cultured erythrocytes was aspirated and smeared on a slide. The slide was allowed to 
air-dry, and submerged in methanol for 10 seconds, then allowed to air-dry. The slides 
were stained for 20 minutes in 10% Giemsa solution, allowed to air-dry, and observed 
by light microscopy under ×100 objective lens magnification for asexual P. falciparum 
parasites. Parasitaemia was measured as the percentage of infected erythrocytes among 
1000 erythrocytes counted. 
Hoechst 33342 is a specific fluorescent dye that labels DNA allowing for easy 
visualization of a cell’s nucleus and other contents (Chazotte 2011). The dye binds 
within the minor groove of double-stranded adenine-thymine-rich regions of DNA, 
and can be used on both live and fixed cells owing to its membrane permeability 
(Chazotte 2011, Portugal and Waring 1988). The binding of Hoechst 33342 to DNA 




count by Giemsa staining, Hoechst 33342 was used to label nuclear DNA of cells 
grown in culture. For Hoechst staining of parasite DNA, a 25 mg lyophilised powder 
of Hoechst 33342 (Cell Signalling Technology, USA) was dissolved at a 5 mg/ml in 
dimethylformamide and used at a final concentration of 1 µg/ml in phosphate buffered 
saline. 20 µL of parasite culture was resuspended in 300 µL of Hoesch solution and 
incubated at 37oC for 45 minutes, according to the manufacturer’s instructions. The 
tubes were protected from light and the flow cytometric analysis done with the BD 
LSR II flow cytometer with 355 and 488 nm argon lasers using the BD FACSDiva 6 
software (BD Biosciences). For the analysis, an electronic acquisition gate was applied 
to the forward/side scatter plot around the red blood cell population, for the exclusion 
of debris from intact cells. 500,000 events were acquired in this gate. The blue 
fluorescence of Hoesch-stained parasite nuclei was measured through a 488 nm band 
pass filter. Data acquired was analysed using FlowJo software (Tree Star). 
6.4.7 Transfer of stock culture into erythrocytes of different blood 
groups 
Stock culture was diluted and transferred into 15 donor cultures (5 each of blood 
groups A, B and O) at a parasitaemia of 1% and maintained in the same pool of AB 
negative serum (TCS Biosciences, UK), with daily culture medium changes and 
monitoring of the parasitaemia by both Giemsa and Hoechst staining. The individual 
cultures were expanded to a volume of 50 ml in a T-75cm2 flask. The parasites were 
maintained under standard growth conditions for a period of 2-weeks in each of the 
blood group erythrocyte, in all completing five growth cycles. Parasite RNA at mid-
trophozoite stage was harvested for sequencing. The reason for the 2 weeks culture 
duration was to generate a preliminary data by investigating the short-term effect of in 
vitro parasite cultivation (Peters et al. 2007, Ringwald et al. 1999) on parasite gene 
expression in erythrocytes of different ABO blood group. Biologically it has been 
shown that the overall abundance of some parasite genes including var gene 
transcripts (one of the most abundant P. falciparum gene) reduces significantly during 





6.4.8 Sorbitol synchronization  
In order to produce a cohort of synchronous parasites 5% (w/v) D-sorbitol (Sigma, 
UK) was used to kill all the highly permeable stages of the Plasmodium parasite (i.e. 
trophozoites and schizonts); the ring forms which are less permeable are not affected 
by the action of the sorbitol (Radfar et al. 2009, Lambros and Vanderberg 1979). On 
the ninth day of parasite cultivation, cultures had high proportion of ring forms, and 
were transferred into 15 ml tubes and centrifuged at 200g and supernatant removed. 
The pellets were re-suspended to the original volume in 5% warm sorbitol (in sterile 
distilled water) and allowed to stand at room temperature for 5 minutes. The culture 
was centrifuged again at 200g, after which the sorbitol solution was removed and pellet 
re-suspended in Incomplete RPMI medium. The culture was washed twice by 
centrifuging in complete RPMI.  
A smear was prepared using about 2 µL of pellet to assess ring enrichment and the 
absence of mature forms of the parasites. A new culture was set up by adding an aliquot 
of complete medium to the pellet obtained by gently resuspending the pellet by 
aspirating and releasing up and down using a plastic pipette and transferring into a new 
culture flask containing complete medium (Radfar et al. 2009). The smear of culture 
was examined after 24 hours and contained mainly large trophozoites. Parasitaemia 
more than 3% trophozoites were diluted with complete medium to 1%. Examination 
after 18 hours showed the appearance of early rings.  
6.4.9 Parasite harvesting 
Cultures were monitored daily with daily medium changes until they were at mid-
trophozoite stage and at an approximate parasitaemia of 5% by Giemsa and Hoechst 
staining. For total RNA, erythrocytes of a 50 ml culture of each donor were pelleted 
by centrifugation at 500g at room temperature for 10 minutes, then washed twice with 
room temperature PBS. The volume of the pellet was estimated, and stored at -80oC 







6.4.10 RNA isolation and purification  
Parasite total RNA samples were processed for RNA sequencing as described below 




Figure 6.4.1: Schematic overview of the methodology and data processing used to 
analyse the RNA-seq. 
Total RNA was extracted following the Direct-zolTM RNA MiniPrep protocol (Zymo 
Research, USA). Three volumes of Trizol reagent was added to each erythrocyte pellet 
and mixed thoroughly for 5 minutes. To remove particulate debris, the mixture was 
centrifuged at 500×g for 5 minutes and supernatant transferred into an RNase-free 
tube. An equal volume of ethanol (95-100%) was added to each supernatant and 
thoroughly mixed. The mixture was transferred into a Zymo-Spin IIC Column in a 
collection tube and centrifuged at 10,000×g for 30 seconds (all centrifugation steps in 
this protocol were at this speed and time, unless otherwise stated). The flow-through 
and the collection tube were discarded, and the column transferred into a new 
collection tube. 400 µL of RNA wash buffer was added to the column and centrifuged. 
For DNase treatment, 5 µL of DNase I (6 U/µL) and 75 µL of DNA digestion buffer 
were mixed in an RNase-free tube and added directly to the column matrix. 400 µL of 
Direct-zol RNA prewash solution was added to the column, centrifuged and the flow-
through discarded. This was followed by the addition of 700 µL of RNA wash buffer 
and centrifuged for 2 minutes to ensure complete removal of the wash buffer. The 
column was carefully transferred into an RNase-free tube. To elute highly concentrated 














6.4.11 RNA quantification and quality 
The RNA obtained was quantified using Nanodrop microvolume spectrophotometer 
and stored at -70oC. To determine the quality of RNA extracted, the samples were ran 
on the Agilent 2100 Bioanalyzer (Agilent Technology, Germany) at a concentration 
of 1 µg/ml. RNA integrity number (RIN) ranged between 8.7 and 9.9 while the 
28S/18S ratio also ranged from 1.1 to 1.4 (Table 6.4.1). The Electropherogram 
summary of one of the samples as obtained on the Agilent 2100 bioanalyzer is shown 
in Figure 6.4.2. The RNA samples were sent to the Edinburgh Genomics, University 
of Edinburgh, for RNA sequencing, where all samples passed internal control 
assessment for quality, quantity and concentration. 
 
Table 6.4.1: The mean RNA integrity number and 28S/18S ratios were similar 
in blood groups A, B and O donors. 
Blood Group RNA integrity number 
(mean ± SD) 
28S/18S ratio 
(mean ± SD) 
A 9.6 ± 0.20 1.3 ± 0.045 
B 9.6 ± 0.21 1.2 ± 0.055 





Figure 6.4.2: Electropherogram summary on 2100 expert Eukaryote Total RNA 
Pico for one sample (blood group A) showing the 18S and 28S. Overall results for 
one sample: RNA Area: 1,149.7, RNA Concentration: 3,190 pg/μl, rRNA Ratio [28s / 
18s]: 1.3, RNA Integrity Number (RIN): 7.5. 
6.4.12 RNA sequencing 
RNA sequencing involves the conversion of a population of RNA to a library of 
complementary DNA (cDNA) fragments with adaptors attached to one or both ends 
(Wang et al. 2009), in order to determine the primary sequence and relative abundance 
of each RNA molecule in a biological sample.  
The RNA sequencing was performed by the Edinburgh Genomics. Briefly, 5 μg of 
RNA for each sample was used to prepare cDNA libraries using a poly-A adaptor at 
the 3′ end. The libraries were sequenced using high throughput Illumina sequencing 
technology. Data from Edinburgh Genomics were downloaded as gzipped FASTQ 
files (with help from Dr. Al Ivens). The quality of the data was assessed using FastQC 
on each set of reads (i.e. 15 samples, 2 ends each) (Andrews 2010). A FastQC 
quantification of one of the samples is shown in Appendix D. Based on the output from 
FASTQC, the relevant primers were removed using Cutadapt v1.9.1 with parameters 
-O 12 -q 20 -m 25 -n 5 -e 0.1 (Martin 2011). The P. falciparum genome was obtained 
from 
ftp://ftp.sanger.ac.uk/pub/project/pathogens/Plasmodium/falciparum/3D7/3D7.latest




Chromosome, apicoplast and mitochondrial sequences were used in FASTA format to 
generate bowtie2 indices (Langmead and Salzberg 2012), (http://bowtie-
bio.sourceforge.net/bowtie2/index.shtml) for alignment purposes. Chromosomes were 
viewed in Artemis (http://www.sanger.ac.uk/science/tools/artemis), and gene sets for 
each chromosome exported as nucleotide and protein. A BED file, containing the map 
locations for all 5541 P. falciparum genes and non-coding RNA genes, was generated 
from the annotation on the exported sequences.  
Read alignment for each sample was performed using bowtie2 (parameters: -very-
sensitive -p 16 --no-unal) and the resulting output sorted and indexed in BAM format 
using samtools v1.3 (http://www.htslib.org/). Alignment statistics were excellent (all 
>93%). Bedtools (v2.23.0, http://bedtools.readthedocs.org/en/latest/) was used to 
extract read-count numbers from the alignment files. Count data were explored in R 
statistical package. Counts within each sample were normalised by scaling to the 
sample with the lowest number of counts (Dillies et al. 2013, Bullard et al. 2010). The 












Table 6.4.2: Read count per sample before and after normalisation. 
Donor ID  Before  After 
A1 35559665 33356268 
A2 34492897 33356228 
A3 40726176 33356251 
A4 36061260 33356208 
A5 37123349 33356234 
B1 33356241 33356241 
B2 34046672 33356294 
B3 38735410 33356289 
B4 39322804 33356247 
B5 38489232 33356246 
O1 41135080 33356236 
O2 40007266 33356288 
O3 41406092 33356247 
O4 37673569 33356248 
O5 39271874 33356218 







6.5.1 Parasite growth in erythrocytes of different ABO blood groups  
This study investigated the abilities of different blood group erythrocytes to support 
the growth of a single clone of 3D7 P. falciparum parasites. P. falciparum 3D7 strain 
was cultured in erythrocytes from three different blood groups (A, B, and O), using a 
common AB negative serum. The parasites were cultured for a period of 2-weeks in 
each of the blood group erythrocyte, thereby completing five growth cycles. 
Parasitaemia was monitored daily and calculated for each sample every 24 h as a 
percentage of infected erythrocytes per 1000 erythrocytes counted. After an initial 
steady growth, peak mean parasitaemia was observed on day six, following daily 
media changes (Group A: 8.2 ± 1.4, Group B: 8.6 ± 0.59, Group O: 8.8 ± 0.89) (Table 
6.5.1).The cultures were diluted 1 in 4 with complete media on day 6 resulting in 
decreased parasitaemia on the 7th day (Table 6.5.1 and Figure 6.5.1). Parasitaemia was 
monitored and media changed on days 7 and 8. On day 9 parasite growth reached that 
observed on day 6 and sorbitol treatment was used to obtain a cohort of synchronous 
parasites which can be seen as decreased parasitaemia 4 hours post-sorbitol treatment 
(Table 6.5.1 and Figure 6.5.1). Parasite cultures of all the blood group types were 
equally viable throughout the two-week period, as monitored by daily blood smears. 
The mean erythrocyte invasion (measured as percent parasitaemia) was similar in all 
blood types on each day and is summarized in Table 6.5.1. 
The cultures were diluted 1 in 4 again on day 10, followed by media changes on days 
11 and 12. Parasites at the trophozoite stage were harvested on day 13 and frozen at -




Table 6.5.1: Daily mean parasitaemia of 3D7 P. falciparum in different ABO blood groups. 
  Day of culture  
Blood 
group 





10 11 12 13 
A Mean 0.76 1.3 1.9 4.8 5.6 8.2 3 5.5 7.9 6.6 9.7 2.9 6.4 6.1 
 
SD 0.05 0.13 0.2 0.51 0.9 1.4 0.34 0.87 0.85 0.68 1.1 0.69 0.68 0.88 
B Mean 0.76 1.3 2 4.9 6 8.6 2.7 5.8 7.6 6.4 10 2.5 6 5.5 
 
SD 0.05 0.07 0.26 0.45 0.58 0.59 0.42 0.67 1.5 0.85 0.99 0.29 0.55 1.3 
O Mean 0.76 1.3 1.9 4.7 5.7 8.8 3.3 6 9 6.9 10 3 5.5 5.2 
 
SD 0.055 0.084 0.089 0.23 0.24 0.89 0.44 0.93 1.7 0.76 1.1 0.73 0.64 0.12 





Figure 6.5.1: Parasite growth in erythrocytes of different ABO blood groups. Parasitaemia was monitored daily by Giemsa-stained thin blood 
films and Hoesch staining for flow cytometry. Each circle represent a donor. Culture medium was changed on days 1-5, 7-8, 11-12; cultures were diluted 
1 in 4 on days 6 and 10; sorbitol synchronisation was performed on day 9 and parasitaemia assessed 4 hr post-sorbitol treatment; parasites at trophozoite 
stage were harvested on day 13. 
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6.5.2 Differential P. falciparum gene expression in different ABO blood 
groups 
Gene expression levels for all 5541 P. falciparum genes and 102 non-coding RNA 
genes (ncRNA) of all classes were initially assessed using principal component 
analysis (PCA). PCA is a standard technique for reducing multivariate data down to 
its main independent features by extracting components according to the amount of 
variation in the data set (Sokal and Rohlf 1995). It was used to determine if gene 
expression levels clustered according to blood group types. PCA analysis of the gene 
expression levels showed no clear pattern of clustering of individuals of the same 
blood group type (Figure 6.5.2). Sample- to sample Pearson correlations (Appendix E) 
for the individual samples were very similar, and may probably explain the non-
clustering of individuals of the same blood groups. 
 
Figure 6.5.2: Principal component analysis of parasite genes showed no pattern 
of blood group clustering. The numbers assigned to the blood group types (A, B and 




Analysis of the normalised log2 expression data for the top 100 most variable 
expression levels (independent of sample blood groups) showed that donor samples do 
partition, but not according to blood group. Although statistically significant loci were 
obtained, there were no loci significant at the 5% level after p-value correction for 
multiple testing, and fold-differences were generally small. These loci included genes 
associated with P. falciparum merozoite surface such as the MSP and rhoptry-
associated proteins; virulence genes such as rifin and P. falciparum erythrocyte 
membrane protein 1, and proteins of unknown functions but probably involved with 
exportation of cellular and host materials (Table 6.5.2 and shown as heat map on 
Figure 6.5.3). In Table 6.5.2, the first 20 of the 100 most variable genes are listed; the 
full list is found in Appendix G.  
Table 6.5.2: First 20 of the 100 most variable genes in decreasing order of 
variance. 
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RhopH3 high molecular weight 




PF3D7_1255000 RIF rifin 1.733 
Pf3D7_09_v3 
 
PF3D7_0917300 Conserved Plasmodium 


























PF3D7_0201000 RIF rifin 1.615 
Pf3D7_08_v3 
 
PF3D7_0832800 RIF rifin 1.615 
Pf3D7_02_v3 
 
PF3D7_0207600 SERA5 serine repeat antigen 5 1.612 
Pf3D7_14_v3 
 





PF3D7_0301200 FIKK3 serine/threonine protein 
kinase, FIKK family 
1.603 










Blood groups are shown as colours on the left hand side of the heat map. Data are 
partitioned by Euclidean distance, indicated by the dendrogram on the left. 
 
Although there appeared to be no blood-group partitioning of the data, group-wise 
comparisons were nevertheless performed (using linear modelling) between the three 
blood groups, treating each sample as a biological replicate (i.e. 5 replicates per group). 
Gene level counts were subsequently normalised across the entire sample set by quantile 
normalisation after conversion to log2 with expression levels initially assessed using heat 
maps for the most variable genes within each blood group. These are shown in Appendix 
F for each blood group type.  
6.5.3 Parasite gene expression levels between blood groups A and B 
donors 
Gene expression profile between blood group types were compared. Taking unadjusted p-
value of 0.05 as significant, there were 404 genes that were differentially expressed in 
blood group A relative to blood group B donors, 986 genes between blood group A relative 
to O donors, and 275 genes differentially expressed in blood group B relative to O donors. 
However, when these were adjusted for multiple testing using Benjamini and Hochberg 
method to control for ‘false’ discovery rate of all the genes analysed (5643 genes) (Reiner 
et al. 2003, Benjamini and Hochberg 1995), these significance were diminished. False 
discovery rate is defined as “the proportion of truly nondifferentially expressed genes that 
are declared differentially expressed” (Gusnanto et al. 2007), owing to the non-application 
of correction for multiple testing. 
Considering the top ten significant loci in each comparison (see Table 6.5.3), six genes 
were differentially upregulated and four genes downregulated in blood group A compared 
to blood group B donors, although multiple correction diminished any observed statistical 
significance. Genes that were differentially upregulated included four conserved 
Plasmodium proteins of unknown functions, and two non-coding RNA genes (ncRNA) 




downregulated in blood group A relative to blood group B donors included EPF4 exported 
protein family 4 (PF3D7_0114300), which alongside its other family members are known 
to encode proteins that are exported to the Maurer's clefts (Mbengue et al. 2013); CYP26 
peptidyl-prolyl cis-trans isomerase (PF3D7_1202400), that accelerates the protein folding 
and catalyses the cis-trans isomerization of proline imidic peptide bonds in oligopeptides 
(Marin-Menendez et al. 2012); TRAPPC5 trafficking protein particle complex subunit 5 
(PF3D7_1437800), that has been suggested to play a role in vesicular transport from 
endoplasmic reticulum to Golgi (Gardner et al. 2002); and a conserved Plasmodium 
protein of unknown function (PF3D7_0312000) (Table 6.5.3). 
Normalised data provide the input for statistical hypothesis testing, in which loci that are 
statistically significantly different between sample groups, (i.e. differences that are 
unlikely to be due to chance) can be identified (Bullard et al. 2010). The degree of 
difference, i.e. the fold-change is also of importance. In the outputs given in the tables 
below, the fold-changes (logFC) are given as log2 values, with a positive logFC 
representing upregulation, and a negative logFC indicating downregulation. For each 
comparison (e.g. A-B, which is the same as 'blood group A relative to 'blood group B'), 
the first group (A) is the numerator, while the second group (B) is the denominator. Thus, 











Table 6.5.3: Conserved and ncRNA genes are differentially expressed in blood 
group A relative to blood group B donors. 








PF3D7_1114600 Conserved Plasmodium 
protein, unknown function 
 
0.594 7.90 16 0.091 




protein, unknown function 
0.652 7.14 2.3 0.367 
PF3D7_0114300 EPF4 exported protein 
family 4, pseudogene 
-1.004 5.66 2.6 0.367 
PF3D7_1202400 CYP26 peptidyl-prolyl cis-
trans isomerase 




protein, unknown function 




protein particle complex 
subunit 5, putative 




protein, unknown function 




protein, unknown function 
0.422 8.14 7.6 0.392 
PF3D7_1148200 ncRNA 0.922 10.43 8.0 0.392 
LogFC: Log base 2 fold change of the probeset; a positive value indicates upregulation, 
while a negative value indicates down regulation in group A relative to B; Av. Expr: 






6.5.4 Parasite gene expression levels between blood groups A and O 
donors 
Similar to the comparison between blood group A and B above, of the top ten significant 
loci, six genes were differentially upregulated in blood group A donors relative to blood 
group O with four genes downregulated in A relative to O donors (Table 6.5.4). Of the 
upregulated genes two are genes that code for conserved P. falciparum membrane protein 
or protein of unknown functions (PF3D7_1135300 and PF3D7_1217400) (Gardner et al. 
2002), two are enzymes involved in the biosynthesis of haem: PBGS delta-aminolevulinic 
acid dehydratase (PF3D7_1440300), (Dhanasekaran et al. 2004, Sato et al. 2004) and SPP 
stromal-processing peptidase (PF3D7_1440200) (van Dooren et al. 2002, Hall et al. 
2002). The others are Vacuolar transporter chaperone (PF3D7_0622300), which plays a 
role in vacuolar membrane fusion (Muller et al. 2003, Muller et al. 2002); and the ncRNA 
gene (PF3D7_1370800) (Table 6.5.4). The ncRNA gene PF3D7_1370800 (previously 
known as PF13TR009:ncRNA) is the only gene in this study that had a pre-adjusted 
significant locus and was relatively upregulated in blood group A individuals compared 
to both blood groups B (P=0.000174, adjusted P=0.367), and O (P=0.000135, adjusted 
P=0.077) (see Table 6.53 on the previous page, and Table 6.5.4 on the next page). Not 
much is known about this gene and its role in Plasmodium invasion or pathogenesis, 
except that it is found on chromosome 13 and downstream of the membrane-associated 
histidine-rich protein 1 (MAHRP1) and in between tRNA and rRNA genes. The MAHRP1 
gene was however, downregulated in blood group A donors relative to group B donors, 
but marginally upregulated in blood groups A and B donors relative to blood group O 
donors.  
The differentially expressed genes that were downregulated in blood group A donors 
relative to blood group O donors included chorismate synthase (PF3D7_0623000), which 
plays a role in the biosynthesis of aromatic fatty acids, chorismate and shikimate (Tapas 
et al. 2011, Fitzpatrick et al. 2001); CS domain protein (PF3D7_0813200), involved in 




involved with the biosynthesis of iron-sulfur (Paddock et al. 2007); as well as a conserved 
Plasmodium protein of unknown function (PF3D7_1303600) (Table 6.5.4). 
Table 6.5.4: Parasite gene expression in blood group A relative to blood group O 
donors. 




















0.628 10.92 29 0.074 





0.42 9.75 6.2 0.074 
 
PF3D7_0813200 CS domain protein, 
putative 












protein, unknown function 
-0.68 7.52 1.1 0.077 




protein, unknown function 





0.468 11.41 1.7 0.077 
LogFC: Log base 2 fold change of the probeset; a positive value indicates upregulation, while a negative 
value indicates down regulation in group A relative to O; Av. Expr: Average log2 signal intensity of the 




6.5.5 Parasite gene expression levels between blood groups B and O  
Of the ten most significant gene loci that were differentially expressed (before adjusting 
for multiple gene comparison), seven and three were respectfully upregulated and 
downregulated in blood group B individuals relative to group O donors (Table 6.5.5). Of 
the upregulated genes, one was a conserved protein of unknown function 
(PF3D7_1366100), with two being exported proteins of unknown functions 
(PF3D7_0115100 and PF3D7_1038700). The rest included Stevo, a pseudogene 
(PF3D7_0114600) that encodes the sub-telomeric variable open reading frame (stevo), 
which is clonally variant, and expressed on both merozoites and at the surface of infected 
erythrocytes, and involved in parasite immune evasion of the host (Niang et al. 2009, 
Blythe et al. 2008, Blythe et al. 2004); Dynein light chain type 2, Vacuolar transporter 
chaperone, which was also upregulated in blood group A donors relative to group O 
donors; and NOT5 CCR4-NOT transcription complex subunit 5 (PF3D7_1006100), 
which is involved in regulation of transcription (Shock et al. 2007).  
The genes downregulated in blood group B donors relative to group O individuals 
included the SR1 serpentine receptor 1 that is involved in cell signalling (Madeira et al. 
2008, Gardner et al. 2002); Haloacid dehalogenase-like hydrolase, (PF3D7_1118400), 








Table 6.5.5: Parasite gene expression in blood group B relative to blood group O 
donors. 










Stevor, pseudogene 1.130 3.99 1.7 0.732 
PF3D7_1131100 
 
SR1 serpentine receptor, 
putative 






0.542 7.10 1.9 0.732 
PF3D7_1114000 
 
Dynein light chain type 2, 
putative 









like hydrolase, putative 




protein, unknown function 










protein, unknown function 





subunit 5, putative 
0.392 9.74 5.5 0.732 
LogFC: Log base 2 fold change of the probeset; a positive value indicates upregulation, 
while a negative value indicates down regulation in group A relative to B; Av. Expr: 






6.5.6 Expression levels of P. falciparum MSP antigens 
In Chapters 3 and 4 of this thesis I explored extensively the immunoepidemiology of 
Plasmodium using merozoite surface proteins 1 and 2 (MSP-1 and MSP-2). In view of 
that I wanted to find out whether these proteins are differentially expressed in relationship 
to parasite growth in the three donor blood groups. The data show that both MSP1 and 
MSP2 genes are very marginally up-regulated in blood group A individuals relative to 
blood group B (Table 6.5.6). 
Table 6.5.6: Log2 fold change in selected P. falciparum genes of interest. 











PF3D7_0930300 MSP-1  0.214 -0.774 -0.988 
Pf3D7_02_v3 PF3D7_0206800 MSP-2  0.128 -0.742 -0.87 
MSP: merozoite surface protein. 
 
6.5.7 Barcoding of expression changes 
I generated a file that contained a barcode representation of the log2 fold changes in the 
three blood group comparisons. The barcode represents only the direction of fold change, 
so no threshold was applied. In this case “Upregulation" means any log2 fold change 
greater than 0, and is represented as a "1", while "Down regulation" means any log2 fold 
change that is zero or negative, and is represented as a "0". As an example, a barcode of 




of 101 means upregulation in comparison 1 (blood group A vs B) and 3 (blood group B 
vs O), but down regulated in comparison 2 (blood group A vs O).  
Although by permutation there are 8 possible barcodes that could be generated, only 6 
were found in the analysis of this dataset, and are shown in Table 6.5.7 with their 
corresponding numbers of genes.  
Table 6.5.7: Barcode representation of the log2 fold changes in the three blood 
group comparison. 
Barcode 000 001 011 100 110 111 
Number of genes 1182 767 935 755 516 1488 
Note: Barcode 000 means the gene is down-regulated in all three blood groups 
comparison; barcode 101 means the gene is upregulation in blood group A relative to B 
and blood group B relative to O, but down regulated in comparison in blood group A 












The intra-erythrocytic niche provides a relatively stable environment for the survival of 
P. falciparum in the human host. In spite of this the parasite faces other environmental 
challenges in the human host which it must quickly adapt to in order to survive and 
establish its niche and cause disease. Some of the challenges encountered by the parasite 
when it infects different human hosts are immune and drug pressures, host genetics, and 
the presence of competing parasites (Rovira-Graells et al. 2012, Mackinnon and Marsh 
2010). The surface structure of the erythrocyte and the different antigens present may also 
present challenges that the Plasmodium parasites must overcome to establish itself. 
Among these surface antigens, the ABO blood group antigens are of importance in malaria 
pathogenesis. In this chapter I have determined if there are any changes in parasite gene 
expression when P. falciparum infects erythrocytes of different ABO blood group 
individuals. 
Through a mechanism of reduced rosetting (Rowe et al. 2007) and increased phagocytosis 
of infected erythrocytes (Wolofsky et al. 2012) individuals of blood group O have been 
reported to have a survival advantage with respect to life-threatening malaria compared to 
non-group O individuals. It stands to reason that parasitaemia would be expected to be 
lower in group O erythrocytes compared with erythrocytes of blood group A and B. In 
this study the mean daily parasitaemia was similar across all blood groups, and although 
there are differences in the surface structure and glycosylation of the different ABO blood 
groups, this did not influence the invasion and maturation of the P. falciparum parasites 
in the erythrocytes of the different donor blood groups. This is consistent with what has 
been shown in P. falciparum ITG, 3D7 and E8B clones, in which no statistical significant 
differences were observed in parasite invasion during two growth cycles in blood group 
A, B and O erythrocytes (Wolofsky et al. 2012). However, in an in vitro study using four 
clones of P. falciparum parasites (3D7, 7G8, Dd2 and RKL9), higher parasitaemia were 
observed in all clones in the erythrocytes of blood group O compared to group A and B 




‘resistant’ towards parasite entry and that the amount of H antigen, which is the blood 
group precursor, being abundant in group O than in group A and B might account for 
differences in parasite invasion of different erythrocytes (Pathak et al. 2016). In the 
current study, all the cultures were initiated at the same parasitaemia and the culture 
conditions and treatment was uniformly maintained throughout the experiment, with the 
only variable factor being the different erythrocytes of the different blood groups used. 
Although significant differential gene expression were seen with respect to the different 
blood group types, this significance diminished after correction for multiple comparisons, 
possibly due to the sample size of five donors in each blood group. The ncRNA 
PF3D7_1370800 was significantly expressed (prior to multiple comparison) in blood 
group A erythrocytes relative to both blood groups B and O. Apart from the chromosome 
position (13) and the location of this gene, not much is known about it. However, the 
MAHRP1 gene where PF3D7_1370800 gene is located downstream is a transmembrane 
protein present throughout the erythrocyte life cycle and exported beyond the parasite's 
surface into parasite-derived structures known as Maurer's cleft (Spycher et al. 2006, 
Spycher et al. 2003). It has been proposed that this gene is essential for trafficking of P. 
falciparum erythrocyte membrane protein 1 to the surface of P. falciparum-infected red 
cells and provides stability to the Maurer's clefts (Spycher et al. 2008). While 
PF3D7_1370800 was upregulated in blood group A donors relative to both groups B and 
O donors, the MAHRP1 gene was marginally downregulated and upregulated in blood 
group A relative to B and O donors respectively. A possible suppression role of 
PF3D7_1370800 on MAHRP1 has yet to be determined. The marginal up and down 
regulations seen in this study owing to the smaller sample sizes and the diminishing 
significance after multiple gene comparison is however, not enough to make a tentative 
conclusion. 
Although this experiment produced a negative result an alternative approach could have 
been to perform this experiment at different time points to identify significant changes, if 




been shown that rosette-forming Plasmodium parasites with a preference for blood group 
A and those with a preference for blood group B are capable of retaining their blood group 
preferences even after being cultivated for more than 100 cycles in blood group O 
erythrocytes (Barragan et al. 2000). This may suggest that P. falciparum parasites could 
have been maintained in the erythrocytes for a longer period of time. While my approach 
was to look at parasite gene expression changes in the host, an alternative approach would 
have been to investigate the possible host response on parasite in peripheral blood 
mononuclear cells. 
In P. falciparum approximately 5,541 protein-coding genes are encoded in the 24 
megabase genome, in addition to about 101 clusters of non-(protein)-coding RNA 
(ncRNAs) genes (Nagano and Fraser 2009). The ncRNAs are RNAs that are transcribed 
from DNA but are not translated into proteins. They are broadly divided into small (<200 
nucleotides) and long ncRNAs (>200 nucleotides), based on the number of nucleotides 
(Bayer-Santos et al. 2017, Mercer et al. 2009), and play roles in the regulation of gene 
expression, RNA processing, and translation as well as protecting an organism’s genome 
from foreign nucleic acids (Cech and Steitz 2014). Protozoan parasites of the 
apicomplexan group such as Plasmodium, Toxoplasma, Leishmania, and Trypanosoma 
are capable of reorganising host cell functions to allow their survival and replication 
(Plattner and Soldati-Favre 2008), including transferring their non-coding RNA molecules 
to the host cells to modulate their functions, via secreted extracellular vesicles (Bayer-
Santos et al. 2017). The evasion of host immunity by P. falciparum involves a mechanism 
of antigenic variation largely mediated by a multifamily virulence var genes that encode 
variant surface antigens, P. falciparum erythrocyte membrane protein 1 (Baruch et al. 
1995, Smith et al. 1995a). The chromatin surrounding these var genes have been shown 
to generate long sense and antisense ncRNAs that associate with it (Epp et al. 2009). The 
long antisense ncRNAs initiating from the var introns have been associated with the active 
var gene, and are capable of triggering the activation of a silent var gene in trans (Amit-
Avraham et al. 2015), suggesting possible regulatory roles of ncRNA in antigenic 




protozoan parasites, infecting approximately one-third of the world’s population. A non-
coding RNA, known as Tg-ncRNA-1, plays a major role in cellular differentiation during 
the parasite’s asexual replication in the human host from the rapidly growing tachyzoites 
to the latent bradyzoite, being upregulated over twenty times during this process (Patil et 
al. 2012, Matrajt 2010). A role for the PF3D7_1370800 gene and why it is differentially 
expressed in blood group A erythrocytes relative to blood groups B and O needs further 
investigation.  
In this study I observed marginal upregulation of MSP-1 and MSP-2 genes in blood group 
A donors relative to blood groups B donors. Merozoite surface proteins play key roles in 
merozoite invasion of red blood cells (Das et al. 2015). Erythrocyte invasion of P. 
falciparum is a highly complex multi-step procedure that involves interaction between 
parasite ligands on the merozoite surfaces and receptors on the erythrocyte surface (Gaur 
et al. 2004). Immediately after schizont rupture, merozoites must find and invade a host 
erythrocyte. Blood group A phenotype has two subclasses, A1 and A2, of which the A1 
account for up to 80% (Dean 2005). Individuals of the A1 subclass have higher number of 
oligosaccharide residues present on the surface of their red cell that enhances recognition 
and attachment of merozoite to their erythrocyte surface (Chung et al. 2005). This may 
enhance higher erythrocyte re-invasion rates by merozoites in blood group A1 individuals 
(Chung et al. 2005). Although the subtypes of the blood group A donors were not 
confirmed in my study, it might be of interest to know whether the marginal upregulation 
of MSP-1 and MSP-2 genes observed in blood group A donors is related to an individual’s 
blood group A subclass. 
The results of the gene expression work in this chapter might have been influenced by 
some technical limitations and factors that were both within and beyond my ability to 
control. Variables in the study design that were within my ability to control, and 
implemented, included using the same AB serum and the same source of 3D7 parasite 
strain for the cultures, and performing the experiment on all the donors simultaneously to 




in different donor erythrocyte at different times. It is however clear that the sample size 
of five donors from each blood group type was probably inadequate to generate enough 
statistical power for analysis of the data, considering the need to account for corrections 
for multiple comparisons, which diminished the statistical significance of expression 
levels observed. It has been suggested that in RNA sequence experiment, 20-40% of 
significantly differential genes can be identified when three biological replicates are used, 
a proportion which increases to more than 85% when the replicates are increased to 20 
(Schurch et al. 2016). Working on numbers more than the fifteen donors would certainly 
have been beyond my ability and would probably have needed the involvement of many 
hands, and over many days of parasite culture. From hindsight, perhaps increasing the 
number of donors in each blood group category would have led to a more robust 
significant differentiation of gene expression (Liu et al. 2014, Auer and Doerge 2010).  
Although the design of the experiment was to harvest parasites at the mid-trophozoite 
stage, there were other asexual stages in the harvested culture, in spite of sorbitol 
synchronisation a few days prior to the harvest. This lack of synchronicity at the harvest 
stage might have had an effect on the RNA sequencing. Differences in parasite gene 
expression between different blood groups might be very subtle, and thus signal to 
background reactivity ratio obtained in this study may be very low and thereby obscure 
such small changes in gene expression. In in vitro studies, 3D7 parasites normally grow 
at between two- and six fold per cycle; however, this growth rate was not achieved in my 
experiment, possibly due to some culture conditions not being optimal. Parasite cultures 
are usually incubated in a mixture of 1% O2, 3% CO2 and 96% N gas (BOC Gases) (Carter 
et al. 1993). This step was not included in my protocol and could have accounted for the 
lower parasite growth rates obtained. Expanding parasite cultures to large scale volumes 
needed for sufficient RNA meant that the demand by parasites for glucose for metabolism 
was equally higher. 3D7 P. falciparum parasites use the glycolytic pathway to generate 
energy. From hindsight, this would probably have required more than the one daily 
medium change I followed, to ensure sufficient amount of energy source for improved 




Service for parasite cultures in my co-supervisor’s laboratory usually have the white blood 
cells removed by passing the blood through a leucodepletion filter attached to the blood 
pack. My donors had their white blood cells removed manually by centrifugation and 
removing as much of the buffy coat as possible by aspiration. By this method I could not 
guarantee that all white blood cells were depleted and their effect on parasite growth and 
RNA sequencing could not be ruled out.  
An alternative I could have chosen was to have performed this work on donors of one 
blood group at a time, completed the culture cycles, harvested parasites and processed for 
RNA extraction. Although this would have reduced the volume of work, it would have 
also introduced other variabilities such as different media preparations (although prepared 
using the same protocol, variations between solutions prepared weeks apart could not be 
ruled out) and the possible variability in incubation conditions. In spite of the above 
limitations, the study provides preliminary data on this ncRNA (PF3D7_1370800) gene 
and how it is differentially expressed in blood group A individuals relative to blood groups 
B and O individuals, for which further research might be needed. 
6.7 Conclusions 
In this chapter I sought to grow a single clone of 3D7 P. falciparum parasites in the 
erythrocytes of three different blood group donors. I observed that parasitaemia, which is 
a measure of parasite growth and viability, was similar in all blood groups. Although some 
Plasmodium genes appear to be differentially expressed in one blood group relative to the 
other, these differences were not very significant after correction for multiple gene 
comparisons. A gene that was prominently expressed in blood group A erythrocytes 
relative to group B and O donors is a non-coding RNA gene, ncRNA PF3D7_1370800, 
for which much is not known about its function, except its location, requiring further 
research to better understand its role, if any, in parasite growth, and pathogenesis of 
disease in different blood group erythrocytes. In the next chapter I discuss the major 




Chapter 7. General discussions and 
conclusions 
7.1 Introduction  
In this thesis I focussed on malaria, an important parasitic disease that affects over half 
the world’s population, most notably children under the age of five years from Sub-
Saharan Africa (WHO 2015, WHO 2013). Two key aspects of my thesis were the 
epidemiology of mixed-Plasmodium species infections and gene expression changes 
when a single clone of parasite infects erythrocytes of different ABO blood groups. 
Diagnosis of malaria in endemic clinical settings is largely by microscopy, which usually 
reports the presence of Plasmodium parasites, but fails to report the species type or the 
presence of mixed-species infections (Obare et al. 2013). Currently available rapid 
diagnostic tools do not differentiate between all four major human Plasmodium species in 
Africa (Graves et al. 2015, Wilson 2012), while molecular techniques such as PCR are 
confined mainly to research environments (Daniels et al. 2017). Although the WHO 
recommends laboratory confirmation of malaria before treatment (WHO 2015, WHO 
2014), most fevers in Sub-Saharan Africa are treated with antimalarial drugs (Singh and 
Sharma 2014, Kyabayinze et al. 2010) thereby possibly overestimating the burden of 
malaria (Bhatt et al. 2015). This may lead to over- or misuse of the limited range of anti-
malarial drugs available, with the potential development of drug-resistant Plasmodium 
strains (Manguin et al. 2017, Chandler et al. 2008).  
A phenotype associated with susceptibility or resistance to the development of severe 
malaria are the ABO blood group antigens (Cooling 2015, Cserti and Dzik 2007, Rowe et 
al. 2007, Reid and Bird 1990, Gupta and Chowdhuri 1980). The Plasmodium parasite, 
being an obligate intracellular parasite spends its entire blood-stage life-cycle in the 




infecting new red blood cells (Bannister and Mitchell 2003). However, changes in parasite 
gene expression when a single clone of P. falciparum parasite infects different ABO blood 
group erythrocytes have not been investigated.  
In this thesis I have determined the seroepidemiology of the different Plasmodium 
parasites in two African countries, Zimbabwe and Sudan (Chapters 3 and 4). I used 
recombinant merozoite surface antigens derived from merozoite surface protein 1, (also 
known as MSP-119) from all four major Plasmodium species, in an ELISA assay, to 
determine IgG antibody responses to these antigens in the two study populations. 
Furthermore, using some observable clinical manifestations (fever, parasitaemia) and 
treatment data from a well-characterised population from Daraweesh, in eastern Sudan, 
with longitudinal sampling spanning a period of eleven years (1990-2000), I compared 
these observable clinical manifestations and treatment requirements in individuals with 
documented clinical malaria who had antibody response to either P. falciparum alone or 
mixed-species MSP-119 antigens (Chapter 4). Both the malaria parasitology and the 
antibody response data of the people of Daraweesh have been used to determine the spatial 
and temporal dynamics of malaria epidemiology in this village (Chapter 6). Finally, I 
determined the gene expression changes when a single clone of P. falciparum parasites 
infect erythrocytes of different blood groups (Chapter 6). This was done by culturing 
Plasmodium parasites in three erythrocytes from A, B and O blood group donors, 
harvesting total RNA and sequencing these to characterise gene expression changes. 
In this present chapter, the major findings with regard to the research aims outlined 
previously in Chapter 1, (Section 1.10) are summarized. The main conclusions based on 
the findings of the studies set forth in the preceding chapters of this thesis are outlined. I 
will conclude the chapter with key suggestions for the diagnosis, disease treatment and 
clinical monitoring of malaria that may aid the design and monitoring of malaria control 





7.2 Malaria diagnosis: merozoite surface proteins as 
potential diagnostic tool 
In accordance with the WHO guidelines, laboratory confirmation of suspected malaria 
cases or patients presenting with symptoms of malaria is a pre-requisite for malaria 
treatment and the development of intervention for the control of the disease (WHO 2015, 
WHO 2014). Accurate detection of the species of Plasmodium causing malaria is 
important to ensure timely and targeted treatment of the infecting parasite. The species of 
Plasmodium, if not confirmed and treated accordingly, has the potential consequences of 
drug treatment failure (Smith et al. 2011) and long term morbidity (Savargaonkar et al. 
2014, Muller-Stover et al. 2008, Vinetz et al. 1998). Such untreated or partially cleared 
parasites can serve as potential source of parasite reservoirs in communities for onward 
transmission, and to impact upon malaria morbidity and mortality (Chang 2016, Kitchen 
et al. 2005). The confirmation of the presence or absence of malaria parasites in patients 
presenting with or suspected of having the disease is traditionally by microscopic 
examination of Giemsa-stained thick blood films for asexual parasites stages (Fleischer 
2004, Giemsa 1904). Confirmation of the species of Plasmodium is usually by examining 
thin blood films for characteristic morphological features of the parasite species (Obare et 
al. 2013, Barber et al. 2013) (outlined previously in Section 1.1.1, Table 1.3.1). Although 
thick blood films are used routinely to detect Plasmodium parasites, thin blood films are 
seldom prepared and so the species of Plasmodium is seldom reported (Obare et al. 2013). 
In cases where thin blood films are examined, there are reports of misclassification of 
species and undiagnosed mixed-species infections even by expert microscopists (Obare et 
al. 2013, McKenzie et al. 2006).  
Available rapid diagnostic tools also fail to detect P. malaria and P. ovale infections 
accurately, with most tests based on antigens from P. falciparum and P. vivax (Graves et 
al. 2015, Wilson 2012). Molecular techniques for malaria parasite speciation are confined 




present in all four Plasmodium species that is sensitive and species-specific and capable 
of detecting the specific Plasmodium species causing malaria.  
In Chapters 3 and 4, I focussed on using MSP-119 antigens from all four major human 
Plasmodium species to determine the specificity of human IgG antibodies to these 
antigens. Using these antigens I determined the seroepidemiology of the different 
Plasmodium species in Zimbabwean and Sudanese populations. Several epidemiological 
studies use the MSP-119 antigens of P. falciparum and/or P. vivax to determine exposure 
patterns of individuals to these antigens (Wang et al. 2016, Osier et al. 2008, Braga et al. 
2002, Cavanagh et al. 1998). However, since the isolation and characterisation of the 
MSP-119 genes for P. malariae and P. ovale (Birkenmeyer et al. 2010), there has been 
only one study that had used all four antigens in limited experimental human primate and 
human malaria studies (Muerhoff et al. 2010). The findings in this thesis show that MSP-
119 antigens are species-specific and that human IgG antibodies directed against these 
antigens do not cross-react with heterologous antigens (Amanfo et al. 2016).  
This finding is important as it presents MSP-119 antigens of the four Plasmodium species 
as the basis of a novel and sensitive assay for development into a diagnostic tool for 
species-specific detection of Plasmodium. To date, only one manufacturer incorporates 
MSP-119 antigens of P. falciparum and P. vivax in their malaria EIA kit for malaria 
screening of blood donors and blood products, which are extensively used in blood 
transfusion services across major western countries (Seed et al. 2005a, Kitchen et al. 
2004). Diagnostic tools currently in use supplement the efforts of the WHO in its quest to 
have all suspected malaria cases confirmed by laboratory test before treatment. Although 
the experimental design in this thesis was based on ELISA that usually takes three days 
to complete, the potential development of MSP-119 antigens from all four Plasmodium 
species into a single assay format could complement microscopy in helping detect and 
report the types of Plasmodium species. Additionally, in peripheral health service areas 




al. 2011, Harvey et al. 2008), these antigens, formulated as RDTs, could be useful in 
reporting accurately the species of Plasmodium causing malaria. 
The implication of using these antigens is that we will be able to assess the true prevalence 
and magnitude of the disease burden caused by the non-falciparum species in endemic 
populations. This will lead to targeted treatment with appropriate drugs, and enable 
governments and policy makers to develop effective control programmes that targets all 
Plasmodium species and not as is the current case in which control programmes are 
targeted only at P. falciparum elimination (Abeyasinghe et al. 2012, Oliveira-Ferreira et 
al. 2010).  
The use of MSP-119 antigens in this thesis has highlighted two important things about 
malaria epidemiology in the two African study sites. Firstly, the data in Chapters 3 and 4 
have confirmed reports of previous studies indicating P. falciparum as being the 
predominant Plasmodium species in both Zimbabwe (Hay et al. 2009, Mabaso et al. 2006, 
Taylor and Mutambu 1986) and Sudan (Hamad et al. 2000, Theander 1998), and probably 
by extension the whole of Sub-Saharan Africa (Gemperli et al. 2006).  
Secondly, my findings have confirmed that the frequency of mixed-species infections has 
been underestimated in African malaria epidemiology. In Zimbabwe I found mixed-
species infections to account for almost half the cases of individuals with antibody 
responses to parasite antigens, while in the Sudanese cohort mixed-species was seen in 
more than a third of all individuals who experienced a first time clinical malaria episode.  
What is of interest is that with the exception of a few individuals in both study countries, 
all mixed-species infections detected by antibody response to MSP-119 antigens were in 
association with P. falciparum responses. What this may mean is that in the context of 
mixed-infections involving P. falciparum and one or more of the non-falciparum species, 
there is the tendency of higher parasitaemia associated with P. falciparum infections to 
obscure the presence of the other malaria parasite species (Collins and Jeffery 2007, 




falciparum infections using microscopy (Obare et al. 2013). In this context, the majority 
of all infections are likely to be attributed to only P. falciparum. It has been shown that 
even expert microscopists are likely to miss mixed-species infections or misclassify them 
as P. falciparum-only infections (Obare et al. 2013, McKenzie et al. 2006). PCR data 
emerging from the continent of Africa support my findings that mixed-species infections 
are more frequent than previously reported (Fru-Cho et al. 2014, Dinko et al. 2013).  
The consequence of this finding is that malaria morbidity and mortality will continuously 
be attributed to P. falciparum without a clear knowledge of the contributions of the non-
falciparum species to the overall malaria burden (Mendis et al. 2001). Moreover, 
intervention programmes may only focus on P. falciparum and may fail to achieve 
maximum effectiveness in terms of prevention and control of disease, as these non-
falciparum species may be potential sources of the next pandemic, as seen in areas where 
controls programmes against P. falciparum have seen some success (Oliveira-Ferreira et 
al. 2010). 
In this thesis, I was able to demonstrate the importance of using a sensitive diagnostic tool 
based on antigens present in all four major human Plasmodium species to improve 
diagnostic accuracy of mixed-species infections as this has implications on the required 
treatment regimens for people with mixed-infections (Vinetz et al. 1998). Accurate 
diagnosis of the type of Plasmodium species infection provides a foundation for treatment 
and management of malaria.  
7.3 Mixed-Plasmodium infections and associated drug 
treatment failure  
Having established the sensitivity and specificity of MSP-119 antigens as a diagnostic tool 
(Chapter 3) I assessed if heterogeneity in clinical presentation and response to drug 
treatment was related to exposure to single vs. mixed-Plasmodium species. The major 
finding in Chapter 4 of this thesis was the significant association of mixed-Plasmodium 




the clinical implications of mixed-infection dynamics remain controversial, this study 
provides one possible reason why initial therapy may fail to eradicate malaria parasites 
and/or alleviate clinical symptoms. Some studies have reported that the faster multiplying 
species in a co-infection may suppress the slower species (Mason and McKenzie 1999, 
Mason et al. 1999), perhaps in a density-dependent manner (Bruce and Day 2002). It has 
been reported that mixed-species infection can be a likely cause of treatment failure 
(Smith et al. 2011).  
Drug resistant parasites are a major threat to disease control and eradication. Although 
chloroquine was the first line drug of use in Daraweesh at the time of the study, the lessons 
learnt from the results obtained could be applicable in current epidemiological settings 
where ACTs have become the first line treatment for uncomplicated malaria. For example, 
artemisinin derivatives in ACTs have been shown to be effective only against intra-
erythrocytic parasites, but are unable to kill parasites in the hepatocytes (Chang 2016). 
This is advantageous to dormant liver stage hypnozoites of P. vivax and P. ovale that have 
the potential to recrudesce, and if undetected, or parasitaemia becomes sub-clinical 
without full cure may have important clinical and therapeutic implications (Kitchen et al. 
2005, Vinetz et al. 1998). Although current ACTs have largely been reported to be highly 
effective against Plasmodium parasites, there are reports of the emergence of resistant 
strains to these drugs (Duffy and Sibley 2005). It is therefore important to extend such 
study of mixed-species Plasmodium infections into areas where resistances to ACTs are 
being reported to understand the contribution, if any, of the non-falciparum species to 
these developments. 
The data on parasitaemia (Chapter 4) in the Daraweesh population supports the 
importance of close monitoring of communities where malaria is endemic. Higher 
proportions of individuals with malaria caused by both single- and mixed-Plasmodium 
species were diagnosed with low parasitaemia. Over the eleven year study period there 
were no malaria related deaths as no individual developed severe malaria with its 




treatment of malaria, and adequate follow ups or management of disease can contribute 
significantly to reducing malaria related morbidities in malaria endemic communities.  
7.4 Household dynamics of malaria in a Daraweesh 
Having established in Chapters 3 and 4 that mixed-species infections are higher than 
previously reported and that these are associated with drug treatment failure, I assessed 
the fine details of malaria epidemiology, often described as mircroepidemiology 
(Bannister-Tyrrell et al. 2017) to understand heterogeneity associated with the risk of 
having disease within a single village. The epidemiology of malaria in Daraweesh showed 
a rain-dependent pattern (Creasey et al. 2004), similar to what is observed in other African 
settings (Bannister-Tyrrell et al. 2017, Seyoum et al. 2017, Alemu et al. 2013). The data 
in Chapter 5 showed that dry seasons temporarily break the transmission of parasites, 
resulting in fewer individuals being clinically infected. The onset of rainfall with its 
correlated increase in the number of clinical episodes is important information for greater 
planning and implementation of control programmes prior to rainy seasons. It is evident 
that closer monitoring, prompt diagnosis and treatment alone offered by the health team 
(Creasey et al. 2004) did not in any way reduce the burden of the disease or eradicate 
malaria in the village. It has been suggested that although mass drug administration 
(MDA) has the potential to reduce Plasmodium parasite transmission, it needs to be 
complemented with other vector control programmes (Brady et al. 2017). This calls for 
other intervention strategies to be implemented even in such a small village setting for 
effective elimination of disease. I also demonstrated that malaria parasite transmission in 
Daraweesh was focal. Two space-time clusters of significantly increased malaria risk were 
identified (1993-1999, and 1998-1999) with marked variation between households, but 
little or no variation in the species of Plasmodium over time. Why the households in the 
southwest and central part of the village experienced the heaviest burden of malaria over 
a longer period may be explained by local factors inherent to those households (Parizo et 
al. 2016). It is possible that the proximity of the village’s deep well to these households 




ecologic habitats for mosquito breeding, relative to other parts of the village. Proximity to 
local water bodies or wells has been shown to influence malaria incidence and clustering 
in rural areas (Peterson et al. 2009). The households identified in cluster 1 had larger 
family sizes and this could be a contributing factor in the increased number of malaria 
cases recorded. This finding is consistent with what has been found elsewhere in which 
households with larger family size experience more malaria (Hulden et al. 2014, Peterson 
et al. 2009, Hulden and Hulden 2009), while a decrease in household size to four 
individuals has been associated with reduced malaria incidence (Hulden et al. 2014, 
Hulden and Hulden 2009). 
The data in this thesis suggests that even in a small geographic area malaria transmission 
shows heterogeneity, and that such data can provide useful information to guide malaria 
control efforts (Seyoum et al. 2017). Identification of a subset of a population who 
experience the heaviest burden of malaria at every point in time can provide useful 
information needed for implementing control programmes that can block the spread of 
malaria across an entire community. My present findings provide new information that 
would be important in the planning and implementation of optimal control strategies 
targeting malaria in smaller geographical settings. In addition, the possible utility of 
antibody screening based on recombinant Plasmodium MSP-119 antigens will help to 
identify carriers of parasites in the later stages of malaria for drug treatment to eradicate 
asymptomatic infections. 
7.5 Gene expression in different ABO blood groups 
The different antigens expressed on the surface of erythrocytes might be a barrier to the 
invasion of the intra-erythrocytic merozoite. In chapter 6 of this thesis I explored the 
relationship between parasite growths in different ABO blood group erythrocytes and 
determined if parasite gene expression differed in a genetically identical parasite clone 
(3D7) grown in either A, B or O type erythrocytes. I observed that 3D7 P. falciparum 
parasite invasion of erythrocytes and their maturation as determined by parasitaemia count 




developing severe malaria compared to non-group O individuals (Rowe et al. 2007, 
Barragan et al. 2000), it could be assumed that parasite invasion and maturation may differ 
between blood group O and the non-group O individuals. However, the data presented in 
this thesis showed no difference in P. falciparum’s ability to invade the different blood 
groups erythrocytes, at least in terms of growth rates. A key finding in this thesis was the 
differential expression of the non-coding RNA gene, PF3D7_1370800, in blood group A 
donors relative to the other blood groups. A comprehensive search of the literature did not 
generate any information on this gene. It is therefore limiting to know the role this gene 
may play in blood group A individuals during malaria. Further studies need to be done to 
confirm the potential role, if any, of this gene. 
7.6 Implications of my research findings for policy 
Approximately 90% of malaria incidence and mortality occur in Sub-Saharan Africa with 
children under the age of five being more at risk (WHO 2015). Laboratory confirmation 
of malaria is important in the treatment and management of the disease. The findings in 
the thesis highlight the need to explore the development of antigens derived from 
merozoite surface proteins as diagnostic tools to complement existing microscopic and 
other diagnostic methods for accurate detection of the type of Plasmodium species in 
malaria endemic populations. This will enable accurate identification of the species type 
as well as mixed-species infections to enable appropriate and timely treatment strategies, 
aimed at improving the current and future health of populations where different species of 
Plasmodium coexist.  
The finding in this thesis of the association of mixed-Plasmodium infections with 
treatment failures is of clinical significance. Health practitioners in clinical settings where 
species identification is possible should monitor closely the therapeutic effectiveness of 
patients diagnosed as being infected with mixed species. In settings where laboratory 
confirmation of the species of Plasmodium is not routine, practitioners should investigate 
further the possible contribution of mixed-species infections in patients who do not 




closely monitored, diagnosed and treated for malaria, this did not suppress malaria 
incidence, confirming recent findings that mass drug administration alone, although 
effective for the short term, needs to be complemented with other vector control 
programmes for effective eradication of malaria (Brady et al. 2017). Spatial analysis of 
malaria epidemiology showed that malaria parasite transmission is very focal. The 
identification of clusters of significantly increased malaria risk suggests that even in a 
smaller geographic area malaria transmission shows heterogeneity. Such data can provide 
useful information to guide malaria control efforts. Such information shows that targeting 
communities at higher risk of infection may be better than targeting whole communities. 
The role of the non-coding RNA gene PF3D7_1370800 identified in this study to be 
differentially expressed in blood group A donors relative to both group B and O 
individuals is unknown. However, this preliminary data on the differential expression of 
this gene presents an avenue to explore further research into the contribution of this gene 
to the dynamics of ABO blood group and malaria pathology. 
The findings presented here will aid researchers and other stakeholders in making 
informed choices about intervention tools for malaria control programmes, as is the case 
of incorporating the important findings in this thesis into new Sudanese malaria research 
and malaria elimination planning. This work opens up an area of research to explore the 
use of MSP-119 antigens in other malaria epidemiological settings and to better understand 
the contributions of all species of Plasmodium to the overall disease burden and drug 
treatment failures. 
7.7 Future prospects and recommendations  
In this thesis I have demonstrated that the shortcomings of malaria diagnosis by the gold 
standard microscopy method result in underestimating the prevalence of mixed-
Plasmodium species infections in African populations. Plasmodium species identification 
can be improved by the use of sensitive serological methods based on merozoite surface 




both clinical and epidemiological settings (Chapters 3 and 4). These MSP-119 antigens 
have shown that in both mesoendemic Zimbabwe and very low transmission village of 
Daraweesh, they can serve as a good reflection of exposure to Plasmodium parasites, and 
show promise to be developed as RDTs. Further epidemiological research in other malaria 
transmission settings using these antigens is proposed, as this will serve to contribute to 
validating these antigens and helping our understanding of the global epidemiology of the 
different Plasmodium species and their contribution to disease burden. I propose 
comparative studies of serological work based on MSP-119 antigens and other molecular 
techniques such as PCR on the same study cohort in other epidemiological settings in 
Africa.  
I have demonstrated that mixed-species infections are associated with chloroquine 
treatment failures in the Daraweesh population (Chapter 5). The Daraweesh study was 
conducted at a period when chloroquine-resistant P. falciparum in Sudan and other parts 
of Africa was becoming apparent (El Sayed et al. 2000). Nevertheless, my study 
demonstrated that a significant number of people with only P. falciparum infections, or 
single infections to P. vivax and P. ovale cleared their infections with a single course of 
chloroquine treatment. Since the year 2000, many African governments have introduced 
ACTs as their first line for treating uncomplicated malaria (WHO 2015). Thus, I propose 
further studies using these antigens in areas where ACTs are currently the first line of 
treatment, in order to compare the therapeutic effects in single- versus mixed-species 
infections detectable by antibody responses to MSP-119 antigens. In view of recent reports 
of Plasmodium-resistant ACT strains in some parts of the world (Chang 2016, Dondorp 
et al. 2009, Duffy and Sibley 2005), it is important to identify at this early stage the 
contribution of the non-falciparum species to these reported resistances in settings of co-
infections. From the historical information about antimalarial drugs I outlined in Table 
1.5.1 in Chapter 1, it is clear that the development of antimalarial drugs takes many 
decades, and resistant parasite strains develop rapidly. Until an effective malaria vaccine 




diagnosed and treatment effectively to prevent the development of drug-resistant strains 
to current ACTs. 
The preliminary results obtained from the ABO and parasite studies should be scaled up 
and possibly, similar gene expression studies conducted in individuals naturally infected 
with malaria. On the basis of the data obtained from the sequencing, there might be no 
need to do RNAseq in subsequent validation experiments. I propose growing the parasites 
in the different blood group erythrocytes, and performing quantitative PCR on 
significantly differentially expressed genes, to determine whether there is an effect as this 
technique only amplifies one gene as oppose to the possibility of background readings 
associated with RNAseq and microarray techniques.  
7.8 Final conclusions  
My thesis has generated several results of research interest, which are of importance for 
health care practitioners, policy makers and stakeholders involved in the control of 
malaria. These findings are timely because of the current renewed global interest to 
address the contribution of the non-falciparum species to malaria burden. 
 The study has confirmed that MSP-119 antigens from the four major human 
Plasmodium parasites are species-specific and that human IgG antibodies directed 
against these antigens do not cross-react. These antigens could be developed into 
diagnostic tools to complement the use of microscopy in detecting malaria 
parasites and confirming the Plasmodium species individuals are infected with. 
This will ensure accurate epidemiology data on African malaria and help better 
our understanding of the contribution of the non-falciparum species to the overall 
malaria burden. 
 
 Using these antigens, the study has confirmed that P. falciparum is indeed the 
predominant Plasmodium species in African malaria epidemiology, but equally 




falciparum species are higher than previously reported in the two study countries. 
This may suggest that microscopic detection of Plasmodium species often fails to 
accurately report on the epidemiology of mixed-species infections and the 
prevalence of the non-falciparum species. By using the more sensitive MSP-119 
IgG serological diagnostic method, I have been able to demonstrate that 
microscopy might misclassify and underestimate mixed-species infections in 
these two populations. These findings further reiterate the need for additional 
diagnostic tools capable of detecting the type of infecting Plasmodium in malaria 
endemic areas.  
 
 Mixed-Plasmodium species infections are associated with drug treatment failures. 
This finding should prompt health care practitioners to evaluate closely the 
treatment regimen administered to individuals who are diagnosed with mixed-
species infections. Since malaria drug development takes many years and 
resistances to drugs pose a major challenge in the elimination of the disease, it is 
important to administer the appropriate drug based on the infection an individual 
carries. 
 
 Spatial analysis of malaria epidemiology showed that malaria parasite 
transmission in Daraweesh was focal. Two space-time clusters of significantly 
increased malaria risk were identified (1993-1999, and 1998-1999) with marked 
variation between households, but little or no variation in the species of 
Plasmodium over time. This may suggest that even in a small geographic area 
malaria transmission shows heterogeneity, and that such data can provide useful 
information to guide malaria control efforts.  
 
 Although the ABO blood group systems plays a major role in the susceptibility or 
resistance to the development of severe malaria, P. falciparum growth was similar 
in all erythrocytes independent of blood groups. The preliminary data from this 




in blood groups A individuals compared to the non-A blood groups, although this 
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Appendix A: ELISA outline 
 
 
Enzyme-linked immunosorbent assay (ELISA) technique for the detection of 
Plasmodium antibody in serum samples. 
The MSP-119 antigens are added to the wells, where it passively binds to the walls. Primary 
IgG antibody (anti-MSP-119) in the test serum binds specifically to the MSP-119 antigen. 
An enzyme-linked secondary antibody (HRP) is added that reacts with a chromogen, 
producing a colour that is proportional to the amount of antibody present in the serum. 





Appendix B: Solutions Used In Enzyme-Linked Immunosorbent Assay 
 




pH to 7.2-7.4 
 
2. Coating Buffer 
                               1.59g Na2CO3 [anhydrous] (15mM) 
                               2.93g NaHCO3 [anhydrous] (35mM) 
                               Made up to 1 litre with distilled water. pH adjusted to 9.4-9.6 
                               Stored in 4oC fridge. 
3. Washing Buffer 
                               PBS plus 0.05% Tween 20 
 
4. Blocking Buffer 
                               1% Marvel Skimmed Milk Powder in Washing Buffer 
 
5. Substrate Buffer for 25 ml 
                               6ml 0.1M citric acid (stored at 4oC) 
                               6.4ml 0.2M Na2HPO4 
                               12.5ml double distilled H2O 
                               10 µL H2O2 
                               10 mg 0-Phenylenediamine Dihydrochloride (OPD) (Sigma) 
 
6. Stopping Buffer 






Appendix C: Competition ELISA showing species specificity of IgG 
antibodies to recombinant Plasmodium MSP-119 antigens 
 
Plasma samples were tested at 1 in 500 dilution. Legends indicate the pairs of competing antigens used, with 
the well-bound capture antigen listed first and the competing homologous (control) or heterologous (test) 
antigen second. The capture antigens were coated at 50 ng/well. In each panel the red and blue solid lines 
with open circle symbols represent competition reactions involving homologous antigens, while the red and 
blue dashed lines with open triangle symbols represent reactions involving heterologous antigens. The y-
axis indicates antibody absorbance measured at 492nm whiles the x-axis shows a titration with increasing 
concentrations of the competitor homologous or heterologous antigen added to the diluted serum sample. 
Panels A, B and C show reactions between P. falciparum (Pf), and P. malariae (Pm), P. ovale (Po) and P. 
vivax (Pv) respectively; Panels D and E involve P. malariae with P. ovale and P. vivax, while panel F shows 
P. ovale and P. vivax. Ag is antigen.  
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Appendix E: Sample- to Sample Pearson correlation of gene expression levels in different blood group 
donors. 
 
Donor ID A1 A2 A3 A4 A5 B1 B2 B3 B4 B5 O1 O2 O3 O4 O5
A1 1 0.99262 0.96732 0.98354 0.98651 0.97916 0.99061 0.97476 0.98873 0.98965 0.98222 0.98154 0.97382 0.98992 0.94967
A2 0.99262 1 0.96463 0.9852 0.98454 0.97648 0.98946 0.97529 0.98971 0.99016 0.97732 0.98172 0.9728 0.99019 0.94622
A3 0.96732 0.96463 1 0.98259 0.98512 0.9883 0.97318 0.98841 0.97501 0.97396 0.98653 0.98739 0.98813 0.95958 0.98664
A4 0.98354 0.9852 0.98259 1 0.98896 0.98819 0.98776 0.98882 0.98842 0.98565 0.98426 0.98727 0.98349 0.98213 0.97111
A5 0.98651 0.98454 0.98512 0.98896 1 0.99246 0.98934 0.98682 0.99083 0.99149 0.99336 0.99379 0.9916 0.98288 0.97738
B1 0.97916 0.97648 0.9883 0.98819 0.99246 1 0.98642 0.99022 0.98689 0.98597 0.99168 0.99126 0.98942 0.9778 0.98259
B2 0.99061 0.98946 0.97318 0.98776 0.98934 0.98642 1 0.98332 0.99165 0.9912 0.98493 0.98608 0.97913 0.99191 0.96043
B3 0.97476 0.97529 0.98841 0.98882 0.98682 0.99022 0.98332 1 0.98624 0.98442 0.98424 0.98904 0.98735 0.97688 0.97892
B4 0.98873 0.98971 0.97501 0.98842 0.99083 0.98689 0.99165 0.98624 1 0.99411 0.98552 0.989 0.98468 0.99102 0.96608
B5 0.98965 0.99016 0.97396 0.98565 0.99149 0.98597 0.9912 0.98442 0.99411 1 0.98583 0.99034 0.98483 0.99143 0.96267
O1 0.98222 0.97732 0.98653 0.98426 0.99336 0.99168 0.98493 0.98424 0.98552 0.98583 1 0.99151 0.99083 0.9767 0.98115
O2 0.98154 0.98172 0.98739 0.98727 0.99379 0.99126 0.98608 0.98904 0.989 0.99034 0.99151 1 0.99332 0.98073 0.98018
O3 0.97382 0.9728 0.98813 0.98349 0.9916 0.98942 0.97913 0.98735 0.98468 0.98483 0.99083 0.99332 1 0.97231 0.98792
O4 0.98992 0.99019 0.95958 0.98213 0.98288 0.9778 0.99191 0.97688 0.99102 0.99143 0.9767 0.98073 0.97231 1 0.94705
O5 0.94967 0.94622 0.98664 0.97111 0.97738 0.98259 0.96043 0.97892 0.96608 0.96267 0.98115 0.98018 0.98792 0.94705 1




















Appendix G: The 100 most variable genes in decreasing order of variance 









Appendix H: Publication of work related to the thesis 
Seroepidemiology of Plasmodium species infections in Zimbabwean population. In 































species infections in Zimbabwean population
Seth A. Amanfo1*, Takafira Mduluza2,3, Nicholas Midzi4, David R. Cavanagh1 and Francisca Mutapi1
Abstract 
Background: Individuals living in malaria-endemic regions may be exposed to more than one Plasmodium species; 
there is paucity of data on the distribution of the different species of Plasmodium in affected populations, in part due 
to the diagnostic method of microscopy, which cannot easily differentiate between the species. Sero-epidemiological 
data can overcome some of the shortcomings of microscopy.
Methods: The specificity of IgG antibodies to recombinant merozoite surface protein 1 (MSP-119) derived from four 
human Plasmodium species (Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale) was 
investigated using competition enzyme-linked immunosorbent assay. Subsequently, these antigens were used to 
determine the exposure prevalence to the different Plasmodium species in serum samples of participants. One-hun-
dred individuals, aged five-18 years, from each of the three Plasmodium meso-endemic Zimbabwean villages (Burma 
Valley, Mutoko, Chiredzi) were recruited in the study.
Results: The study demonstrated that the host serum reactivity to MSP-119 antigens was species-specific and that no 
cross-reactivity occurred. The overall prevalence of antibody response to MSP-119 antigens was 61 % in Burma Valley, 
31 % in Mutoko and 32 % in Chiredzi. Single species IgG responses to MSP-119 were most frequent against P. falcipa-
rum, followed by P. malariae and P. ovale, with responses to P. vivax being the least prevalent. Interestingly, 78–87 and 
50 % of sera with IgG responses to P. malariae and P. ovale MSP-119, respectively, also had IgG specific response for P. 
falciparum MSP-119 antigens, indicating that exposure to these species is a common occurrence in these populations. 
Single species IgG responses to the non-falciparum species were at a very low frequency, ranging between 0 and 
13 % for P. malariae.
Conclusions: There is evidence of a higher exposure to the non-falciparum parasite species than previously reported 
in Zimbabwe. The recombinant MSP-119 antigens could be used as additional diagnostic tools in antibody assays for 
the detection of exposure to the different Plasmodium species. The results also introduce an interesting concept of 
the co-infection of non-falciparum Plasmodium almost always with P. falciparum, which requires further validation and 
mechanistic studies.
Keywords: Antibody, Merozoite surface protein 1 (MSP-119), Plasmodium, Microscopy
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Background
Malaria is a major public health problem in sub-Saharan 
Africa, and is responsible for over half a million deaths 
annually, especially in children under the age of 5  years 
[1]. Four major species of the protozoan parasite, Plas-
modium, (Plasmodium falciparum, Plasmodium vivax, 
Plasmodium malariae, Plasmodium ovale) cause human 
malaria in sub-Saharan Africa. In malaria-endemic coun-
tries, there is an overlap in the geographic distribution 
of the different Plasmodium species and the Anoph-
eles mosquito vectors that transmit these parasites, and 
that individuals may be exposed to, and harbour multi-
ple Plasmodium species [2]. However, the epidemiology 
of the different Plasmodium species in endemic human 
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populations is not well documented [3]. Diagnosis of 
malaria in endemic clinical settings is predominantly by 
the ‘gold standard’ blood film microscopic examination, 
and rapid diagnostic tests (RDT), both of which lack 
sensitivity in differentiating the species of Plasmodium 
causing malaria. Microscopic examination has several 
limitations such as the inability to detect low levels of 
parasitaemia, and the difficulty in species differentiation 
owing to subtle differences in the morphology of blood 
stage parasites [4]. This results in the species of Plasmo-
dium causing disease being rarely reported, and almost 
all cases of malaria are therefore attributed to P. falcipa-
rum, the species causing the most serious form of malaria 
[3]. This has led to underestimates of the prevalence of 
both mixed-species and non-falciparum species infec-
tions [5]. These non-falciparum species are of significant 
clinical importance; for example, P. vivax and P. ovale 
which form latent liver stage ‘hypnozoites’ are capable of 
causing disease several months or years after the primary 
infection [6]. Incidences of the diagnosis of systemic dis-
eases caused by P. malariae several months or years after 
people have returned from malaria-endemic regions have 
been reported [7]. In some cases, drug treatment failure 
attributable to the misdiagnosis of primary infections 
caused by the non-falciparum species or as co-infecting 
species with P. falciparum have been observed [8]. While 
PCR typing of infecting Plasmodium species is not fre-
quently available or applicable in many African field set-
tings, most RDTs may not differentiate non-falciparum 
species [3]. There is an urgent need for additional diag-
nostic tools [2–4] capable of rapid detection of all four 
infecting Plasmodium species for effective treatment and 
control of malaria.
In this study, a new assay has been developed that 
detects exposure to all four human Plasmodium spe-
cies based on serum antibody responses to merozoite 
surface protein 1 (MSP-1). The surface of the invasive 
merozoite is coated in MSP-1 that constitutes 31 % of the 
GPI-anchored proteins on P. falciparum merozoites [9]. 
MSP-1 is expressed by all four human Plasmodium spe-
cies. In P. falciparum, MSP-1 undergoes two proteolytic 
cleavages resulting in a C-terminal MSP-119 fragment 
that is carried into the erythrocyte during merozoite 
invasion [10, 11]. Until recently, only the MSP-1 genes 
of P. falciparum and P. vivax had been characterized. 
Recently, the sequences of the MSP-119 gene fragments 
for P. malariae and P. ovale have been determined with 
limited characterization of the responses to these para-
site proteins [12]. Although the gene sequences of MSP-
119 antigens are unique to each of these four Plasmodium 
species, extensive homology can be found among them. 
The number and relative positions of cysteine resi-
dues within the C-terminus fragments of MSP-119 are 
comparable in all four Plasmodium species [12]. For 
example, there are about 32 amino acid sites within the 
MSP-119 gene where all four parasite species share the 
same amino acid, and about 30 sites where the same 
amino acid is conserved in two or three species (Addi-
tional file 1: Figure S1). To date, there has been no field 
study using MSP-119 antigens from all four malaria para-
site species to characterize the epidemiology of exposure 
to Plasmodium in any African population.
In Zimbabwe over half of the population are exposed to 
malaria, with P. falciparum being the predominant spe-
cies, accounting for almost all cases of the disease [13]. 
There is little epidemiological data of exposure to non-
falciparum species and/or mixed Plasmodium infections 
in Zimbabwe. The aim of this study is to determine the 
species specificity of IgG antibody responses to recom-
binant Plasmodium MSP-119 antigens in three meso-
endemic villages of Zimbabwe: Burma Valley, Mutoko 
and Chiredzi. Using these antigens as diagnostic tools, 
this study describes the sero-epidemiology of multiple 
Plasmodium species infections in these study sites.
Methods
Study sites and population
Serum samples were collected in three Zimbabwean vil-
lages where malaria parasite transmission is described as 
meso-endemic [13], as part of studies investigating the 
immuno-epidemiology of schistosomiasis in villages with 
Plasmodium co-infection. The study sites were Burma 
Valley in the northeast, where samples were collected in 
1994, Chiredzi in the southeast where samples were col-
lected in 1999 and Mutoko in central Zimbabwe, where 
samples were collected in 2003. The study cohort con-
sisted of 100 participants aged between 5 and 18  years 
(both males and females) in each study site (Table  1). 
Antibody responses to merozoite surface proteins were 
detected using enzyme-linked immunosorbent assays 
(ELISA).
Ethical approval and consent
The studies in the different study sites received ethical 
approval from the Medical Research Council of Zimba-
bwe. Permission to conduct the work in each of the three 
Table 1 Summary of study population
100 individuals from each village were recruited into the study









Burma valley 6–15 10 49 51
Mutoko 5–18 9.5 36 64
Chiredzi 7–16 11 52 48
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villages was obtained from the Provincial Medical Direc-
tor, the District Educational Officer and Heads of schools 
in the study sites. Project aims and procedures were fully 
explained to the study participants and/or their guardian. 
Informed oral consent/assent was obtained from parents/
guardians, or participants if older than 10 years, prior to 
enrolment of the participants into the study. The partici-
pants were recruited into the study on a voluntary basis 
and were free to withdraw with no further obligation.
Recombinant antigens
MSP-1 antigens used in the ELISAs were expressed in 
Escherichia coli transformed with pGEX-derived plas-
mid constructs [14–17] as recombinant proteins fused to 
glutathione S-transferase (GST). These were purified by 
affinity chromatography using HiTrap glutathione Sepha-
rose columns on an AKTAprime system and quantified 
by the Bradford protein assay.
Serology
Sera were tested by ELISA for the presence of IgG 
antibodies able to recognize the recombinant mero-
zoite surface proteins as an indication of recent or cur-
rent exposure; 96-well plates (Immulon4 HBX; Dynex, 
Greiner Microlon) were coated with 100  μL of 0.5  μg/
mL of recombinant antigen in carbonate bicarbonate 
buffer (15  mM Na2CO3, 35  mM NaHCO3, pH 9.4) and 
incubated overnight at 4 °C in a humidified atmosphere. 
Plates were washed four times in washing buffer (0.05 % 
Tween-20 in PBS) using Skatron Skanwasher to remove 
unbound antigens and blotted on paper towels (Kimber-
ley Clark 3-ply hand towels Cat No. 6771). Free binding 
sites in wells were blocked with 200 μL per well of block-
ing buffer (1  % (w/v) skimmed milk powder in the PBS 
buffer) for 5 h at room temperature and then plates fur-
ther washed four times. Human serum diluted 1:500 in 
the blocking buffer (100 μL per well) was added in dupli-
cate to the Ag-coated wells and incubated overnight at 
4 °C. After four washes, the wells were incubated for 3 h 
at room temperature with 100  μL per well of horserad-
ish peroxidase-conjugated rabbit antihuman IgG (1:5000) 
(Dako Ltd, High Wycombe, UK). Plates were washed four 
times to remove unbound secondary antibody before 
reaction development with 100  μL of substrate buffer 
[(0.04  mg/mL of o-phenylenediamine; Sigma, St Louis, 
MO, USA; 0.012 % H2O2 in development buffer (24.5 mM 
citric acid monohydrate and 52 mM Na2HPO4, pH 5.0)] 
for 10–15 min at room temperature. An unstopped posi-
tive control plate was read at an optical density (OD) 
450 nm, with an OD 450 nm of 0.7–0.8 taken to be equiv-
alent to OD 492 nm of 2.5–3.0. The reaction was stopped 
by the addition of 25 μL of 2 M H2SO4 per well, and OD 
was measured at 492 nm (Labsystems Multiskan Ascent 
microtitre plate reader). GST protein, purified from 
Escherichia coli transfected with pGEX-2T alone, was 
used as a control to determine the non-specific (back-
ground) binding of human IgG to the GST. Corrected 
OD values for each plasma sample were calculated by 
subtracting the mean OD value of wells containing con-
trol GST protein from the mean OD value obtained with 
each test MSP-1 antigen. Cut-off values at which binding 
of Ab from malaria-exposed individuals was regarded as 
significantly above background were calculated as cor-
rected OD above the mean plus 4 standard deviation 
of OD readings obtained with sera from eight Scottish 
blood donors with no history of exposure to malaria. 
The same positive controls (pooled sera from Brefet, The 
Gambia) were run in duplicate, on each plate, to allow for 
standardization of plate-to-plate variations.
Competition ELISA
Competition ELISA was performed for individuals with 
substantial antibody reactivity to more than one MSP-
119 antigen, to assess whether human anti-MSP-119 IgG 
antibodies specific for MSP-119 were species-specific or 
cross-reacted with each other. Serum was pre-incubated 
with different concentrations of MSP-119 antigen, and 
then added to the wells of microtitre plates coated with 
either the homologous or heterologous MSP-119 antigen. 
The rationale of the competition ELISA is that appropri-
ate antigen epitopes will react with their corresponding 
paratopes in the sera, so that with increasing antigen 
concentration, all paratopes in the sera react with the 
antigen, leaving none available to bind to antigen on the 
plate [18]. In the case of antigens without correspond-
ing paratopes in the sera, there will be no prior reactiv-
ity between the serum and antigens, regardless of the 
antigen concentration. The same ELISA protocol above 
was followed with slight modification. Plates were coated 
with recombinant MSP-119 Ag and incubated overnight 
at 4  °C. Serum was diluted (1:500) and pre-incubated 
with increasing concentrations (0–10  μg/mL) of soluble 
competing homologous or heterologous Ag, i.e., with up 
to 20-fold excess over the 0.50  μg/mL immobilized Ag 
to allow sera to bind to the antigen before reacting with 
the antigen bound on the plate, then tested on the plate-
bound Ag overnight. This was followed by washing and 
incubation with a horseradish peroxidase-conjugated 
second Ab, as described above.
Statistical analyses
To determine if exposure prevalence derived from single 
species data differed from that based on multiple species, 
Chi square (χ2) tests were used.
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Results
Specificity of Plasmodium MSP‑119 antigens
Competition ELISA showed that in sera reactive 
against recombinant MSP-119 antigens from more 
than one parasite species, anti-MSP-119 IgG antibody 
responses were species-specific and did not cross-react. 
As a positive control, when P. falciparum MSP-119 anti-
gen was coated onto microtitre plates (as capture Ag), 
sera pre-incubated with P. falciparum MSP-119 (com-
peting homologous Ag), were inhibited from binding 
in a dose-dependent manner (Fig.  1). This inhibition 
occurred at competing homologous Ag concentration 
as low as 0.1  μg/mL. Similar results were observed 
when the homologous competitor Ags were either P. 
malariae or P. ovale MSP-119. To assess anti-MSP-119 
cross-reactivity, P. falciparum MSP-119 antigen was 
coated onto microtitre plates and dual specificity sera 
were pre-incubated with increasing concentrations of 
the heterologous P. malariae or P. ovale MSP-119 anti-
gens. IgG binding to P. falciparum MSP-119 antigen 
was not inhibited by soluble heterologous P. malariae 
or P. ovale MSP-119, even at concentration 20 times 
the capture antigen. This was also true when the coat-
ing and competing antigens were reversed in the assay 
(Fig. 1).
Prevalence of human IgG antibodies to recombinant 
MSP‑119 antigens from four Plasmodium species
Antibody recognition of the panel of four Plasmodium 
recombinant MSP-119 antigens was tested by ELISA 
against 100 sera from each of the three study sites (Burma 
Valley, Mutoko, Chiredzi). The observed overall preva-
lence of IgG response to all recombinant MSP-119 anti-
gens was 61, 31 and 32  % in the Burma Valley, Mutoko 
and Chiredzi villages, respectively (Table 2). There were 
no significant differences between the exposure preva-
lence between the villages (Burma Valley vs Mutoko: 
χ2 = 0.002, df = 1, P = 0.97), (Burma Valley vs Chiredzi: 
χ2 = 0.423, df = 1, P = 0.52) and (Mutoko vs Chiredzi: 
χ2 = 0.001, df = 1, P = 0.97).
Fig. 1 Competition ELISA showing species specificity of Abs to recombinant Plasmodium MSP-119 antigens for individuals 1 and 2. Sera were 
tested at 1:500 dilution. Legends indicate the pairs of competing antigens used, with the well-bound capture antigen listed first and the competing 
homologous or heterologous antigen second. The capture antigens were coated at 50 ng/well. The x-axis indicates increasing concentrations of 
competing antigen added to the diluted sera
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Single vs multiple Plasmodium species anti‑MSP‑119 
responses
Of the individuals with anti-MSP-119 responses in 
all three study areas, Burma Valley (n  =  61), Mutoko 
(n = 31) and Chiredzi (n = 32), single species responses 
were the most common occurrence, and these were pre-
dominantly directed against P. falciparum MSP-119 anti-
gens (80, 68.8 and 78.3 %, respectively), with responses to 
P. malariae or P. ovale ranging from 0 to 31.2 % (Table 2). 
The proportion of individuals with single versus multiple 
species anti-MSP-119 responses in all three study villages 
were comparable.
In responders with antibodies to multiple Plasmo-
dium species, antibody responses to the non-falciparum 
species were almost always accompanied by responses 
against P. falciparum MSP-119 antigens in all three study 
areas. Multiple responses to P. falciparum- and P. malar-
iae MSP-119 were the most common, with about 78–87 
and 50  % of all sera with IgG responses to P. malariae 
and P. ovale MSP-119, respectively, also having IgG-spe-
cific response for P. falciparum MSP-119 antigens. The 
high exposure prevalence of IgG responses to P. malariae 
MSP-119 antigens suggests that infection with this para-
site species is at a higher frequency in these populations 
than has been previously reported, and are predomi-
nantly co-responses to the main response to P. falcipa-
rum MSP-119 antigen.
While there were no single species responders to P. 
malariae MSP-119 in Mutoko, a much higher propor-
tion (31.2  %) responded to three parasite antigens (P. 
malariae, P. falciparum, P. ovale) compared to the other 
two villages. Only one individual in Chiredzi had an 
antibody response to P. vivax antigen in addition to a 
response to P. falciparum (Table 2). When single species 
responses involving only P. falciparum was compared to 
multiple species responses involving P. falciparum with 
P. malariae and/or P. ovale, no significant difference was 
observed in all three villages (Fig. 2).
When the cohort was divided into two age groups, 
based on the median ages (i.e., those below 10 years and 
those 10 years and above), it was observed that the over-
all exposure prevalence in the two age groups were com-
parable in both Burma Valley (χ2 = 3.5, df = 1, P = 0.06) 
and Mutoko (χ2 =  0.05, df =  1, P =  0.83). However, in 
Chiredzi a significantly higher exposure prevalence 
was observed in responders aged 10  years and above 
compared to those below 10  years (χ2  =  6.13, df  =  1, 
P  =  0.01) (Table  3). Differences between the two age 
groups in responders to single and multiple species in 
all three study areas were not compared because of the 
smaller sample sizes involved.
Discussion
In this current study, IgG responses to recombinant 
MSP-119 antigens (an indication of prior exposure to 
Plasmodium antigens) from the four major human 
Plasmodium species were evaluated in three Zimba-
bwean villages with meso-endemic malaria transmission 
dynamics. Individuals living in malaria-endemic regions 
may harbour multiple Plasmodium species owing to the 
Fig. 2 Prevalence of single Plasmodium falciparum vs multiple species anti-MSP-119 responses. Observed prevalence of single spp. P. falciparum 
anti-MSP-119 responses were compared with multiple responses involving P. falciparum with P. malariae and/or P. ovale in all three study sites
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geographical overlap of the four major human Plasmo-
dium species [4, 19, 20]. Malaria diagnosis in most Afri-
can field settings is largely by microscopy of blood films, 
which reports the presence or absence of Plasmodium 
parasites without cognisance to the species causing dis-
ease. Low-level parasitaemia of the non-falciparum spe-
cies in mixed infection with P. falciparum accounts for 
the misdiagnosis of these species. There have been case 
study reports of treatment failures [21] and acute renal 
injury [22] attributable to undiagnosed P. malariae infec-
tion or co-infection. Knowledge of the type of infecting 
species is therefore essential for effective treatment as 
well as the implementation of control programmes. IgG 
responses to P. falciparum MSP-119 antigens have been 
shown to rise following clinical episodes of malaria and 
decline in the absence of the disease [15]. In the cur-
rent study, the antibody response to Plasmodium species 
recombinant MSP-119 antigens in humans was seen to be 
highly species-specific. Furthermore, the study showed 
that the responses were not cross-reactive, despite the 
amino acid sequence similarities between the four Plas-
modium MSP-119 antigens. In experimental monkey 
and human studies utilizing all four Plasmodium species 
MSP-119 antigens, a superior sensitivity was seen when 
compared to commercially available antibody assays 
which only utilize MSP-119 antigens from P. falciparum 
and P. vivax and depend on cross-reactivity in detecting 
the other two species [23]. The specificity of antibodies to 
these antigens supports the evidence that these antigens 
could be used in pan-malaria diagnostic assay to enable 
the rapid detection of the type of Plasmodium species 
causing malaria [23].
In many malaria-endemic countries in sub-Saharan 
Africa, P. falciparum is the predominant species that 
causes malaria, thus it was not surprising that the anti-
body response to P. falciparum MSP-119 antigens was 
predominant in all three study sites. Since P. falcipa-
rum infections have higher parasitaemias than the other 
malaria parasite species [20, 24], it is likely that individu-
als will have a stronger immune response to P. falcipa-
rum infection. The novel results from this study were the 
indication that the exposure prevalence of P. malariae 
and P. ovale is higher, as previous reports have attributed 
about 98  % of malaria in Zimbabwe to be caused by P. 
falciparum. More importantly, the observed higher expo-
sure prevalence of P. malariae in the Burma Valley dis-
trict was striking, as reports suggest that this species only 
accounts for between 1 and 2.6 % of all malaria cases by 
light microscopy [25–27].
Microscopy has long been known to underestimate 
the prevalence of the non-falciparum species owing to 
difficulties in distinguishing the subtle differences in the 
morphology of the different species as well as the chal-
lenge posed in detecting minority species in a blood 
film with high density P. falciparum parasitaemia. It 
is therefore not surprising that these assays detected 
a higher sero-prevalence of these species, as this also 
reflects recent and concurrent parasite exposure. Studies 
employing nucleic acid based techniques for Plasmodium 
parasite detection and species identification in some 
African countries have reported prevalence of the non-
falciparum species to be between 1 and 17 % [20, 24].
While antibody responses to single species P. falcipa-
rum antigens were common, single species responses 
to P. malariae and P. ovale antigens were infrequently 
detected. A significant proportion of individuals with 
IgG responses to P. malariae and/or P. ovale MSP-119 
almost always had responses to P. falciparum MSP-119. 
This results support the findings of a recent study in 
Ghana, which reported frequent detection of P. malar-
iae and P. ovale in individuals who are also PCR positive 
for P. falciparum [28]. The reasons for this co-occur-
rence of the non-falciparum species with P. falciparum 
may be both epidemiological and biological. Of the 
epidemiological reasons, it has been suggested that the 
same Anopheles mosquito circulating in a population 
might be responsible for the simultaneous or sequential 
inoculation of the different species [4], thereby increas-
ing the likelihood of multiple species infections. Biolog-
ical reasons may include selective advantages for these 
minor species when co-infecting with P. falciparum. 
For example, due to density-dependent regulation of 
immune responses directed against the majority spe-
cies (P. falciparum), these non-falciparum species may 
be able to evade host immune responses and establish 
disease [29, 30]. There are parallels in other infectious 
diseases, such as the obligate satellite virus hepatitis 
D, which is unable to establish disease independent of 
hepatitis B virus [31]. Hepatitis D virus co-infection 
in Hepatitis B-infected individuals worsens hepatic 
damage and inflammation, and is more likely to lead 
to hepatocellular carcinoma [32, 33]. The results show 
some single species P. malariae responses, indicat-
ing that this species is capable of establishing infection 
independent of other Plasmodium. However, the sig-
nificant proportion of individuals with co-occurrence 
of antibody responses to P. falciparum suggests a pos-
sible dependency on P. falciparum receptors or proteins 
for successful disease by P. malariae. These non-falci-
parum species, which usually exist as part of a complex 
mixed-infections with P. falciparum [2, 34] may cause 
chronic, sub-clinical disease with potential health con-
sequences, including treatment failure, disease relapse 
and long-term systemic consequences [5–7]. A recent 
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study in Indonesia found P. malariae to be associated 
with a lower mean haemoglobin, nephrotic syndrome 
and death [27].
Antibody responses to P. vivax MSP-119 were rarely 
observed in this study. Plasmodium vivax requires the 
Duffy antigen to establish a successful infection [35], and 
is predominantly endemic in Asian and Latin American 
countries. It has long been known that the Duffy anti-
gen is absent in most African populations [35]; it was 
therefore not surprising to observe a low frequency of 
responses to P. vivax MSP-119. In recent years however, 
there have been reports of P. vivax infections in both 
Duffy positive and negative individuals in Cameroon 
[36] suggesting that this species might have evolved and 
adapted to using other receptors to invade erythrocytes 
and establish disease.
Serological responses generally increase with age. In 
this present study, age was not a confounding factor in 
Burma Valley and Mutoko, while is Chiredzi respond-
ers 10 years old and above had a higher overall exposure 
prevalence to parasite antigens. Although all three vil-
lages are described as meso-endemic, the observed dif-
ferences in age responses could be due to the respective 
transmission dynamics of the different seasons in which 
sampling was done. In very low and unstable malaria 
transmission areas such as Daraweesh in eastern Sudan, 
reports suggest that the age dynamics associated with 
malaria and serological responses are not apparent, as 
malaria affects all age groups [37, 38].
Conclusions
This study has shown for the first time that IgG antibod-
ies to recombinant MSP-119 antigens of the four major 
human Plasmodium species are species-specific. The 
study also demonstrates that in Zimbabwean popula-
tions exposed to Plasmodium infections, the prevalence 
of the non-falciparum species responses is higher than 
previously reported in many other cross-sectional studies 
(reviewed in [3]). Finally, the study has demonstrated that 
a high proportion of individuals with antibody responses 
to non-falciparum MSP-119 antigens also had antibodies 
to P. falciparum MSP-119. MSP-119 antigens from all four 
major species of human malaria parasite offer a poten-
tial diagnostic tool for the rapid detection of exposure 
to multiple Plasmodium species such as in blood trans-
fusion screening services. It remains to be established if 
these exposure responses to multiple Plasmodium spe-
cies indicated by the serological survey correspond to 
concurrent or sequential exposure to previous or current 
infections.
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